
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Infection, Genetics and Evolution 96 (2021) 105098

Contents lists available at ScienceDirect

Infection, Genetics and Evolution

journal homepage: www.elsevier.com/locate/meegid

Research paper

# Association of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients

Rasoul Abdollahzadeh [a,*,1], Mohammad Hossein Shushizadeh [b,1], Mina Barazandehrokh [c], Sepideh Choopani [d], Asaad Azarnezhad [e,*], Sahereh Paknahad [a], Maryam Pirhoushiaran [a], S. Zahra Makani [f], Razieh Zarifian Yeganeh [a], Ahmed Al-Kateb [g], Roozbeh Heidarzadehpilehrood [h]

[a] Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
[b] Pasteur Medical Lab, Shush Danial, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
[c] Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran
[d] Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
[e] Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
[f] Babol Razi Pathology and Genetic Laboratory, Babol, Iran
[g] Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
[h] Department of Obstetrics & Gynaecology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia

ARTICLE INFO

*Keywords:*
COVID-19
Vitamin D receptor
Single nucleotide polymorphisms (SNPs)
Genetic predisposition
Clinical outcomes

ABSTRACT

*Introduction:* Growing evidence documented the critical impacts of vitamin D (VD) in the prognosis of COVID-19 patients. The functions of VD are dependent on the vitamin D receptor (VDR) in the VD/VDR signaling pathway. Therefore, we aimed to assess the association of VDR gene polymorphisms with COVID-19 outcomes.

*Methods:* In the present study, eight VDR single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 500 COVID-19 patients in Iran, including 160 asymptomatic, 250 mild/moderate, and 90 severe/critical cases. The association of these polymorphisms with severity, clinical outcomes, and comorbidities were evaluated through the calculation of the Odds ratio (OR).

*Results:* Interestingly, significant associations were disclosed for some of the SNP-related alleles and/or genotypes in one or more genetic models with different clinical data in COVID-19 patients. Significant association of VDR-SNPs with signs, symptoms, and comorbidities was as follows: *Apa*I with shortness of breath ($P < 0.001$) and asthma ($P = 0.034$) in severe/critical patients (group III); *Bsm*I with chronic renal disease ($P = 0.010$) in mild/moderate patients (group II); Tru9I with vomiting ($P = 0.031$), shortness of breath ($P = 0.04$), and hypertension ($P = 0.030$); *Fok*I with fever and hypertension ($P = 0.027$) in severe/critical patients (group III); CDX2 with shortness of breath ($P = 0.022$), hypertension ($P = 0.036$), and diabetes ($P = 0.042$) in severe/critical patients (group III); *Eco*RV with diabetes ($P < 0.001$ and $P = 0.045$ in mild/moderate patients (group II) and severe/critical patients (group III), respectively). However, the association of VDR TaqI and *Bgl*I polymorphisms with clinical symptoms and comorbidities in COVID-19 patients was not significant.

*Conclusion:* VDR gene polymorphisms might play critical roles in the vulnerability to infection and severity of COVID-19, probably by altering the risk of comorbidities. However, these results require further validation in larger studies with different ethnicities and geographical regions.

* Corresponding authors.
*E-mail addresses:* RASOUL142857@gmail.com (R. Abdollahzadeh), asad.azarnezhad@muk.ac.ir (A. Azarnezhad), Ahmedalaakateb@gmail.com (A. Al-Kateb), roozbeh.heidarzadeh@gmail.com (R. Heidarzadehpilehrood).
[1] Rasoul Abdollahzadeh and Mohammad Hossein Shushizadeh contributed equally to this work.

https://doi.org/10.1016/j.meegid.2021.105098
Received 15 May 2021; Received in revised form 11 September 2021; Accepted 27 September 2021
Available online 2 October 2021

## 1. Introduction

The ongoing global epidemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, certainly represents one of the most important clinical emergencies of the 21st century (Sohrabi et al., 2020; De Wit et al., 2016). COVID-19 can manifest a wide spectrum of clinical symptoms, which range from lack of symptoms, or mild symptoms of the upper respiratory tract to severe pneumonia with acute respiratory distress syndrome (ARDS) and death (Richardson et al., 2020; Grasselli et al., 2020). This highly phenotypic heterogeneity seems to depend on patient age, gender, underlying health conditions, and inter-individual genetic unevenness (Xie and Chen, 2020). Vitamin D (VD) has been demonstrated to perform critical roles in a wide range of immunomodulatory, anti-inflammatory, antifibrotic, and antioxidant functions. Therefore, its deficiency and insufficiency contribute to many pathogenic conditions, including autoimmune disorders, respiratory infections, cancer, cardiovascular disorders, osteoporosis, sarcopenia, and diabetes (Bizzaro et al., 2017; Kunadian et al., 2014; Amrein et al., 2020; Zdrenghea et al., 2017). There is growing evidence to indicate that VD insufficiency is strongly associated with an increased risk of acquiring COVID-19 infection (Meltzer et al., 2020), as well as developing COVID-19-associated thrombosis (Weir et al., 2020). Furthermore, VD deficiency was demonstrated to be a fatal co-morbidity in COVID-19 patients (Biesalski, 2020). On the other hand, mounting investigations declare that VD supplementation, especially FDA-approved analog (generic name, paricalcitol), prevents COVID-19 infection-induced multi-organ damage (Aygun, 2020), coagulopathy (Ali, 2020), mortality (Grant et al., 2020; Ilie et al., 2020), as well as attenuates the risk and severity of COVID-19 (Hribar et al., 2020). Therefore it has been postulated that daily supplementation with moderate doses of vitamin D3 is a safe treatment for COVID-19 patients (Zemb et al., 2020).

The mechanisms by which VD insufficiency exacerbates COVID-19-associated pneumonia remain poorly understood. However, most studies have focused on the pivotal roles of the VD/VD receptor (VDR) pathway in alleviating acute lung injury (ALI) and ARDS, a crucial component of the pathophysiological processes that occurred in almost 20% of the hospitalized patients (including ICU and non-ICU patients) with COVID-19 (Xu et al., 2020; Chen et al., 2020). The two principal pathophysiological mechanisms involved in ARDS include the release of large amounts of pro-inflammatory cytokines and chemokines, known as a cytokine storm, and aberrant activation of the renin-angiotensin system (RAS) with a decrease of angiotensin-converting enzyme2 (ACE2) (Channappanavar and Perlman, 2017; Cameron et al., 2008; Imai et al., 2005). Most previous work has revealed that the VD/VDR signaling axis may provide some beneficial effects in COVID-19 infection and especially in related ARDS phenotype through several mechanisms, such as attenuating the storm of cytokines and chemokines, modulating of the RAS, regulating the activity of a wide range of the immune cell types *i.e.*, neutrophil and monocytes/macrophages, maintaining the integrity of the pulmonary epithelial barrier and stimulating epithelial repair, declining coagulation and thrombosis, and attenuating endothelial dysfunction (Xu et al., 2017; Shi et al., 2016; Kong et al., 2013; Zheng et al., 2020; Zhang et al., 2020a).

VDR exerts its pleiotropic effects *via* binding with its active ligand, vitamin D, 1α,25-dihydroxy vitamin D3 [1,25(OH)2D3], and functions as a transcription factor (TF) on ~5% of human genes through binding to more than 23,000 cell-specific genomic locations, known as vitamin D response elements (VDREs) (Tuoresmäki et al., 2014; Rhodes et al., 2020). The VDR gene is mapped at chromosome 12q13.11 which spans ~100 kb and has five promoters, eight coding exons, and six untranslated exons (K-i et al., 1997). Genetic variations in the VDR gene such as single nucleotide polymorphisms (SNPs) might influence the activity, stability, and expression levels of VDR products (mRNAs and/or proteins), subsequently altering the VD-VDR signaling axis, ultimately leading to disturbance of VD immune-regulatory functions. To date, a vast amount of investigations have been accomplished regarding the association of VDR polymorphisms with susceptibility to different diseases, including autoimmune disorders, cancers, viral and bacterial respiratory infections (Valdivielso and Fernandez, 2006; Laplana et al., 2018; Abdollahzadeh et al., 2016; Abdollahzadeh et al., 2018). Collectively, a few VDR gene variants that have been observed in relation to predisposing to various conditions with contradictory results include *Apa*I (rs7975232; intron 8; C > A), *Bsm*I (rs1544410; intron 8; G > A), Tru9I (rs757343; intron 8; G > A), TaqI (rs731236; exon 9; A > G), *Bgl*I (rs739837; 3′UTR region; C > T), *Fok*I (rs2228570; exon 2; C > T), CDX2 (rs11568820; promoter; G > A), and *Eco*RV or A-1012G/GATA (rs4516035; promoter; T > C). Hence, we aimed to evaluate the potential association of the aforementioned eight SNPs located in the 5′ end (FokI, CDX2, and EcoRV) and also 3'end (*Apa*I, *Bsm*I, Tru9I, TaqI, and *Bgl*I) of the VDR gene with the severity of COVID-19 in an Iranian population. The identification of genetic variants linked with variable susceptibility of individuals to COVID-19 infection and severity of adverse complications could ultimately help open new avenues, including innovative personalized treatments, stratifying individuals according to the risk, and prioritization of subjects at greater risk for protection, assisting current biomedical research efforts to combat the virus, and also guide current genetics and genomics research towards candidate gene variants that warrant further investigation in larger studies.

## 2. Material and methods

### 2.1. COVID-19 patients

Five hundred COVID-19 patients were recruited in the current study that hospitalized at several different hospitals (Iran), during the period between May 5 and September 25, 2020. The COVID-19 diagnoses were established based on a positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and/or pharyngeal swabs, following WHO interim guidance (Organization WH, 2020). The enrolled patients were categorized into 3 groups based on clinical manifestations: group I, 160 asymptomatic subjects, according to the absence of clinical symptoms and no need for hospitalization or ventilation; group II, 250 mild/moderate patients with a wide range of symptoms, including fever, sore throat, dry cough, headache, shortness of breath, diarrhea, myalgia, fatigue, nausea, vomiting, and parageusia; and group III, 90 subjects with a severe/critical condition. Regarding respiratory impairment, severe cases require non-invasive ventilation, while critical patients, defined as respiratory failure, requiring invasive ventilation and intensive care unit (ICU) admission. The presence of comorbidities (hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy) was obtained from the participant's medical records (Table 1). The current research was conducted in agreement with the ethical principles of the Declaration of Helsinki and all the patients or their representatives gave their consent to participate.

### 2.2. VDR gene polymorphisms genotyping by PCR-RFLP

Peripheral blood was taken from each of the participants and DNA extraction was applied by High Pure PCR Template Preparation Kit (Roche Applied Science, USA) following the manufacturer's recommendations. The concentration and purity, as well as quality of DNA, were determined by NanoDropND-1000 Spectrometer (ThermoScientific, Boston, MA) and gel electrophoresis, respectively. The target SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Primers were designed using PRIMER3 online software (version 4.1.0) (https://primer3.ut.ee/) and their specificity was assessed using primer blast and possible secondary structures were analyzed using GENE RUNNER software (Gene Runner version 6.5.52). The primer sequences, PCR thermal profiles, expected amplicon size, and RFLP patterns are summarized in Table 2. It should be noted that in the present study, regardless of the type of substituted nucleotide

**Table 1**
Baseline features of COVID-19 participants.

| Variables | Status | | Asymptomatic patients (group I) | Mild/moderate illness (group II) | Severe and critical illness (group III) | P- value (I and II) | P- value (I and III) | P- value (II and III) | Overall P-value |
|---|---|---|---|---|---|---|---|---|---|
| Number (%) | 500 (100.0) | | 160 (32.0) | 250 (50.0) | 90 (18.0) | | | | |
| Age (mean ± Std. Deviation) | 53.30 ± 16.16 | | 50.28 ± 16.76 | 53.10 ± 16.10 | 59.19 ± 13.62 | 0.187 | **< 0.001** | **0.006** | **< 0.001** |
| Gender | Male | 293 (58.60) | 90 (56.3) | 142 (56.8) | 61 (67.8) | 0.988 | 0.090 | 0.069 | 0.161 |
| | Female | 207 (41.40) | 70 (43.7) | 108 (43.2) | 29 (32.2) | | | | |

Signs and symptoms

| Variables | Status | Asymptomatic patients (group I) | Mild/moderate illness (group II) | Severe and critical illness (group III) | P- value (II and III) |
|---|---|---|---|---|---|
| Fever | Yes | 0 (0.0) | 141 (56.4) | 52 (57.8) | 0.821 |
| | No | 160 (100.0) | 109 (43.6) | 38 (42.2) | |
| Sore throat | Yes | 0 (0.0) | 82 (32.8) | 26 (28.9) | 0.494 |
| | No | 160 (100.0) | 168 (67.2) | 64 (71.1) | |
| Dry cough | Yes | 0 (0.0) | 144 (57.6) | 44 (48.9) | 0.154 |
| | No | 160 (100.0) | 106 (42.4) | 46 (51.1) | |
| Headache | Yes | 0 (0.0) | 49 (19.6) | 10 (11.1) | 0.068 |
| | No | 160 (100.0) | 201 (80.4) | 80 (88.9) | |
| Shortness of breath | Yes | 0 (0.0) | 32 (12.8) | 58 (64.4) | **< 0.001** |
| | No | 160 (100.0) | 218 (87.2) | 32 (35.6) | |
| Diarrhea | Yes | 0 (0.0) | 19 (7.6) | 11 (12.2) | 0.185 |
| | No | 160 (100.0) | 231 (92.4) | 79 (87.8) | |
| Myalgia | Yes | 0 (0.0) | 62 (24.8) | 17 (18.9) | 0.255 |
| | No | 160 (100.0) | 188 (75.2) | 73 (81.1) | |
| Fatigue | Yes | 0 (0.0) | 26 (10.4) | 31 (34.4) | **< 0.001** |
| | No | 160 (100.0) | 224 (89.6) | 59 (56.6) | |
| Nausea | Yes | 0 (0.0) | 24 (9.6) | 15 (16.7) | 0.071 |
| | No | 160 (100.0) | 226 (90.4) | 75 (83.3) | |
| Vomiting | Yes | 0 (0.0) | 18 (7.2) | 11 (12.2) | 0.144 |
| | No | 160 (100.0) | 232 (92.8) | 79 (87.8) | |
| Parageusia | Yes | 0 (0.0) | 12 (4.8) | 26 (28.9) | **< 0.001** |
| | No | 160 (100.0) | 238 (95.2) | 64 (71.1) | |

Comorbidities

| Variables | Status | Asymptomatic patients (group I) | Mild/moderate illness (group II) | Severe and critical illness (group III) | P- value (I and II) | P- value (I and III) | P- value (II and III) | Overall P-value |
|---|---|---|---|---|---|---|---|---|
| Hypertension | Yes | 19 (11.9) | 44 (17.6) | 45 (50.0) | 0.117 | **< 0.001** | **< 0.001** | **< 0.001** |
| | No | 141 (88.1) | 206 (82.4) | 45 (50.0) | | | | |
| | **OR (95% CI)$_{III\ vs.\ I}$ = 7.42 (3.94–13.97), OR (95% CI)$_{III\ vs.\ II}$ = 4.68 (2.77–7.92)** | | | | | | | |
| Diabetes | Yes | 16 (10.0) | 44 (17.6) | 32 (35.6) | **0.034** | **< 0.001** | **< 0.001** | **< 0.001** |
| | No | 144 (90.0) | 206 (82.4) | 58 (64.4) | | | | |
| | **OR (95% CI) $_{II\ vs.\ I}$ = 1.92 (1.04–3.54), OR (95% CI)$_{III\ vs.\ I}$ = 4.97 (2.53–9.73), OR (95% CI)$_{III\ vs.\ II}$ = 2.58 (1.50–4.44)** | | | | | | | |
| Asthma | Yes | 22 (13.8) | 14 (5.6) | 15 (16.7) | **0.002** | **< 0.001** | **0.001** | **< 0.001** |
| | No | 138 (86.2) | 236 (94.4) | 75 (83.3) | | | | |
| | **OR (95% CI) $_{II\ vs.\ I}$ = 0.37 (0.18–0.75), OR (95% CI)$_{III\ vs.\ II}$ = 3.37 (1.56–7.31)** | | | | | | | |
| Cardiovascular disease | Yes | 18 (11.2) | 24 (9.6) | 11 (12.2) | 0.591 | 0.818 | 0.483 | 0.746 |
| | No | 142 (88.8) | 226 (90.4) | 79 (87.8) | | | | |
| Chronic renal disease | Yes | 11 (6.9) | 39 (15.6) | 25 (27.8) | **0.008** | **< 0.001** | **0.011** | **< 0.001** |
| | No | 149 (93.1) | 211 (84.4) | 65 (72.2) | | | | |
| | **OR (95% CI) $_{II\ vs.\ I}$ = 2.50 (1.24–5.05), OR (95% CI)$_{III\ vs.\ I}$ = 5.21 (2.42–11.22), OR (95% CI)$_{III\ vs.\ II}$ = 2.08 (1.17–3.69)** | | | | | | | |
| Malignancy | Yes | 9 (5.6) | 10 (4.0) | 10 (11.1) | 0.445 | 0.116 | **0.014** | **0.046** |
| | No | 151 (94.4) | 240 (96.0) | 80 (88.9) | | | | |
| | **OR (95% CI)$_{III\ vs.\ II}$ = 3.00 (1.21–7.47)** | | | | | | | |

Bold items indicate an statistically significant levels.

(s) in SNP locations, the "capital" letter represents SNP-related major allele, and the small letter indicate minor allele. Accordingly, the major and minor alleles of *Apa*I [C and A (C > A), respectively] indicate as "A" and "a", *Bsm*I alleles indicate as "B" and "b", Tru9I alleles indicate as "U" and "u", TaqI alleles indicate as "T" and "t", *Bgl*I alleles indicate as "G" and "g", *Fok*I alleles indicate as "F" and "f", CDX2 alleles indicate as "C" and "c", and *Eco*RV alleles indicate as "E" and "e". It is expected that the restriction enzymes can digest PCR products of major alleles (capital letters) in SNPs *Apa*I, *Bsm*I, BglI, CDX2, and EcoRV, and digest PCR products of minor alleles (small letters) in Tru9I, TaqI, and FokI. PCR reactions were carried out in a 25 μl reaction mixture containing 12.5 μl Taq DNA Polymerase 2× Master Mix (Amplicon, DENMARK), 1 μl of each primer (10 pmol), 1 μl genomic DNA (50 ng/μl), and 9.5 μl d.d.H2O in a thermal cycler instrument (Applied Biosystems, GeneAmp 2720, Singapore) under the PCR parameters indicated in Table 2. The PCR products were examined by 1.5% agarose gel electrophoresis to ensure appropriate amplification. Subsequently, the amplified PCR products were digested with the corresponding restriction enzymes including *Apa*I, *Bsm*I, *Mse*I (isoschizomer of Tru9I enzyme), TaqI, *Bgl*I, *Fok*I, *Hpy*-CH4III (used to genotyping CDX2), and *Eco*RV following the manufacturer's instructions. Digested products were then electrophoresed on 2–3% agarose gel and the genotypes of all the SNPs were determined based on digestion patterns.

**Table 2**
Primers sequences, PCR thermocycling profile, amplicon size, and RFLP pattern of different genotypes for the selected VDR gene polymorphisms.

| SNP (RefSNPs)/other names | restriction enzymes | Primers sequences and PCR thermal profiles | Amplicon (bp) | Restriction fragments (bp) |
|---|---|---|---|---|
| rs7975232 | ApaI | Forward: 5′CTGCCGTTGAGTGTCTGTGT3′<br>Reverse: 5′TCGGCTAGCTTCTGGATCAT3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 242 | C: 191 + 51<br>A: 242 |
| rs1544410 | BsmI | Forward: 5′GGGAGACGTAGCAAAAGGAG3′<br>Reverse: 5′CCATCTCTCAGGCTCCAAAG3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 57 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 297 | G: 192 + 105<br>A: 297 |
| rs739837 | BglI | Forward: 5′CACCCAGCCCATTCTCTCTC3′<br>Reverse: 5′**GCAGGTGTCTCTGTCCCTGA**3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 248 | C: 178+ 70<br>T: 248 |
| rs731236 | TaqI | Forward: 5′CCCATGAAGCTTAGGAGGAA3′<br>Reverse: 5′TCATCTTGGCATAGAGCAGGT3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 50 s, and final extension: 72 °C for 10 min | 699 | T: 699<br>C: 604 + 95 |
| rs757343 | Tru9I/MseI | Forward: 5′CTTTGGAGCCTGAGAGATGG3′<br>Reverse: 5′CTCCAGTCCAGGAAAGCATC3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 59 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 235 | G: 235<br>A: 162 + 73 |
| rs2228570 | FokI | Forward: 5′CTGGCACTGACTCTGGCTCT3′<br>Reverse: 5′TGCTTCTTCTCCCTCCCTTT3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 247 | C: 247<br>T: 185 + 62 |
| rs11568820/CDX2 | HpyCH4III | Forward:: 5′AGGAGGGAGGGAGGAAGG3′<br>Reverse: 5′TGAGAGACATGAGCGTGGAG3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 61 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 414 | G: 254 + 110 + 50<br>A: 254 + 160 |
| rs4516035/GATA/A-1012G | EcoRV | Forward: 5′GAGGACAGGTGAAAAAGATGGGGTTC3′<br>Reverse: 5′CCTCCTCTGTAAGAGGCGAATAGCGAT3′<br>Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 68 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min | 181 | T: 154 + 27<br>C: 181 |

Bold items indicate an statistically significant levels.

### 2.3. Statistical analysis

All statistical analyses were implemented in the Statistical Package for the Social Sciences version 19 (IBM SPSS Inc., Chicago, IL, USA) and https://www.medcalc.org/calc/odds_ratio.php. The One-Sample Kolmogorov-Smirnov test was used to check the normal distribution of numerical variables. Student's unpaired *t*-tests and chi-square ($\chi^2$) tests were used to compare quantitative clinical data and qualitative demographic data between paired-groups of COVID-19, including asymptomatic *vs* mild and moderate (I *vs.* II), asymptomatic *vs.* severe/critical (I *vs.* III), and mild/moderate *vs* severe/critical groups (II *vs.* III). Odds ratios (ORs) and their associated 95% confidence intervals (95% CIs) were calculated by https://www.medcalc.org/calc/odds_ratio.php, as a measure to show the strength of associations with three groups of COVID-19, demographic data, and clinical outcomes. In all statistical tests, P-values <0.05 were considered to show statistically significant values.

## 3. Results

### 3.1. Baseline characteristics of patients

In our study, 500 COVID-19 patients were enrolled that were confirmed with a positive viral RT-PCR test, with an average age of 53.30 ± 16.16 years and 58.6% of them were men. The participants consisted of 32.0% asymptomatic patients (group I; average age 50.28 ± 16.76 years), 50.0% mild/moderate subjects (group II; average age 53.10 ± 16.10 years), and 18.0% severe/critical cases (group III; average age 59.19 ± 13.62 years). As presented in Table 1, no significant differences were found in sex ratio, defined as ($\frac{\text{No.of males}}{\text{No.of females}}$), among three groups (P = 0.161), as well as between the paired-groups I *vs* II, I *vs* III, and II *vs* III (P = 0.988, P = 0.090, and P = 0.069, respectively). However, we observed significant differences in the average age of participants among three groups (P < 0.001), and also in I than III and II *vs.* III, but not between groups I and II (I *vs.* II) (P < 0.001, P = 0.006, and P = 0.187, respectively). Significant differences were observed between groups II and III in some features, including shortness of breath, fatigue, and parageusia (P values < 0.001), but not in other variables, such as fever, sore throat, dry cough, headache, diarrhea, myalgia, nausea, and vomiting (P values >0.05).

In the case of comorbidities, we observed significant differences among three groups and also paired-groups of I-II, I-III, and II-III for diabetes, chronic renal disease, and asthma. According to these conditions, we found negative associations with the severity of COVID-19 patients. Higher remarkable frequencies of diabetes were observed in group II against group I, as well as in group III against groups I + II. Similar to diabetes, our data showed higher frequencies of chronic renal disease in group II than group I, as well as in group III than group I and also group II. Additionally, significantly higher frequencies of asthma conditions were observed in group III compared to group II. Interestingly, we found a higher frequency of asthma disease in group I *versus* group II, and the hypertension was noticeably higher in group III compared to group I and group II, but not in group pair I-II (P = 0.117). Additionally, a higher frequency of malignancy was shown in group III than group II, but not in paired-groups I-II and I-III (P = 0.445 and P = 0.116, respectively). We did not found any significant differences between/or among patients' groups for the cardiovascular disorder (P values >0.05).

### 3.2. VDR gene polymorphism genotype and allelic distribution in three various groups of COVID-19 patients

VDR gene polymorphisms were genotyped for all studied participants, and the resulted RFLP products were visualized by 2–3% agarose

gel electrophoresis (Fig. 1). Distribution of genotypes with the respective allele frequencies and associations of the *Fok*I, CDX2, and *Eco*RV or A-1012G/GATA, *Apa*I, *Bsm*I, Tru9I, TaqI, *Bgl*I VDR polymorphisms were analyzed in COVID-19 patients consisting of three groups of asymptomatic (I), mild/moderate (II), severe/critical patients (III) (Tables 3 and 4).

As it is indicated in Table 3, significant differences were found between asymptomatic (I) and symptomatic (II + III) patients in the genotypic distribution of *Fok*I SNP only in the recessive genetic model, in which wild-type allele ("F") is recessive against to mutant allele ("f"). Based on this genetic model, a significantly lower genotypic frequency of "FF vs. ff + Ff" ($P = 0.037$) was observed in symptomatic compared to asymptomatic cases. Furthermore, genotypic distributions of the FokI showed a remarkable discrepancy in severe/critical patients compared to asymptomatic cases in recessive and codominant. No significant discrepancies were observed between asymptomatic and mild/moderate patients, as well as between mild/moderate and severe/critical patients for none of the proposed genetic models. Similar to genotypes, remarkable differences were found for FokI allelic distribution between symptomatic and asymptomatic, as well as between severe/critical and asymptomatic COVID-19 subjects. No remarkable discrepancies were found between asymptomatic and mild/moderate groups, as well as mild/moderate and severe/critical patients.

The genotypic distributions of the second selected 5′-end's VDR gene polymorphism, CDX2, in three various groups of COVID-19 patients were indicated in Table 3. The allelic frequency of CDX2 polymorphism, which is known as "C" (Wild-type) and "c" (mutated), was different in asymptomatic, mild/moderate, and severe/critical patients. We observed significant discrepancies in CDX2 genotypic distribution between symptomatic (II + III) and asymptomatic (I) groups only in the recessive genetic model. Moreover, significant differences were showed in the distribution of CDX2 genotypes in severe/critical compared to asymptomatic cases in the dominant model, in the recessive model, and in the codominant model, however, the genotypic distribution of CDX2 was not significantly different in the overdominant model. CDX2 allelic distributions in three various types of COVID-19 patients demonstrated results similar to *Fok*I. The CDX2 allele frequency was found to be higher in symptomatic patients (II + III) than asymptomatic patients. Moreover, the allelic frequency of CDX2 was revealed to be significantly different in group III than group I. No significant discrepancies were identified in allelic and genotypic distribution of CDX2 SNP between mild/moderate *vs.* asymptomatic, as well as mild/moderate *vs.* severe/critical groups [P values >0.05].

*Eco*RV polymorphism was the last selected SNP located in the 5′-end of the VDR gene, which showed more complexity in allelic and genotypic distributions (Table 3). Significantly, *Eco*RV genotypes were differentially distributed between symptomatic group (II + III) and asymptomatic group in three genetic models, including recessive, overdominant, and codominant ("Ee vs. EE") genetic models ($P < 0.05$). Similarly, our results showed a significantly different EcoRV genotypic distribution in both severe/critical group and mild/moderate group against the asymptomatic group in recessive, overdominant, and codominant ("Ee *vs.* EE") models ($P < 0.05$). The EcoRV genotypic distribution showed significant deviation between severe/critical patients and mild/moderate patients in two genetic models, including overdominant and codominant ($P < 0.05$). Furthermore, our findings demonstrated the significant allelic distribution of the EcoRV SNP between whole paired groups, excluding in Group III *vs.* group II.

The first selected 3′-end VDR gene polymorphism to evaluate its association with COVID-19 patients' severity was *Apa*I. As it has been shown in Table 4, ApaI genotypic distributions were remarkably different between symptomatic group (II + III) and asymptomatic group in two genetic models, including overdominant and codominant ($P < 0.05$). Moreover, we observed significant differences in the distribution of ApaI genotypes in the severe/critical group than the mild/moderate group in the overdominant genetic model, as well as in the mild/moderate group compared to asymptomatic patients in recessive and overdominant genetic models. Amazingly, we did not find any significant discrepancies in ApaI genotypic distribution between severe/critical and asymptomatic groups in any of the proposed genetic models. Moreover, no significant differences were found in ApaI allelic distribution among three different types of COVID-19 ($P > 0.05$).

The genotypic distribution of *Bsm*I, the second studied SNP located in the 3′-end's VDR gene, revealed remarkable discrepancies only in the severe/critical group compared to the mild/moderate group for two genetic models, including recessive and overdominant models, in which wild-type allele (B) is recessive against mutant allele (b) (Table 4). As presented in Table 4, BsmI genotypic distributions were not significantly different between other COVID-19 patients' groups, including groups II & III *vs.* group I, group III *vs.* group I, group II *vs.* group I ($P > 0.05$). We also didn't found remarkable discrepancies in BsmI allelic distribution between all paired groups, except between the severe/critical group and mild/moderate group ($P < 0.05$).

As it is shown in Table 4, the genotypic distributions of Tru9I, the third studied SNP located in the 3′ end's VDR gene, were not observed significantly different for any proposed genetic models, between three groups of COVID-19 patients, including symptomatic (II + III) and asymptomatic groups, severe/critical and asymptomatic groups, mild/moderate and asymptomatic groups, and eventually, severe/critical and mild/moderate groups ($P > 0.05$). Moreover, no significant discrepancies were found in Tru9I allelic distribution between paired groups, excluding in severe/critical group compared to mild/moderate group, in which lower rates of "U" *vs.* "u" and higher rates of "u" *vs.* "U" were significantly different between groups. TaqI polymorphism was another selected SNP in the present study that is located in the 3′ end's VDR gene. As is indicated in Table 4, our data didn't reveal any remarkable




**Fig. 1.** The PCR-RFLP patterns of eight selected VDR polymorphisms. (A) Genotypes were determined from lanes 1–12 for *Apa*I, *Bsm*I, *Fok*I, and TaqI polymorphisms; (B) Genotyping results for BgII, *Hpy*CH4III, Tru9I/Msel, and EcorVI polymorphisms. The RFLP product sizes for each genotype of the selected SNPs are indicated in Table 2.

**Table 3**
Allelic and genotypic comparison of selected polymorphisms in the 5′-end of VDR gene among three different groups of COVID-19 patients.

FokI (rs2228570)

| Genotypes and alleles | Group I (%) | Group II (%) | Group III (%) |
|---|---|---|---|
| FF (%) | 75 (46.88) | 96 (38.40) | 30 (34.44) |
| Ff (%) | 66 (41.25) | 116 (46.40) | 42 (33.33) |
| ff (%) | 19 (11.87) | 38(15.20) | 18 (32.23) |
| F (%) | 216 (67.50) | 308 (61.60) | 102 (56.67) |
| f (%) | 104 (32.50) | 192 (38.40) | 78 (43.33) |
| HWE Chi-squared value* (P- value) | 0.57 (0.449) | 0.09 (0.761) | 0.22 (0.637) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | FF + Ff vs. ff | 0.68 (0.39–1.19), P = 0.181 | 0.54 (0.27–1.09), P = 0.086 | 0.72 (0.39–1.34), P = 0.294 | 0.75 (0.42–1.36), P = 0.344 |
| | ff vs. FF + Ff | 1.47 (0.84–2.56), P = 0.181 | 1.85 (0.92–3.70), P = 0.086 | 1.39 (0.75–2.56), P = 0.294 | 1.33 (0.39–2.38), P = 0.344 |
| Recessive | ff + Ff vs. FF | **1.50 (1.02–2.19), P = 0.037** | **1.77 (1.03–3.02), P = 0.038** | 1.25 (0.75–2.07), P = 0.394 | 1.42 (0.95–2.12), P = 0.090 |
| | FF vs. ff + Ff | **0.67 (0.46–0.98), P = 0.037** | **0.57 (0.33–0.97), P = 0.038** | 0.80 (0.48–1.33), P = 0.394 | 0.70 (0.47–1.05), P = 0.090 |
| Overdominant | Ff vs. FF + ff | 1.24 (0.85–1.81), P = 0.274 | 1.25 (0.74–2.10), P = 0.407 | 1.01 (0.62–1.64), P = 0.965 | 1.23 (0.83–1.84), P = 0.306 |
| | ff + FF vs. Ff | 0.81 (0.55–1.18), P = 0.274 | 0.80 (0.85–1.82), P = 0.407 | 0.99 (0.61–1.61),P = 0.965 | 0.81 (0.54–1.21),P = 0.306 |
| Codominant | ff vs. FF | 1.75 (0.97–3.18), P = 0.064 | **2.37 (1.10–5.12), P = 0.028** | 1.52 (0.76–3.04), P = 0.241 | 1.56 (0.83–2.93), P = 0.164 |
| | Ff vs. FF | 1.42 (0.95–2.14), P = 0.087 | 1.59 (0.90–2.82), P = 0.113 | 1.16 (0.68–1.99), P = 0.594 | 1.37 (0.90–2.11), P = 0.146 |
| Allelic | F vs. f | **0.73 (0.55–0.97), P = 0.028** | **0.63 (0.43–0.92), P = 0.016** | 0.82 (0.58–1.15), P = 0.246 | 0.77 (0.58–1.04), P = 0.087 |
| | f vs. F | **1.37 (1.03–1.82), P = 0.028** | **1.59 (1.09–2.33), P = 0.016** | 1.22 (0.87–1.72), P = 0.246 | 1.30 (0.96–1.72), P = 0.087 |

CDX2 (rs11568820)

| Genotypes and alleles | Group I | Group II | Group III |
|---|---|---|---|
| CC (%) | 73 (45.63) | 95 (38.00) | 28 (31.11) |
| Cc (%) | 62 (38.75) | 110 (44.00) | 37 (41.11) |
| cc (%) | 25 (15.62) | 45 (18.00) | 25 (27.78) |
| C (%) | 208 (65.00) | 300 (60.00) | 93 (51.67) |
| c (%) | 112 (35.00) | 200 (40.00) | 87 (48.33) |
| HWE Chi-squared value* (P- value) | 3.52 (0.061) | 1.74 (0.188) | 2.82 (0.093) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | CC + Cc vs. cc | 0.71 (0.43–1.18), P = 0.188 | **0.48 (0.26–0.90), P = 0.023** | 0.57 (0.33–1.00), P = 0.051 | 0.84 (0.49–1.44), P = 0.533 |
| | cc vs. CC + Cc | 1.40 (0.85–2.33), P = 0.188 | **2.08 (1.11–3.85),P = 0.023** | 1.75 (1.00–3.03), P = 0.051 | 1.19 (0.69–2.04), P = 0.533 |
| Recessive | cc + Cc vs. CC | **1.48 (1.01–2.17), P = 0.044** | **1.86 (1.08–3.20), P = 0.026** | 1.36 (0.81–2.27), P = 0.244 | 1.37 (0.92–2.05), P = 0.126 |
| | CC vs. cc + Cc | **0.68 (0.46–0.99), P = 0.044** | **0.54 (0.31–0.93), P = 0.026** | 0.74 (0.44–1.24), P = 0.244 | 0.73 (0.49–1.09), P = 0.126 |
| Overdominant | Cc vs. CC + cc | 1.20 (0.82–1.77), P = 0.343 | 1.10 (0.65–1.87), P = 0.714 | 0.89 (0.55–1.45), P = 0.635 | 1.24 (0.83–1.86), P = 0.294 |
| | CC + cc vs. Cc | 0.83 (0.57–1.22), P = 0.343 | 0.91 (0.54–1.54), P = 0.714 | 1.12 (0.69–1.82), P = 0.635 | 0.81 (0.54–1.21), P = 0.294 |
| Codominant | cc vs. CC | 1.67 (0.97–2.86), P = 0.066 | **2.63 (1.28–5.26), P = 0.008** | 1.89 (0.99–3.57), P = 0.054 | 1.39 (0.78–2.44), P = 0.270 |
| | Cc vs. CC | 1.41 (0.93–2.13), P = 0.106 | 1.56 (0.86–2.83), P = 0.146 | 1.14 (0.65–2.00), P = 0.645 | 1.36 (0.88–2.11), P = 0.163 |
| Allelic | C vs. c | **0.74 (0.56–0.97), P = 0.030** | **0.58 (0.40–0.84), P = 0.004** | 0.71 (0.51–1.00), P = 0.053 | 0.81 (0.60–1.08), P = 0.151 |
| | c vs. C | **1.35 (1.03–1.79), P = 0.030** | **1.72 (1.19–2.50), P = 0.004** | 1.41 (1.00–1.96), P = 0.053 | 1.24 (0.93–1.67), P = 0.151 |

EcoRV (rs4516035)

| Genotypes and alleles | Group I | Group II | Group III |
|---|---|---|---|
| EE (%) | 107 (66.88) | 134 (53.60) | 39 (43.33) |
| Ee (%) | 43 (26.87) | 95 (38.00) | 46 (51.11) |
| ee (%) | 10 (6.25) | 21 (8.40) | 5 (2.56) |
| E (%) | 257 (80.31) | 363 (72.60) | 124 (68.89) |
| e (%) | 63 (19.69) | 137 (27.40) | 56 (31.11) |
| HWE Chi-squared value* (P- value) | 3.61 (0.058) | 0.50 (0.478) | 3.332 (0.068) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | EE + Ee vs. ee | 0.81 (0.38–1.71), P = 0.574 | 1.13 (0.38–3.43), P = 0.823 | 1.56 (0.57–4.27), P = 0.387 | 0.73 (0.33–1.59), P = 0.423 |
| | ee vs. EE + Ee | 1.24 (0.59–2.63), P = 0.574 | 0.89 (0.29–2.63), P = 0.823 | 0.64 (0.23–1.75), P = 0.387 | 1.37 (0.63–3.00), P = 0.423 |
| Recessive | ee + Ee vs. EE | **1.95 (1.32–2.88), P < 0.001** | **2.64 (1.55–4.49), P < 0.001** | 1.51 (0.93–2.46), P = 0.096 | **1.75 (1.16–2.64), P = 0.008** |
| | EE vs. ee + Ee | **0.51 (0.35–0.76), P < 0.001** | **0.38 (0.22–0.65), P < 0.001** | 0.66 (0.41–1.08), P = 0.096 | **0.57 (0.38–0.86), P = 0.008** |
| Overdominant | Ee vs. EE + ee | **1.93 (1.28–2.91), P = 0.002** | **2.85 (1.66–4.89), P < 0.001** | **1.71 (1.05–2.77), P = 0.031** | **1.67 (1.08–2.57), P = 0.021** |
| | EE + ee vs. Ee | **0.52 (0.34–0.78), P = 0.002** | **0.35 (0.21–0.60), P < 0.001** | **0.59 (0.36–0.95), P = 0.031** | **0.60 (0.39–0.93), P = 0.021** |
| Codominant | ee vs. EE | 1.61 (0.75–3.47), P = 0.226 | 1.37 (0.44–4.27), P = 0.585 | 0.82 (0.29–2.31), P = 0.705 | 1.68 (0.76–3.71), P = 0.202 |
| | Ee vs. EE | **2.03 (1.34–3.08), P < 0.001** | **2.94 (1.69–5.11), P < 0.001** | **1.66 (1.01–2.75), P = 0.047** | **1.76 (1.14–2.74), P = 0.012** |
| Allelic | E vs. e | **0.62 (0.45–0.85), P = 0.004** | **0.54 (0.36–0.83), P = 0.004** | 0.84 (0.58–1.21), P = 0.344 | **0.65 (0.46–0.91), P = 0.013** |
| | e vs. E | **1.61 (1.18–2.22), P = 0.004** | **1.85 (1.21–2.78), P = 0.004** | 1.19 (0.83–1.72), P = 0.344 | **1.54 (1.10–2.17), P = 0.013** |

Bold items indicate an statistically significant levels.

**Table 4**
Allelic and genotypic comparison of 3′ end's VDR polymorphisms among three different groups of COVID-19 patients.

ApaI (rs7975232)

| Genotypes and Alleles | Group I (%) | Group II (%) | Group III (%) |
|---|---|---|---|
| AA (%) | 51 (31.88) | 107 (42.80) | 31 (34.44) |
| Aa (%) | 88 (55.00) | 103 (41.20) | 50 (55.56) |
| aa (%) | 21 (13.12) | 40 (16.00) | 9 (10.00) |
| A (%) | 190 (59.38) | 317 (63.40) | 112 (62.22) |
| a (%) | 130 (40.62) | 183 (36.60) | 68 (37.78) |
| HWE Chi-squared value* (P- value) | 3.14 (0.076) | 3.15 (0.076) | 2.97 (0.085) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | AA + Aa vs. aa | 0.90 (0.52–1.56), P = 0.699 | 1.36 (0.59–3.11), P = 0.467 | 1.71 (0.80–3.69), P = 0.169 | 0.79 (0.45–1.40), P = 0.426 |
| | aa vs. AA + Aa | 1.11 (0.64–1.92), P = 0.699 | 0.74 (0.32–1.70), P = 0.467 | 0.59 (0.27–1.25), P = 0.169 | 1.27 (0.71–2.22), P = 0.426 |
| Recessive | aa + Aa vs. AA | 0.69 (0.46–1.02), P = 0.062 | 0.89 (0.52–1.54), P = 0.678 | 1.42 (0.86–2.35), P = 0.167 | **0.63 (0.41–0.95), P = 0.027** |
| | AA vs. aa + Aa | 1.45 (0.98–2.17), P = 0.062 | 1.12 (0.65–1.92), P = 0.678 | 0.70 (0.43–1.16), P = 0.167 | **1.59 (1.05–2.44), P = 0.027** |
| Overdominant | Aa vs. AA + aa | **0.67 (0.46–0.98), P = 0.037** | 1.02 (0.61–1.72), P = 0.932 | **1.78 (1.10–2.90), P = 0.020** | **0.57 (0.38–0.86), P = 0.007** |
| | AA + aa vs. Aa | **1.49 (1.02–2.17), P = 0.037** | 0.98 (0.58–1.64), P = 0.932 | **0.56 (0.35–0.91), P = 0.020** | **1.75 (1.16–2.63), P = 0.007** |
| Codominant | aa vs. AA | 0.86 (0.47–1.58), P = 0.631 | 0.71 (0.29–1.73), P = 0.446 | 0.78 (0.34–1.77), P = 0.549 | 0.91 (0.49–1.70), P = 0.762 |
| | Aa vs. AA | **0.64 (0.42–0.97), P = 0.037** | 0.94 (0.53–1.65), P = 0.815 | 1.68 (0.99–2.83), P = 0.053 | **0.56 (0.36–0.87), P = 0.009** |
| Allelic | A vs. a | 1.17 (0.89–1.54), P = 0.260 | 1.13 (0.78–1.64), P = 0.532 | 0.95 (0.67–1.35), P = 0.779 | 1.19 (0.89–1.58), P = 0.247 |
| | a vs. A | 0.86 (0.65–1.12), P = 0.260 | 0.89 (0.61–1.28), P = 0.532 | 1.05 (0.74–1.49), P = 0.779 | 0.84 (0.63–1.12), P = 0.247 |

BsmI (rs1544410)

| Genotypes and alleles | Group I | Group II | Group III |
|---|---|---|---|
| BB (%) | 63 (39.38) | 112 (44.80) | 29 (32.22) |
| Bb (%) | 82 (51.25) | 119 (47.60) | 50 (55.56) |
| bb (%) | 15 (9.37) | 19 (7.60) | 11 (12.22) |
| B (%) | 208 (65.00) | 343 (68.60) | 108 (60.00) |
| b (%) | 112 (35.00) | 157 (31.40) | 72 (40.00) |
| HWE Chi-squared value* (P- value) | 2.56 (0.110) | 2.75 (0.097) | 2.23 (0.135) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | BB + Bb vs. bb | 1.07 (0.56–2.05), P = 0.841 | 0.74 (0.33–1.70), P = 0.480 | 0.59 (0.27–1.30), P = 0.189 | 1.26 (0.62–2.55), P = 0.526 |
| | bb vs. BB + Bb | 0.94 (0.49–1.79), P = 0.841 | 1.35 (0.59–3.00), P = 0.480 | 1.70 (0.77–3.70), P = 0.189 | 0.79 (0.39–1.61), P = 0.526 |
| Recessive | bb + Bb vs. BB | 0.92 (0.63–1.35), P = 0.657 | 1.37 (0.79–2.35), P = 0.261 | **1.71 (1.03–2.84), P = 0.039** | 1.38 (0.94–2.04), P = 0.104 |
| | BB vs. bb + Bb | 1.09 (0.74–1.59), P = 0.657 | 0.73 (0.43–1.27), P = 0.261 | **0.59 (0.35–0.97), P = 0.039** | 0.73 (0.49–1.06), P = 0.104 |
| Overdominant | Bb vs. BB + bb | 0.94 (0.65–1.37), P = 0.747 | 1.19 (0.71–2.00), P = 0.513 | **2.43 (1.52–3.89), P < 0.001** | 0.86 (0.58–1.29), P = 0.471 |
| | BB + bb vs. Bb | 1.06 (0.73–1.54), P = 0.747 | 0.84 (0.50–1.41), P = 0.513 | **0.41 (0.26–0.66), P < 0.001** | 1.16 (0.78–1.72), P = 0.471 |
| Codominant | bb vs. BB | 0.89 (0.45–1.78), P = 0.748 | 1.59 (0.65–3.89), P = 0.307 | 2.24 (0.96–5.22), P = 0.063 | 0.71 (0.34–1.50), P = 0.372 |
| | Bb vs. BB | 0.92 (0.62–1.37), P = 0.684 | 1.33 (0.75–2.33), P = 0.328 | 1.62 (0.96–2.74), P = 0.071 | 0.82 (0.54–1.24), P = 0.341 |
| Allelic | B vs. b | 1.06 (0.80–1.40), P = 0.681 | 0.81 (0.55–1.18), P = 0.266 | **0.69 (0.48–0.98), P = 0.037** | 1.18 (0.87–1.58), P = 0.284 |
| | b vs. B | 0.94 (0.71–1.25), P = 0.681 | 1.24 (0.85–1.82), P = 0.266 | **1.45 (1.02–2.08), P = 0.037** | 0.85 (0.63–1.15), P = 0.284 |

Tru9I (rs757343)

| Genotypes and alleles | Group I | Group II | Group III |
|---|---|---|---|
| UU (%) | 119 (74.37) | 199 (79.60) | 63 (70.00) |
| Uu (%) | 35 (21.88) | 45 (18.00) | 22 (24.44) |
| uu (%) | 6 (3.75) | 6 (2.40) | 5 (5.56) |
| U (%) | 273 (85.31) | 443 (88.60) | 148 (82.22) |
| u (%) | 47 (14.69) | 57 (11.40) | 32 (17.78) |
| HWE Chi-squared value* (P- value) | 2.59 (0.108) | 2.97 (0.085) | 2.42 (0.120) |

Odds ratio (95% CI) and P- values

| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
|---|---|---|---|---|---|
| Dominant | UU + Uu vs. uu | 1.17 (0.42–3.21), P = 0.767 | 0.66 (0.20–2.24), P = 0.507 | 0.42 (0.12–1.41), P = 0.159 | 1.58 (0.50–5.00), P = 0.433 |
| | uu vs. UU + Uu | 0.86 (0.31–2.38), P = 0.676 | 1.52 (0.45–5.00), P = 0.507 | 2.38 (0.71–8.33), P = 0.159 | 0.63 (0.20–2.00), P = 0.433 |
| Recessive | uu + Uu vs. UU | 0.86 (0.56–1.37), P = 0.511 | 1.24 (0.70–2.21), P = 0.456 | 1.67 (0.97–2.89), P = 0.065 | 0.74 (0.47–1.19), P = 0.217 |
| | UU vs. uu + Uu | 1.16 (0.73–1.79), P = 0.511 | 0.81 (0.45–1.43), P = 0.456 | 0.60 (0.35–1.03), P = 0.065 | 1.35 (0.84–1.13), P = 0.217 |
| Overdominant | Uu vs. UU + uu | 0.88 (0.53–1.39), P = 0.575 | 1.16 (0.63–2.13), P = 0.642 | 1.47 (0.83–2.63), P = 0.189 | 0.78 (0.48–1.29), P = 0.335 |
| | UU + uu vs. Uu | 1.14 (0.72–1.89), P = 0.575 | 0.86 (0.47–1.59), P = 0.642 | 0.68 (0.38–1.21), P = 0.189 | 1.28 (0.78–2.08), P = 0.335 |
| Codominant | uu vs. UU | 0.83 (0.30–2.31), P = 0.725 | 1.57 (0.46–5.36), P = 0.468 | 2.63 (0.78–8.92), P = 0.120 | 0.60 (0.19–1.90), P = 0.383 |
| | Uu vs. UU | 0.87 (0.55–1.38), P = 0.554 | 1.19 (0.64–2.20), P = 0.584 | 1.54 (0.86–2.77), P = 0.144 | 0.77 (0.47–1.26), P = 0.300 |
| Allelic | U vs. u | 1.14 (0.78–1.67), P = 0.492 | 0.80 (0.49–1.30), P = 0.364 | **0.60 (0.37–0.95), P = 0.031** | 1.34 (0.88–2.03), P = 0.169 |
| | u vs. U | 0.88 (0.60–1.28), P = 0.492 | 1.25 (0.77–2.04), P = 0.364 | **1.67 (1.05–2.70), P = 0.031** | 0.75 (0.49–1.14), P = 0.169 |

| TaqI (rs731236) | | | | |
|---|---|---|---|---|
| Genotypes and alleles | | Group I | Group II | Group III |
| TT (%) | | 87 (54.38) | 121 (48.40) | 51 (56.67) |
| Tt (%) | | 56 (35.00) | 96 (38.40) | 29 (32.22) |
| tt (%) | | 17 (10.62) | 33 (13.20) | 10 (11.11) |
| T (%) | | 230 (71.88) | 338 (67.60) | 131 (72.78) |
| t (%) | | 90 (28.13) | 162 (32.40) | 49 (27.22) |
| HWE Chi-squared value* (P- value) | | 2.89 (0.089) | 3.81 (0.051) | 3.14 (0.076) |
| Odds ratio (95% CI) and P- values | | | | |
| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
| Dominant | TT + Tt vs. tt | 0.82 (0.45–1.49), P = 0.517 | 0.95 (0.42–2.18), P = 0.905 | 1.22 (0.57–2.58), P = 0.610 | 0.78 (0.42–1.46), P = 0.438 |
| | tt vs. TT + Tt | 1.22 (0.67–2.22), P = 0.517 | 1.05 (0.46–2.38), P = 0.905 | 0.82 (0.39–1.75), P = 0.610 | 1.28 (0.69–2.38), P = 0.438 |
| Recessive | tt + Tt vs. TT | 1.16 (0.80–1.70), P = 0.429 | 0.91 (0.54–1.53), P = 0.727 | 0.72 (0.44–1.17), P = 0.179 | 1.27 (0.85–1.89), P = 0.238 |
| | TT vs. tt + Tt | 0.86 (0.59–1.25), P = 0.429 | 1.10 (0.65–1.85), P = 0.727 | 1.39 (0.86–2.27), P = 0.179 | 0.79 (0.53–1.18), P = 0.238 |
| Overdominant | Tt vs. TT + tt | 1.08 (0.73–1.60), P = 0.702 | 0.88 (0.51–1.53), P = 0.656 | 0.76 (0.46–1.27), P = 0.298 | 1.16 (0.77–1.75), P = 0.487 |
| | TT + tt vs. Tt | 0.93 (0.63–1.37), P = 0.702 | 1.14 (0.65–1.96), P = 0.656 | 1.32 (0.79–21.17), P = 0.298 | 0.86 (0.57–1.30), P = 0.487 |
| Codominant | tt vs. TT | 1.28 (0.69–2.37), P = 0.435 | 1.00 (0.43–2.36), P = 0.994 | 0.72 (0.33–1.57), P = 0.407 | 1.40 (0.73–2.67), P = 0.312 |
| | Tt vs. TT | 1.13 (0.75–1.70), P = 0.559 | 0.883 (0.50–1.56), P = 0.668 | 0.72 (0.42–1.22), P = 0.217 | 1.23 (0.80–1.89), P = 0.340 |
| Allelic | T vs. t | 0.87 (0.65–1.17), P = 0.351 | 1.05 (0.70–1.57), P = 0.829 | 1.28 (0.89–1.87), P = 0.199 | 0.82 (0.60–1.11), P = 0.196 |
| | t vs. T | 1.15 (0.59–1.54), P = 0.351 | 0.95 (0.64–1.43), P = 0.829 | 0.78 (0.54–1.12), P = 0.199 | 1.22 (0.90–1.67), P = 0.196 |

| BglI (rs739837) | | | | |
|---|---|---|---|---|
| Genotypes and alleles | | Group I | Group II | Group III |
| GG (%) | | 98 (61.25) | 160 (64.00) | 60 (66.67) |
| Gg (%) | | 56 (35.00) | 74 (29.60) | 24 (26.66) |
| gg (%) | | 6 (3.75) | 16 (6.40) | 6 (6.67) |
| G (%) | | 252 (78.75) | 394 (78.80) | 144 (80.00) |
| g (%) | | 68 (21.25) | 106 (21.20) | 36 (20.00) |
| HWE Chi-squared value* (P- value) | | 0.34 (0.563) | 3.25 (0.071) | 2.50 (0.114) |
| Odds ratio (95% CI) and P- values | | | | |
| Genetic models | | Groups II & III vs. group I | Group III vs. group I | Group III vs. group II | Group II vs. group I |
| Dominant | GG + Gg vs. gg | 0.56 (0.22–1.42), P = 0.223 | 0.55 (0.17–1.74), P = 0.307 | 0.96 (0.36–2.53), P = 0.930 | 0.57 (0.22–1.49), P = 0.251 |
| | gg vs. GG + Gg | 1.79 (0.70–4.55), P = 0.223 | 1.82 (0.58–5.88), P = 0.307 | 1.04 (0.40–2.78), P = 0.930 | 1.75 (0.67–4.55), P = 0.251 |
| Recessive | gg + Gg vs. GG | 0.86 (0.59–1.27), P = 0.454 | 0.79 (0.46–1.36), P = 0.394 | 0.89 (0.54–1.48), P = 0.650 | 0.89 (0.59–1.34), P = 0.574 |
| | GG vs. gg + Gg | 1.16 (0.79–1.70), P = 0.454 | 1.27 (0.74–2.17), P = 0.394 | 1.12 (0.68–1.85), P = 0.650 | 1.12 (0.75–1.70), P = 0.574 |
| Overdominant | Gg vs. GG + gg | 0.75 (0.51–1.12), P = 0.164 | 0.68 (0.38–1.19), P = 0.176 | 0.87 (0.50–1.49), P = 0.599 | 0.78 (0.51–1.19), P = 0.252 |
| | GG + gg vs. Gg | 1.33 (0.89–1.96), P = 0.164 | 1.47 (0.84–2.63), P = 0.176 | 1.15 (0.67–2.00), P = 0.599 | 1.28 (0.84–1.96), P = 0.252 |
| Codominant | gg vs. GG | 1.63 (0.64–4.16), P = 0.303 | 1.63 (0.50–5.30), P = 0.414 | 1.00 (0.37–2.68), P = 1.000 | 1.63 (0.62–4.32), P = 0.322 |
| | Gg vs. GG | 0.78 (0.52–1.17), P = 0.229 | 0.70 (0.39–1.25), P = 0.225 | 0.87 (0.50–1.50), P = 0.603 | 0.81 (0.53–1.24), P = 0.334 |
| Allelic | G vs. g | 1.02 (0.74–1.42), P = 0.894 | 1.08 (0.69–1.70), P = 0.741 | 1.08 (0.71–1.64), P = 0.734 | 1.00 (0.71–1.41), P = 0.986 |
| | g vs. AG | 0.98 (0.70–1.35), P = 0.894 | 0.93 (0.59–1.45), P = 0.741 | 0.93 (0.61–1.41), P = 0.734 | 1.00 (0.71–1.41), P = 0.986 |

Bold items indicate an statistically significant levels.

discrepancies in genotypic and allelic distributions of TaqI and *Bgl*I SNPs, for any recommended genetic models, between various groups of COVID-19 patients (P > 0.05).

### 3.3. Association of VDR gene polymorphisms with demographic and clinical features, and comorbidities of COVID-19 patients

We evaluate the potential association of selected VDR SNPs with various demographic and clinical features of patients, including gender, fever, sore throat, dry cough, headache, shortness of breath, diarrhea, myalgia, fatigue, nausea, vomiting, and parageusia (Tables 5 and 6). Additionally, the association of VDR gene polymorphisms with multifactorial diseases that are revealed to function as critical prognostic comorbidities including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy, were measured in three groups of COVID-19 patients (Tables 5 and 6). Our results didn't show any significant associations between studied VDR gene SNPs and the aforementioned demographic/clinical features as well as comorbidities in both asymptomatic and in the mild/moderate COVID-19 patients (P values >0.05). However, regarding the comorbidities, we found significant associations of *Eco*RV and *Bsm*I SNPs with diabetes and chronic renal disease, respectively (P < 0.001 and P = 0.010, respectively). However, no significant associations were observed between VDR polymorphisms and other comorbidities in mild/moderate patients (P values >0.05).

As presented in Table 7, remarkable differences were detected in BsmI genotypic distribution between mild/moderate patients with a positive/negative history of chronic renal disease in three genetic models, including recessive, overdominant, and codominant (P < 0.05). Similarly, significant discrepancies were identified in both allelic and genotypic distributions of EcoRV between mild/moderate patients with a positive history of diabetes *versus* cases with no diabetes, in all suggested genetic models. Accordingly, declined ratios of "EE + Ee vs. ee", "EE + ee vs. Ee", and "E vs. e" were seen in group II cases with diabetes *versus* group II cases without diabetes.

Remarkable associations between VDR gene polymorphisms with more clinical variables and comorbidities were represented in group III of COCID-19 patients (Tables 5 and 6). Regarding the signs and symptoms, significant associations were found between *Apa*I and CDX2 SNPs with shortness of breath, and Tru9I SNP with vomiting (P < 0.001, P = 0.022, and P = 0.031, respectively). Our data showed a significant association of both ApaI genotypes and alleles with shortness of breath in all proposed genetic models except the dominant model (Table 7). Our results also revealed remarkable associations of CDX2 genotypes and

**Table 5**
Association of 5′ end's VDR polymorphisms- related genotypes with different clinical data in COVID-19 patients.

| Variables | Status | FokI | | | | CDX2 | | | | EcoRV | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | FF | Ff | ff | P | CC | Cc | cc | P | EE | Ee | ee | P |
| Asymptomatic patients (group I) | | | | | | | | | | | | | |
| Gender | Male | 48 (53.3) | 30 (33.3) | 12 (13.3) | 0.070 | 41 (45.6) | 38 (42.2) | 11 (12.2) | 0.339 | 61 (67.8) | 24 (26.7) | 5 (5.6) | 0.911 |
| | Female | 27 (38.6) | 36 (51.4) | 7 (1.0) | | 32 (45.7) | 24 (34.3) | 14 (20.0) | | 46 (65.7) | 19 (27.1) | 5 (7.1) | |
| Hypertension | Yes | 9(47.4) | 9 (47.4) | 1 (5.3) | 0.609 | 9 (47.4) | 8 (42.1) | 2 (10.5) | 0.804 | 12 (63.2) | 4 (21.4) | 3 (15.8) | 0.178 |
| | No | 66 (46.8) | 57 (4.4) | 18 (12.8) | | 64 (45.4) | 54 (38.3) | 23 (16.3) | | 95 (67.4) | 39 (27.7) | 7 (5.0) | |
| Diabetes | Yes | 6(37.5) | 6 (37.5) | 4 (25.0) | 0.226 | 5 (31.2) | 8 (50.0) | 3 (18.8) | 0.473 | 13 (81.2) | 2 (12.5) | 1 (6.2) | 0.384 |
| | No | 69 (47.9) | 60 (41.7) | 15 (10.4) | | 68 (47.2) | 54 (37.5) | 22 (15.3) | | 94 (65.3) | 41 (28.5) | 9 (6.2) | |
| Asthma | Yes | 8(36.4) | 10 (45.5) | 4 (18.2) | 0.457 | 9 (40.9) | 10 (45.5) | 3 (13.6) | 0.785 | 13 (59.1) | 9 (40.9) | 0 (0.0) | 0.158 |
| | No | 67 (48.6) | 56 (40.6) | 15 (10.9) | | 64 (46.4) | 52 (37.7) | 22 (15.9) | | 94 (68.1) | 34 (24.6) | 10 (7.2) | |
| Cardiovascular disease | Yes | 6(33.3) | 10 (55.6) | 2 (11.1) | 0.405 | 8 (44.4) | 7 (38.9) | 3 (16.7) | 0.990 | 9 (50.0) | 7 (38.9) | 2 (11.1) | 0.257 |
| | No | 69 (48.6) | 56 (39.4) | 17 (12.0) | | 65 (45.8) | 55 (38.7) | 22 (15.5) | | 98 (69.0) | 36 (25.4) | 8 (5.6) | |
| Chronic renal disease | Yes | 3 (27.3) | 7 (63.6) | 1 (9.1) | 0.289 | 5 (45.5) | 5 (45.5) | 1 (9.1) | 0.795 | 10 (90.9) | 1 (9.1) | 0 (0.0) | 0.207 |
| | No | 72 (48.3) | 59 (39.6) | 18 (12.1) | | 68 (54.6) | 57 (38.3) | 24 (16.1) | | 97 (65.1) | 42 (28.2) | 10 (6.7) | |
| Malignancy | Yes | 3 (33.3) | 5 (55.6) | 1 (11.1) | 0.653 | 2 (22.2) | 4 (44.4) | 3 (33.3) | 0.208 | 7 (77.8) | 2 (22.2) | 0 (0.0) | 0.656 |
| | No | 72 (47.7) | 61 (40.4) | 18 (11.9) | | 71 (47.0) | 58 (38.4) | 22 (14.6) | | 100 (66.2) | 41 (27.2) | 10 (6.6) | |
| Mild/moderate patients (group II) | | | | | | | | | | | | | |
| Gender | Male | 52 (36.6) | 72 (50.7) | 18 (12.7) | 0.227 | 52 (36.6) | 61 (43.0) | 29 (20.4) | 0.517 | 70 (49.3) | 56 (39.4) | 16 (11.3) | 0.104 |
| | Female | 44 (40.7) | 44 (40.7) | 20 (18.5) | | 43 (39.8) | 49 (45.4) | 16 (14.8) | | 64 (59.3) | 39 (36.1) | 5 (4.6) | |
| Fever | Yes | 50 (35.5) | 65 (46.1) | 26 (18.4) | 0.227 | 58 (41.1) | 58 (41.1) | 25 (17.7) | 0.484 | 77 (54.6) | 54 (38.3) | 10 (7.1) | 0.695 |
| | No | 46 (42.2) | 51 (46.8) | 12 (11.0) | | 37 (33.9) | 52 (47.7) | 20 (18.3) | | 57 (52.3) | 41 (37.6) | 11 (10.1) | |
| Sore throat | Yes | 31 (37.8) | 37 (45.1) | 14 (17.1) | 0.845 | 28 (34.1) | 40 (48.8) | 14 (17.1) | 0.557 | 43 (52.4) | 34 (41.5) | 5 (6.1) | 0.553 |
| | No | 65 (38.7) | 79 (47.0) | 24 (14.3) | | 67 (39.9) | 70 (41.7) | 31 (18.5) | | 91 (54.2) | 61 (36.3) | 16 (9.5) | |
| Dry cough | Yes | 56 (38.9) | 69 (47.9) | 19 (13.2) | 0.580 | 61 (42.4) | 59 (41.0) | 24 (16.7) | 0.254 | 79 (54.9) | 52 (36.1) | 13 (9.0) | 0.749 |
| | No | 40 (37.7) | 47 (44.3) | 19 (17.9) | | 34 (32.1) | 51 (48.1) | 21 (19.8) | | 55 (51.9) | 43 (40.6) | 8 (7.5) | |
| Headache | Yes | 19 (38.8) | 24 (49.0) | 6 (12.2) | 0.803 | 17 (34.7) | 21 (42.9) | 11 (22.4) | 0.649 | 51 (42.9) | 23 (46.9) | 5 (10.2) | 0.243 |
| | No | 77 (38.3) | 92 (45.8) | 32 (15.9) | | 78 (38.8) | 89 (44.3) | 34 (16.9) | | 113 (56.2) | 72 (35.8) | 16 (8.0) | |
| Shortness of breath | Yes | 15 (46.9) | 10 (31.2) | 7 (21.9) | 0.167 | 10 (31.2) | 14 (43.8) | 8 (25.0) | 0.487 | 15 (46.9) | 13 (40.6) | 4 (12.5) | 0.574 |
| | No | 81 (37.2) | 106 (48.6) | 31 (14.2) | | 85 (39.0) | 96 (44.0) | 37 (17.0) | | 119 (54.6) | 82 (37.6) | 17 (7.8) | |
| Diarrhea | Yes | 6 (31.6) | 10 (52.6) | 3 (15.8) | 0.808 | 5 (26.3) | 11 (57.9) | 3 (15.8) | 0.428 | 14 (73.7) | 4 (21.1) | 1 (5.3) | 0.188 |
| | No | 90 (39.0) | 106 (45.9) | 35 (15.2) | | 90 (39.0) | 99 (42.9) | 42 (18.2) | | 120 (51.9) | 91 (31.4) | 20 (8.7) | |
| Myalgia | Yes | 21 (33.9) | 32 (51.6) | 9 (14.5) | 0.622 | 27 (43.5) | 24 (38.7) | 11 (17.7) | 0.550 | 39 (62.9) | 20 (32.3) | 3 (4.8) | 0.193 |
| | No | 75 (39.9) | 84 (44.7) | 29 (15.4) | | 68 (36.2) | 86 (45.7) | 34 (18.1) | | 95 (50.5) | 75 (39.9) | 18 (9.6) | |
| Fatigue | Yes | 8 (30.8) | 13 (50.0) | 5 (19.2) | 0.660 | 11 (42.3) | 11 (42.3) | 4 (15.4) | 0.873 | 12 (46.2) | 12 (46.2) | 2 (7.7) | 0.662 |
| | No | 88 (39.3) | 103 (46.0) | 33 (14.7) | | 84 (37.5) | 99 (44.2) | 41 (18.3) | | 122 (54.5) | 83 (37.1) | 19 (8.5) | |
| Nausea | Yes | 10 (41.7) | 10 (41.7) | 4 (16.7) | 0.887 | 7 (29.2) | 14 (58.3) | 3 (12.5) | 0.328 | 15 (62.5) | 6 (25.0) | 3 (12.5) | 0.349 |
| | No | 86 (38.1) | 116 (46.9) | 34 (15.0) | | 88 (38.9) | 96 (42.5) | 42 (18.6) | | 119 (52.7) | 89 (39.4) | 18 (8.0) | |
| Vomiting | Yes | 7 (38.9) | 9 (50.5) | 2 (11.1) | 0.847 | 9 (50.0) | 5 (27.8) | 4 (22.2) | 0.352 | 9 (50.0) | 7 (38.9) | 2 (11.1) | 0.896 |
| | No | 89 (38.4) | 107 (46.1) | 36 (15.5) | | 86 (37.1) | 105 (45.3) | 41 (17.7) | | 125 (53.9) | 88 (37.9) | 19 (8.2) | |

(continued on next page)

**Table 5** (*continued*)

| Variables | Status | FokI | | | | CDX2 | | | | EcoRV | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | FF | Ff | ff | P | CC | Cc | cc | P | EE | Ee | ee | P |
| Parageusia | Yes | 5 (41.7) | 6 (50.0) | 1 (8.3) | 0.794 | 5 (41.7) | 4 (33.3) | 3 (25.0) | 0.700 | 8 (66.7) | 3 (25.0) | 1 (8.3) | 0.618 |
| | No | 91 (38.2) | 110 (46.2) | 37 (15.5) | | 90 (37.8) | 106 (44.5) | 42 (17.6) 0.700 | | 126 (52.9) | 92 (38.7) | 20 (8.4) | |
| Hypertension | Yes | 13 (29.5) | 23 (52.3) | 8 (18.2) | 0.407 | 12 (27.3) | 20 (45.5) | 12 (27.3) | 0.123 | 26 (59.1) | 14 (31.8) | 4 (9.1) | 0.648 |
| | No | 83 (40.3) | 93 (45.1) | 30 (14.6) | | 83 (40.3) | 90 (43.7) | 33 (16.0) | | 108 (52.4) | 81 (39.3) | 17 (8.3) | |
| Diabetes | Yes | 14 (31.8) | 23 (52.3) | 7 (15.9) | 0.601 | 12 (27.3) | 22 (50.0) | 10 (22.7) | 0.257 | 11 (25.0) | 23 (52.3) | 10 (22.7) | **< 0.001** |
| | No | 82 (39.8) | 93 (45.1) | 31 (15.0) | | 83 (40.3) | 88 (42.7) | 35 (17.0) | | 123 (59.7) | 72 (35.0) | 11 (5.3) | |
| Asthma | Yes | 3 (21.4) | 8 (57.1) | 3 (21.4) | 0.395 | 6 (42.9) | 7 (50.0) | 1 (7.1) | 0.553 | 6 (42.9) | 6 (42.9) | 2 (14.3) | 0.600 |
| | No | 93 (39.4) | 108 (45.8) | 35 (14.8) | | 89 (37.7) | 103 (43.6) | 44 (18.6) | | 128 (54.2) | 89 (37.7) | 19 (8.1) | |
| Cardiovascular disease | Yes | 12 (50.0) | 7 (29.2) | 5 (20.8) | 0.204 | 9 (37.5) | 11 (45.8) | 4 (16.7) | 0.976 | 12 (50.0) | 9 (37.5) | 3 (12.5) | 0.742 |
| | No | 84 (37.2) | 109 (48.2) | 33 (14.6) | | 86 (38.1) | 99 (43.8) | 41 (18.1) | | 122 (54.0) | 86 (38.1) | 18 (8.0) | |
| Chronic renal disease | Yes | 18 (46.2) | 15 (38.5) | 6 (15.4) | 0.509 | 14 (35.9) | 19 (48.7) | 6 (15.4) | 0.793 | 20 (51.3) | 17 (43.6) | 2 (5.1) | 0.602 |
| | No | 78 (37.0) | 101 (47.9) | 32 (15.2) | | 81 (38.4) | 91 (43.1) | 39 (18.5) | | 114 (54.0) | 78 (37.0) | 19 (9.0) | |
| Malignancy | Yes | 4 (40.0) | 5 (50.0) | 1 (10.0) | 0.895 | 5 (50.0) | 5 (50.0) | 0 (0.0) | 0.308 | 7 (70.0) | 1 (10.0) | 2 (20.0) | 0.114 |
| | No | 92 (38.3) | 111 (46.2) | 37 (15.4) | | 90 (37.5) | 105 (43.8) | 45 (18.8) | | 127 (52.9) | 94 (39.2) | 19 (7.9) | |
| Severe and critical patients (group III) | | | | | | | | | | | | | |
| Gender | Male | 19 (31.1) | 27 (44.3) | 15 (24.6) | 0.286 | 16 (26.2) | 25 (41.0) | 20 (32.8) | 0.206 | 26 (42.6) | 31 (50.8) | 4 (6.6) | 0.832 |
| | Female | 11 (37.9) | 15 (51.7) | 3 (10.3) | | 12 (41.4) | 12 (41.4) | 5 (17.2) | | 13 (44.8) | 15 (51.7) | 1 (3.4) | |
| Fever | Yes | 16 (30.8) | 22 (42.3) | 14 (26.9) | 0.158 | 18 (34.6) | 23 (44.2) | 11 (21.2) | 0.256 | 23 (44.2) | 25 (48.1) | 4 (7.7) | 0.533 |
| | No | 14 (36.8) | 20 (52.6) | 4 (10.5) | | 10 (26.3) | 14 (36.8) | 14 (36.8) | | 16 (42.1) | 21 (55.3) | 1 (2.6) | |
| Sore throat | Yes | 6 (23.1) | 11 (42.3) | 9 (34.6) | 0.074 | 6 (23.1) | 11 (42.3) | 9 (34.6) | 0.500 | 12 (46.2) | 12 (46.2) | 2 (7.7) | 0.762 |
| | No | 24 (37.5) | 31 (48.4) | 9 (14.1) | | 22 (34.4) | 26 (40.6) | 16 (25.0) | | 27 (42.2) | 34 (53.1) | 3 (4.7) | |
| Dry cough | Yes | 10 (22.7) | 22 (50.0) | 12 (27.3) | 0.068 | 15 (34.1) | 16 (36.4) | 13 (29.5) | 0.665 | 22 (50.0) | 19 (43.2) | 3 (6.8) | 0.335 |
| | No | 20 (43.5) | 20 (43.5) | 6 (13.0) | | 13 (28.3) | 21 (45.7) | 12 (26.1) | | 17 (37.0) | 27 (58.7) | 2 (4.3) | |
| Headache | Yes | 2 (20.0) | 6 (60.0) | 2 (20.0) | 0.598 | 3 (30.0) | 5 (50.0) | 2 (20.0) | 0.792 | 5 (50.0) | 3 (30.0) | 2 (20.0) | 0.070 |
| | No | 28 (35.0) | 36 (45.0) | 16 (20.0) | | 25 (31.2) | 32 (40.0) | 23 (28.7) | | 34 (42.5) | 43 (53.8) | 3 (3.8) | |
| Shortness of breath | Yes | 19 (32.2) | 27 (45.8) | 13 (22.0) | 0.799 | 22 (37.3) | 26 (44.1) | 11 (18.6) | **0.022** | 29 (49.2) | 26 (44.1) | 4 (6.8) | 0.177 |
| | No | 11 (35.5) | 15 (48.4) | 5 (16.1) | | 6 (19.4) | 11 (35.5) | 14 (45.2) | | 10 (32.3) | 20 (64.5) | 1 (3.2) | |
| Diarrhea | Yes | 3 (27.3) | 5 (45.5) | 3 (27.3) | 0.789 | 4 (36.4) | 3 (27.3) | 4 (36.4) | 0.598 | 4 (36.4) | 6 (54.5) | 1 (9.1) | 0.798 |
| | No | 27 (34.2) | 37 (46.8) | 15 (19.0) | | 24 (30.4) | 34 (43.0) | 21 (26.6) | | 35 (44.3) | 40 (50.6) | 4 (5.1) | |
| Myalgia | Yes | 5 (29.4) | 8 (47.1) | 4 (23.5) | 0.892 | 4 (23.5) | 9 (52.9) | 4 (23.5) | 0.539 | 6 (35.3) | 9 (52.9) | 2 (11.8) | 0.410 |
| | No | 25 (34.2) | 34 (46.6) | 14 (19.2) | | 24 (32.9) | 28 (38.4) | 21 (27.8) | | 33 (45.2) | 37 (50.7) | 3 (4.1) | |
| Fatigue | Yes | 12 (38.7) | 13 (41.9) | 6 (19.4) | 0.724 | 12 (38.7) | 12 (38.7) | 7 (22.6) | 0.496 | 16 (51.6) | 14 (45.2) | 1 (3.2) | 0.464 |
| | No | 18 (30.5) | 29 (49.2) | 12 (20.3) | | 16 (27.1) | 25 (42.4) | 18 (30.5) | | 23 (39.) | 32 (54.2) | 4 (6.8) | |
| Nausea | Yes | 4 (26.7) | 8 (53.3) | 3 (20.0) | 0.814 | 5 (33.3) | 3 (20.0) | 7 (46.7) | 0.117 | 4 (26.7) | 10 (66.7) | 1 (6.7) | 0.360 |
| | No | 26 (34.7) | 34 (45.3) | 15 (20.0) | | 23 (30.7) | 34 (45.3) | 18 (24.0) | | 35 (46.7) | 36 (48.0) | 4 (5.3) | |
| Vomiting | Yes | 2 (18.2) | 7 (63.6) | 2 (18.2) | 0.437 | 0 (0.0) | 6 (54.5) | 5 (45.5) | 0.053 | 4 (36.4) | 6 (54.5) | 1 (9.1) | 0.798 |
| | No | 28 (35.4) | 35 (44.3) | 16 (20.3) | | 28 (35.4) | 31 (39.2) | 20 (25.3) | | 35 (44.3) | 40 (50.6) | 4 (5.1) | |
| Parageusia | Yes | 12 (46.2) | 11 (42.3) | 3 (11.5) | 0.196 | 8 (30.8) | 11 (42.3) | 7 (26.9) | 0.988 | 10 (38.5) | 15 (57.7) | 1 (3.8) | 0.704 |
| | No | 18 (21.8) | 31 (48.4) | 15 (23.4) | | 20 (31.2) | 26 (40.6) | 18 (28.1) | | 29 (45.3) | 31 (48.4) | 4 (6.2) | |
| Hypertension | Yes | 14 (31.1) | 17 (37.8) | 14 (31.1) | **0.027** | 15 (33.3) | 13 (28.9) | 17 (37.8) | **0.036** | 15 (33.3) | 27 (60.0) | 3 (6.7) | 0.160 |
| | No | | | 4 (8.9) | | | | 8 (17.8) | | | | 2 (4.4) | |

(*continued on next page*)

**Table 5** (*continued*)

| Variables | Status | FokI | | | | CDX2 | | | | EcoRV | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | FF | Ff | ff | P | CC | Cc | cc | P | EE | Ee | ee | P |
| | | 16 (35.6) | 25 (55.6) | | | 13 (28.9) | 24 (53.3) | | | 24 (53.3) | 19 (42.2) | | |
| Diabetes | Yes | 12 (37.5) | 12 (37.5) | 8 (25.0) | 0.412 | 8 (25.0) | 10 (31.2) | 14 (43.8) | **0.042** | 9 (28.1) | 22 (68.8) | 1 (3.1) | **0.045** |
| | No | 18 (31.0) | 30 (51.7) | 10 (17.2) | | 20 (34.5) | 27 (46.6) | 11 (19.0) | | 30 (51.7) | 24 (41.4) | 4 (6.9) | |
| Asthma | Yes | 7 ()46.7 | 5 (33.3) | 3 (20.0) | 0.439 | 4 (26.7) | 8 (53.3) | 3 (20.0) | 0.560 | 8 (53.3) | 6 (40.0) | 1 (6.7) | 0.641 |
| | No | 23 (30.7) | 37 (49.3) | 15 (20.0) | | 24 (32.0) | 29 (38.7) | 22 (29.3) | | 31 (41.3) | 40 (53.3) | 4 (5.3) | |
| Cardiovascular disease | Yes | 4 (36.4) | 3 (27.3) | 4 (36.4) | 0.256 | 6 (54.5) | 4 (36.4) | 1 (9.1) | 0.145 | 6 (54.5) | 5 (45.5) | 0 (0.0) | 0.566 |
| | No | 26 (32.9) | 39 (49.4) | 14 (17.7) | | 22 (27.8) | 33 (41.8) | 24 (30.4) | | 33 (41.8) | 41 (51.9) | 5 (6.3) | |
| Chronic renal disease | Yes | 8 (32.0) | 10 (40.0) | 17 (28.0) | 0.483 | 10 (40.0) | 10 (40.0) | 5 (20.0) | 0.440 | 10 (40.0) | 15 (60.0) | 0 (0.0) | 0.280 |
| | No | 22 (33.8) | 32 (49.2) | 11 (16.9) | | 18 (27.7) | 27 (41.5) | 20 (30.8) | | 29 (44.6) | 31 (47.7) | 5 (7.7) | |
| Malignancy | Yes | 2 (20.0) | 5 (50.0) | 3 (30.0) | 0.552 | 3 (30.0) | 5 (50.0) | 2 (20.0) | 0.792 | 4 (40.0) | 5 (50.0) | 1 (10.0) | 0.675 |
| | No | 28 (35.0) | 37 (46.2) | 15 (18.8) | | 25 (31.2) | 32 (40.0) | 23 (28.7) | | 34 (42.5) | 42 (52.5) | 4 (5.0) | |

Bold items indicate an statistically significant levels.

alleles with shortness of breath in dominant and codominant genetic models (Table 7). It was shown that rates of "CC + Cc vs. cc" and "C vs. c" were higher in severe/critical patients with shortness of breath, while the frequency of "cc vs. CC + Cc", "cc vs. CC", and "c vs. C" were lower.

Additionally, significant associations were observed between VDR gene variants and more comorbidities in severe/critical COVID-19 patients, including ApaI and asthma (P = 0.034), *Bsm*I and chronic renal disease (P = 0.014), *Fok*I and hypertension (P = 0.027), CDX2 and both hypertension and diabetes (P = 0.36 and P = 0.42, respectively), *Eco*RV and diabetes (P = 0.045) (Tables 5 and 6). As presented in Table 7, a significant association was found between ApaI and asthma in severe/critical COVID-19 patients only in the dominant genetic model, in which diminished proportion of the "AA + Aa vs. aa" and elevated proportion of the "aa vs. AA + Aa" were disclosed. Regarding the BsmI SNP, significant associations were found with chronic renal disease in dominant and codominant genetic models. Accordingly, a higher amount of "bb vs. BB + Bb" and "bb vs. BB" were found in severe/critical patients with chronic renal disease than those didn't have this comorbidity, while "BB + Bb vs. bb" was lower. The association of FokI genotypic distribution with hypertension was significant in severe/critical patients in dominant and codominant genetic models. The data revealed a reduced rate of "FF + Ff vs. ff", but increased rates of the "ff vs. FF + Ff" and "ff vs. FF" in group III patients with hypertension compared to negative hypertension history (Table 7). The results of the present study showed a significant CDX2 genotypic discrepancies in severe/critical patients with hypertension in dominant and overdominant genetic models, as well as cases with diabetes in dominant and codominant models compared to negative cases for these comorbidities (Table 7). Significantly, higher frequency of "cc vs. CC + Cc" and "CC + cc vs. Cc" were observed in group III COVID-19 patients with hypertension than patients with negative history of hypertension, while the frequency of "CC + Cc vs. cc" and "Cc vs. CC + cc" were considered to be reduced. Additionally, the results showed significantly increased amounts of "cc *vs.* CC + Cc", "cc vs. CC", and "c vs. C", and decreased frequency of "CC + Cc *vs.* cc" and "C vs. c" in severe/critical COVID-19 patients with diabetes compared to patients without diabetes. Finally, we observed significant association of *Eco*RV with diabetes in severe/critical patients in recessive, overdominant, and codominant genetic models, in which higher proportions of "ee + Ee vs. EE", "Ee vs. EE + ee", and "Ee vs. EE" were found in group III patients with diabetes than negative diabetes cases, while proportions of the "EE vs. ee + Ee" and "EE + ee vs. Ee" were lower (Table 7).

To improve the validity of achieved results, we evaluate the potential association of selected VDR SNPs with signs/symptoms and with comorbidities in all symptomatic COVID-19 patients by combining whole data, regardless of the types of COVID-19 ($N = 340$ cases, $N = 500$ cases, respectively). As presented in Table 8, interesting associations of VDR SNPs with symptoms and comorbidities were found that are briefly mentioned: *Apa*I with fever and asthma (P = 0.001 and P = 0.023, respectively), *Bsm*I with chronic renal disease (P = 0.029), Tru9I with shortness of breath and hypertension (P = 0.040 and P = 0.003, respectively), *Fok*I with fever and hypertension (P = 0.042 and P = 0.045, respectively), CDX2 with headache, hypertension, and diabetes (P = 0.019, P = 0.005 and P = 0.015, respectively), and EcoRV with diabetes (P < 0.001).

As detailed in Table 9, the observed associations of genotypic and allelic VDR polymorphisms with signs, symptoms, and comorbidities of COVID-19 patients (regardless of the group of disease) strongly depend on the genetic models. For instance, significant associations of both allelic and genotypic distributions with the fever of COVID-19 patients were detected in recessive, overdominant, and codominant genetic models. Additionally, we found a remarkable association of ApaI genotypic distribution with asthma in dominant and overdominant genetic models, but not in recessive and overdominant models, as well as in allelic distribution. Similar to our finding in the earlier section, significant differences in the distribution of genotypes were revealed between COVID-19 patients with the chronic renal disease compared to negative cases only in dominant and overdominant genetic models. Accordingly, a higher frequency of "bb vs. BB + Bb" and "BB + bb vs. Bb" were found, while the frequency of "BB + Bb vs. bb" and "Bb vs. BB + bb" were decreased. Despite the no significant association of Tru9I polymorphism with clinical characteristics in various groups of COVID-19 patients, significant associations of Tru9I with shortness of breath in the combined population of COVID-19 patients were found in recessive, codominant, as well as allelic genetic models. According to Table 9, increased rates of "uu + Uu vs. UU", "Uu vs. UU", and "u vs. U", and decreased rates of "UU vs. uu + Uu" and "U vs. u" were seen in COVID-19 patients with shortness of breath *versus* those who didn't have this symptom. The higher frequency of *Fok*I variant showed significant associations with fever and hypertension in dominant, codominant, and allelic models, but not in recessive and overdominant genetic models (Table 9).

Moreover, CDX2 polymorphism was disclosed to have significant associations with three clinical features, including headache, hypertension, and diabetes. In respect of headache and hypertension, significant differences were illustrated in the allelic distribution, as well as in the dominant and codominant models for genotypic distributions, but not in recessive and overdominant genetic models (Table 9). According to both headache and hypertension features, the results revealed

**Table 6**
Association of 3′ end's VDR polymorphisms- related genotypes with different clinical data in COVID-19 patients.

| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| Asymptomatic patients (group I) | | | | | | | | | | | | | | | | | | | | | |
| Gender | Male | 29 (32.2) | 47 (52.2) | 14 (15.6) | 0.543 | 34 (37.8) | 44 (48.9) | 12 (13.3) | 0.150 | 70 (77.8) | 17 (18.9) | 3 (3.3) | 0.534 | 46 (51.1) | 36 (40.0) | 8 (8.9) | 0.293 | 52 (57.8) | 33 (36.7) | 5 (5.6) | 0.308 |
| | Female | 22 (31.4) | 41 (58.6) | 7 (10.0) | | 29 (41.4) | 38 (54.3) | 3 (4.3) | | 49 (70.0) | 18 (21.9) | 3 (4.3) | | 41 (58.6) | 20 (28.6) | 9 (12.9) | | 46 (65.7) | 23 (32.9) | 1 (1.4) | |
| Hypertension | Yes | 4 (21.1) | 13 (68.4) | 2 (10.5) | 0.447 | 11 (57.9) | 7 (36.8) | 1 (5.3) | 0.208 | 16 (84.2) | 3 (15.8) | 0 (0.0) | 0.483 | 11 (57.9) | 6 (31.6) | 2 (10.5) | 0.941 | 13 (68.4) | 5 (26.3) | 1 (5.3) | 0.678 |
| | No | 47 (33.3) | 75 (53.2) | 19 (13.5) | | 52 (36.9) | 75 (53.2) | 14 (9.9) | | 103 (73.0) | 32 (22.7) | 6 (4.3) | | 76 (53.9) | 50 (35.5) | 15 (10.6) | | 85 (60.3) | 51 (36.2) | 5 (3.5) | |
| Diabetes | Yes | 5 (31.2) | 8 (50.0) | 3 (18.8) | 0.774 | 8 (50.0) | 7 (43.8) | 1 (6.2) | 0.641 | 13 (81.2) | 3 (18.8) | 0 (0.0) | 0.651 | 6 (37.5) | 9 (56.2) | 1 (6.2) | 0.170 | 8 (50.0) | 8 (50.0) | 0 (0.0) | 0.337 |
| | No | 46 (31.9) | 80 (55.6) | 18 (12.5) | | 55 (38.2) | 75 (52.1) | 14 (9.7) | | 106 (73.6) | 32 (22.2) | 6 (4.2) | | 81 (56.2) | 47 (32.6) | 16 (11.1) | | 90 (62.5) | 48 (33.3) | 6 (4.2) | |
| Asthma | Yes | 8 (36.4) | 10 (45.5) | 4 (18.2) | 0.583 | 11 (50.0) | 9 (40.9) | 2 (9.1) | 0.531 | 16 (72.7) | 5 (22.7) | 1 (4.5) | 0.970 | 13 (59.1) | 8 (36.4) | 1 (4.5) | 0.605 | 13 (59.1) | 8 (36.4) | 1 (4.5) | 0.963 |
| | No | 43 (31.2) | 78 (56.5) | 17 (12.3) | | 52 (37.7) | 73 (52.9) | 13 (9.4) | | 103 (74.6) | 30 (21.7) | 5 (3.6) | | 74 (3.6) | 48 (34.8) | 16 (11.6) | | 85 (61.6) | 48 (34.8) | 5 (3.6) | |
| Cardiovascular disease | Yes | 5 (27.8) | 10 (55.6) | 3 (16.7) | 0.860 | 9 (50.0) | 7 (38.9) | 2 (11.1) | 0.535 | 15 (83.3) | 3 (16.7) | 0 (0.0) | 0.540 | 11 (61.1) | 5 (27.8) | 2 (11.1) | 0.788 | 13 (72.2) | 4 (22.2) | 1 (5.6) | 0.467 |
| | No | 46 (32.4) | 78 (54.9) | 18 (12.7) | | 54 (38.0) | 75 (52.8) | 13 (9.2) | | 104 (73.2) | 32 (22.5) | 6 (4.2) | | 76 (53.5) | 51 (35.9) | 15 (10.6) | | 85 (59.9) | 52 (36.6) | 5 (3.5) | |
| Chronic renal disease | Yes | 3 (27.3) | 7 (63.6) | 1 (9.1) | 0.825 | 5 (45.5) | 6 (54.5) | 0 (0.0) | 0.537 | 8 (72.7) | 3 (27.3) | 0 (0.0) | 0.739 | 6 (54.5) | 4 (36.4) | 1 (9.1) | 0.984 | 6 (54.5) | 5 (45.5) | 0 (0.0) | 0.638 |
| | No | 48 (32.2) | 81 (54.4) | 20 (13.4) | | 58 (38.9) | 76 (51.0) | 15 (10.1) | | 111 (74.5) | 32 (21.5) | 6 (4.0) | | 81 (54.5) | 52 (34.9) | 16 (10.7) | | 92 (61.7) | 51 (34.2) | 6 (4.0) | |
| Malignancy | Yes | 4 (44.4) | 3 (33.3) | 2 (2.22) | 0.389 | 6 (66.7) | 3 (33.3) | 0 (0.0) | 0.193 | 5 (55.6) | 4 (44.4) | 0 (0.0) | 0.220 | 4 (44.4) | 4 (44.4) | 1 (11.1) | 0.811 | 5 (55.6) | 4 (44.4) | 0 (0.0) | 0.722 |
| | No | 47 (31.1) | 85 (56.3) | 19 (12.6) | | 57 (37.7) | 79 (52.3) | 15 (9.9) | | 114 (75.5) | 31 (20.5) | 6 (4.0) | | 83 (55.0) | 52 (34.4) | 16 (10.6) | | 93 (61.6) | 52 (34.4) | 6 (4.0) | |
| Mild/moderate patients (group II) | | | | | | | | | | | | | | | | | | | | | |
| Gender | Male | 60 (42.3) | 59 (41.5) | 23 (16.2) | 0.980 | 63 (44.4) | 68 (47.9) | 11 (7.7) | 0.986 | 112 (78.9) | 26 (18.3) | 4 (2.8) | 0.870 | 71 (50.0) | 49 (34.5) | 22 (15.5) | 0.249 | 96 (67.6) | 39 (27.5) | 7 (4.9) | 0.319 |
| | Female | 47 (43.5) | 44 (40.7) | 17 (15.7) | | 49 (45.4) | 51 (47.2) | 8 (7.4) | | 87 (80.6) | 19 (17.6) | 2 (1.9) | | 50 (46.3) | 47 (43.5) | 11 (10.2) | | 64 (59.3) | 35 (32.4) | 9 (8.3) | |
| Fever | Yes | 59 (41.8) | 60 (42.6) | 22 (15.6) | 0.885 | 60 (42.6) | 70 (49.6) | 11 (7.8) | 0.717 | 108 (76.6) | 29 (20.6) | 4 (2.8) | 0.405 | 61 (43.3) | 62 (44.0) | 18 (12.8) | 0.109 | 82 (58.2) | 50 (35.5) | 9 (6.4) | 0.065 |
| | No | 48 (44.0) | 43 (39.4) | 18 (16.5) | | 52 (47.7) | 49 (45.0) | 8 (7.3) | | 91 (83.5) | 16 (14.7) | 2 (1.8) | | 60 (55.0) | 34 (31.2) | 15 (13.8) | | 78 (71.6) | 24 (22.0) | 7 (6.4) | |
| Sore throat | Yes | 39 (47.6) | 31 (37.8) | 12 (14.6) | 0.568 | 34 (41.5) | 42 (51.2) | 6 (7.3) | 0.722 | 71 (86.6) | 9 (11.0) | 2 (2.4) | 0.129 | 37 (41.5) | 32 (39.0) | 13 (15.9) | 0.627 | 52 (63.4) | 24 (29.3) | 6 (7.3) | 0.918 |
| | No | 68 (40.5) | 72 (42.9) | 28 (16.7) | | 78 (46.4) | 77 (45.8) | 13 (7.7) | | 128 (76.2) | 36 (21.4) | 4 (2.4) | | 84 (50.0) | 64 (38.1) | 20 (11.9) | | 108 (64.3) | 50 (29.8) | 10 (6.0) | |
| Dry cough | Yes | 62 (43.1) | 59 (41.0) | 23 (16.0) | 0.995 | 64 (44.4) | 70 (48.6) | 10 (6.9) | 0.872 | 111 (77.1) | 30 (208) | 3 (2.1) | 0.382 | 72 (50.0) | 50 (34.7) | 22 (15.3) | 0.288 | 92 (63.9) | 43 (29.9) | 9 (6.2) | 0.990 |
| | No | 45 (42.5) | 44 (41.5) | 17 (16.0) | | 48 (45.3) | 49 (46.2) | 9 (8.5) | | 88 (83.0) | 15 (14.2) | 3 (2.8) | | 49 (46.2) | 46 (43.4) | 11 (10.4) | | 68 (64.2) | 31 (29.2) | 7 (6.6) | |
| Headache | Yes | 23 (46.9) | 17 (34.7) | 9 (18.4) | 0.582 | 21 (42.9) | 24 (49.0) | 4 (8.2) | 0.951 | 40 (81.6) | 7 (14.3) | 2 (4.1) | 0.544 | 26 (53.1) | 18 (36.7) | 5 (10.2) | 0.694 | 34 (69.4) | 13 (26.5) | 2 (4.1) | 0.612 |
| | No | 84 (41.8) | 86 (42.8) | 31 (15.4) | | 91 (45.3) | 95 (47.3) | 15 (7.5) | | 159 (79.1) | 38 (18.9) | 4 (2.0) | | 95 (47.3) | 78 (38.8) | 28 (13.9) | | 126 (62.7) | 61 (30.3) | 14 (7.0) | |
| Shortness of breath | Yes | 14 (43.8) | 13 (40.6) | 5 (15.6) | 0.993 | 17 (53.1) | 12 (37.5) | 3 (9.4) | 0.471 | 27 (84.4) | 5 (15.6) | 0 (0.0) | 0.577 | 15 (46.9) | 12 (37.5) | 6 (15.6) | 0.910 | 23 (71.9) | 7 (21.9) | 2 (6.2) | 0.578 |

(*continued on next page*)

**Table 6** (*continued*)

| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| | No | 93 (42.7) | 90 (41.3) | 35 (16.1) | | 95 (43.6) | 107 (49.1) | 16 (7.3) | | 172 (78.9) | 40 (18.3) | 6 (2.8) | | 106 (48.6) | 84 (38.5) | 28 (12.8) | | 137 (62.8) | 67 (30.7) | 14 (6.4) | |
| Diarrhea | Yes | 9 (47.4) | 7 (36.8) | 3 (15.8) | 0.907 | 10 (52.6) | 8 (42.1) | 1 (5.3) | 0.756 | 15 (78.9) | 4 (21.1) | 0 (0.0) | 0.740 | 9 (47.4) | 6 (31.6) | 4 (21.1) | 0.545 | 15 (78.9) | 4 (21.1) | 0 (0.0) | 0.281 |
| | No | 98 (42.4) | 96 (41.6) | 37 (16.0) | | 102 (44.2) | 111 (48.1) | 18 (7.8) | | 184 (79.7) | 41 (17.7) | 6 (2.6) | | 112 (48.5) | 90 (39.0) | 29 (12.6) | | 145 (62.8) | 70 (30.3) | 16 (6.9) | |
| Myalgia | Yes | 26 (41.9) | 30 (48.4) | 6 (9.7) | 0.211 | 26 (41.9) | 31 (50.0) | 5 (8.1) | 0.872 | 48 (77.4) | 14 (22.6) | 0 (0.0) | 0.224 | 29 (46.8) | 27 (43.5) | 6 (9.7) | 0.499 | 45 72.6() | 12 (19.4) | 5 (8.1) | 0.121 |
| | No | 81 (43.1) | 73 (38.8) | 34 (18.1) | | 86 (45.7) | 88 (46.8) | 14 (7.4) | | 151 (80.3) | 31 (16.5) | 6 (3.2) | | 92 (48.9) | 69 (36.7) | 27 (14.4) | | 115 (61.2) | 62 (33.0) | 11 (5.9) | |
| Fatigue | Yes | 11 (42.3) | 12 (46.2) | 3 (11.5) | 0.765 | 11 (42.3) | 14 (53.8) | 1 (3.8) | 0.665 | 19 (73.1) | 6 (23.1) | 1 (3.8) | 0.662 | 10 (38.5) | 12 (46.2) | 4 (15.4) | 0.562 | 17 (65.4) | 7 (26.9) | 2 (7.7) | 0.926 |
| | No | 96 (42.9) | 91 (40.6) | 37 (16.5) | | 101 (45.1) | 105 (46.9) | 18 (8.0) | | 180 (80.4) | 39 (17.4) | 5 (2.2) | | 111 (49.6) | 84 (37.5) | 29 (12.9) | | 143 (63.8) | 67 (29.9) | 14 (6.2) | |
| Nausea | Yes | 8 (33.3) | 11 (45.8) | 5 (20.8) | 0.582 | 9 (37.5) | 14 (58.3) | 1 (4.2) | 0.504 | 17 (70.8) | 6 (25.0) | 1 (4.2) | 0.516 | 9 (37.5) | 14 (58.3) | 1 (4.2) | 0.080 | 16 (66.7) | 6 (25.0) | 2 (8.3) | 0.829 |
| | No | 99 (43.8) | 92 (40.7) | 35 (15.5) | | 103 (45.6) | 105 (46.5) | 18 (8.0) | | 182 (80.5) | 39 (17.3) | 5 (2.4) | | 112 (49.6) | 82 (36.3) | 32 (14.2) | | 144 (63.7) | 68 (30.1) | 14 (6.2) | |
| Vomiting | Yes | 8 (44.4) | 6 (33.3) | 4 (22.2) | 0.679 | 6 (33.3) | 11 (61.1) | 1 (5.6) | 0.492 | 16 (88.9) | 2 (11.1) | 0 (0.0) | 0.552 | 9 (50.0) | 9 (50.0) | 0 (0.0) | 0.197 | 13 (72.2) | 4 (22.2) | 1 (5.6) | 0.747 |
| | No | 99 (42.7) | 7 (41.8) | 36 (15.5) | | 106 (45.7) | 108 (46.6) | 18 (7.8) | | 183 (78.9) | 43 (18.5) | 6 (2.6) | | 112 (48.3) | 87 (37.5) | 33 (14.2) | | 147 (63.4) | 70 (30.2) | 15 (6.5) | |
| Parageusia | Yes | 7 (58.3) | 3 (25.0) | 2 (16.7) | 0.468 | 5 (41.7) | 6 (50.0) | 1 (8.3) | 0.974 | 9 (75.0) | 3 (25.0) | 0 (0.0) | 0.712 | 8 (66.7) | 4 (33.3) | 0 (0.0) | 0.270 | 7 (58.3) | 5 (41.7) | 0 (0.0) | 0.475 |
| | No | 100 (42.0) | 100 (42.0) | 38 (16.0) | | 107 (45.0) | 113 (47.5) | 18 (7.6) | | 190 (79.8) | 42 (17.6) | 6 (2.5) | | 113 (47.5) | 92 (38.7) | 33 (13.9) | | 153 (64.3) | 69 (29.0) | 16 (6.7) | |
| Hypertension | Yes | 16 (36.4) | 19 (43.2) | 9 (20.5) | 0.541 | 17 (38.6) | 24 (54.5) | 3 (6.8) | 0.595 | 31 (70.5) | 12 (27.3) | 1 (2.3) | 0.211 | 19 (43.2) | 20 (45.5) | 5 (11.4) | 0.569 | 28 (63.6) | 13 (29.5) | 3 (6.8) | 0.992 |
| | No | 91 (44.2) | 84 (40.8) | 31 (15.0) | | 95 (46.1) | 95 (46.1) | 16 (7.8) | | 168 (81.6) | 33 (16.0) | 5 (2.4) | | 102 (49.5) | 76 (36.9) | 28 (13.6) | | 132 (64.1) | 61 (29.6) | 16 (6.3) | |
| Diabetes | Yes | 18 (40.9) | 21 (47.7) | 5 (11.4) | 0.518 | 22 (50.0) | 18 (40.9) | 4 (9.1) | 0.612 | 35 (79.5) | 8 (18.2) | 1 (2.3) | 0.998 | 17 (38.6) | 20 (45.5) | 7 (15.9) | 0.360 | 29 (65.9) | 12 (27.3) | 3 (6.8) | 0.931 |
| | No | 89 (43.2) | 82 (39.8) | 35 (17.0) | | 90 (43.7) | 101 (49.0) | 15 (7.3) | | 164 (79.6) | 37 (18.0) | 5 (2.4) | | 104 (50.5) | 76 (36.9) | 26 (12.6) | | 131 (63.6) | 62 (30.1) | 13 (6.3) | |
| Asthma | Yes | 6 (42.9) | 5 (35.7) | 3 (21.4) | 0.826 | 7 (50.0) | 7 (50.0) | 0 (0.0) | 0.539 | 10 (71.4) | 3 (21.4) | 1 (7.1) | 0.447 | 5 (35.7) | 6 (42.9) | 3 (21.4) | 0.514 | 9 (64.3) | 3 (21.4) | 2 (14.3) | 0.412 |
| | No | 101 (42.8) | 98 (41.5) | 37 (15.7) | | 105 (44.5) | 112 (47.5) | 19 (8.1) | | 189 (80.1) | 42 (17.8) | 5 (2.1) | | 116 (49.2) | 90 (38.1) | 30 (12.7) | | 151 (64.0) | 71 (30.1) | 14 (5.9) | |
| Cardiovascular disease | Yes | 9 (37.5) | 13 (54.2) | 2 (8.3) | 0.327 | 13 (54.2) | 9 (37.5) | 2 (8.3) | 0.575 | 19 (79.2) | 3 (12.5) | 2 (8.3) | 0.114 | 9 (37.5) | 11 (45.8) | 4 (16.7) | 0.528 | 14 (58.3) | 9 (37.5) | 1 (4.2) | 0.638 |
| | No | 98 (43.4) | 90 (39.8) | 38 (16.8) | | 99 (43.8) | 110 (48.7) | 17 (7.5) | | 180 (79.6) | 42 (18.6) | 4 (1.8) | | 112 (49.6) | 85 (37.6) | 29 (12.8) | | 146 (64.6) | 65 (28.8) | 15 (6.6) | |
| Chronic renal disease | Yes | 17 (43.6) | 15 (38.5) | 7 (17.9) | 0.905 | 24 (61.5) | 10 (25.6) | 5 (12.8) | **0.010** | 33 (84.6) | 6 (15.4) | 0 (0.0) | 0.489 | 18 (46.2) | 19 (48.7) | 2 (5.1) | 0.164 | 27 (69.2) | 9 (23.1) | 3 (7.7) | 0.612 |
| | No | 90 (42.7) | 88 (41.7) | 33 (15.6) | | 88 (41.7) | 109 (51.7) | 14 (6.6) | | 166 (78.7) | 39 (18.5) | 6 (2.8) | | 103 (48.8) | 77 (36.5) | 31 (14.7) | | 133 (63.0) | 65 (30.8) | 13 (6.2) | |
| Malignancy | Yes | 3 (30.0) | 4 (40.0) | 3 (30.0) | 0.432 | 6 (60.0) | 3 (30.0) | 1 (10.0) | 0.524 | 8 (80.0) | 2 (20.0) | 0 (0.0) | 0.872 | 3 (30.0) | 5 (50.0) | 2 (20.0) | 0.482 | 7 (70.0) | 1 (10.0) | 2 (20.0) | 0.110 |
| | No | 104 (43.3) | 99 (41.2) | 37 (15.4) | | 106 (44.2) | 116 (48.3) | 18 (7.5) | | 191 (79.6) | 43 (17.9) | 6 (2.5) | | 118 (49.2) | 91 (37.9) | 31 (12.9) | | 153 (63.7) | 73 (30.4) | 14 (5.8) | |
| Severe and critical patients (group III) | | | | | | | | | | | | | | | | | | | | | |
| Gender | Male | 17 (27.9) | 37 (60.7) | 7 (11.5) | 0.159 | 21 (34.4) | 31 (50.8) | 9 (14.8) | 0.360 | 42 (68.9) | 16 (26.2) | 3 (4.9) | 0.810 | 34 (55.7) | 20 (32.8) | 7 (11.5) | 0.966 | 41 (67.2) | 16 (26.2) | 4 (6.6) | 0.987 |

(*continued on next page*)

**Table 6** (*continued*)

| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| | Female | 14 (48.3) | 13 (44.8) | 2 (6.9) | | 8 (27.6) | 19 (65.5) | 2 (6.9) | | 21 (72.4) | 6 (20.7) | 2 (6.9) | | 17 (58.6) | 9 (31.0) | 3 (10.3) | | 19 (65.5) | 8 (27.6) | 2 (6.9) | |
| Fever | Yes | 14 (26.9) | 32 (61.5) | 6 (11.5) | 0.211 | 19 (36.5) | 28 (53.8) | 5 (9.6) | 0.482 | 35 (67.3) | 15 (28.8) | 2 (3.8) | 0.417 | 25 (48.1) | 21 (40.4) | 6 (11.5) | 0.124 | 36 (69.2) | 14 (26.9) | 2 (3.8) | 0.451 |
| | No | 17 (44.7) | 18 (47.4) | 3 (7.9) | | 10 (26.3) | 22 (57.9) | 6 (15.8) | | 28 (73.7) | 7 (18.4) | 3 (7.9) | | 26 (68.4) | 8 (21.1) | 4 (10.5) | | 24 (63.2) | 10 (26.3) | 4 (10.5) | |
| Sore throat | Yes | 11 (42.3) | 11 (42.3) | 4 (15.4) | 0.238 | 6 (23.1) | 17 (65.4) | 3 (11.5) | 0.450 | 17 (65.4) | 8 (30.8) | 1 (3.8) | 0.637 | 13 (50.0) | 9 (34.6) | 4 (15.4) | 0.621 | 18 (69.2) | 7 (26.9) | 1 (3.8) | 0.789 |
| | No | 20 (31.2) | 39 (60.9) | 5 (7.8) | | 23 (35.9) | 33 (51.6) | 8 (12.5) | | 46 (71.9) | 14 (21.9) | 4 (6.2) | | 38 (59.4) | 20 (31.2) | 6 (9.4) | | 42 (65.6) | 17 (26.6) | 5 (7.8) | |
| Dry cough | Yes | 13 (29.5) | 26 (59.1) | 5 (11.4) | 0.621 | 16 (36.4) | 24 (54.5) | 4 (9.1) | 0.559 | 26 (59.1) | 14 (31.8) | 4 (9.1) | 0.070 | 23 (52.3) | 15 (34.1) | 6 (13.6) | 0.644 | 27 (61.4) | 14 (31.8) | 3 (6.8) | 0.543 |
| | No | 18 (39.1) | 24 (52.2) | 4 (8.7) | | 13 (28.3) | 28 (56.5) | 7 (15.2) | | 37 (80.4) | 8 (17.4) | 1 (2.2) | | 28 (60.9) | 14 (30.4) | 4 (8.7) | | 33 (71.7) | 10 (21.7) | 3 (6.5) | |
| Headache | Yes | 1 (10.0) | 8 (80.0) | 1 (10.0) | 0.208 | 4 (40.0) | 6 (60.0) | 0 (0.0) | 0.443 | 6 (60.0) | 3 (30.0) | 1 (10.0) | 0.704 | 5 (50.0) | 3 (30.0) | 2 (20.0) | 0.636 | 6 (60.0) | 3 (30.0) | 1 (10.0) | 0.857 |
| | No | 30 (37.5) | 42 (52.5) | 8 (10.0) | | 25 (31.2) | 44 (55.0) | 11 (13.8) | | 57 (71.2) | 19 (23.8) | 4 (5.0) | | 46 (57.5) | 26 (32.5) | 8 (10.0) | | 54 (67.5) | 21 (26.2) | 5 (6.2) | |
| Shortness of breath | Yes | 11 (18.6) | 41 (69.5) | 7 (11.9) | **< 0.001** | 23 (39.0) | 30 (50.8) | 6 (10.2) | 0.157 | 39 (66.1) | 16 (27.1) | 4 (6.8) | 0.513 | 30 (50.8) | 22 (37.3) | 7 (11.9) | 0.290 | 41 (69.5) | 15 (25.4) | 3 (5.1) | 0.623 |
| | No | 20 (64.5) | 9 (29.0) | 2 (6.5) | | 6 (19.4) | 20 (64.5) | 5 (16.1) | | 24 (77.4) | 6 (19.4) | 1 (3.2) | | 21 (67.7) | 7 (22.6) | 3 (9.7) | | 19 (61.3) | 9 (29.0) | 3 (9.7) | |
| Diarrhea | Yes | 5 (45.5) | 6 (54.5) | 0 (0.0) | 0.428 | 3 (27.3) | 7 (63.6) | 1 (9.1) | 0.842 | 6 (54.5) | 4 (36.4) | 1 (9.1) | 0.487 | 5 (45.5) | 4 (36.4) | 2 (18.2) | 0.635 | 8 (72.7) | 3 (27.3) | 0 (0.0) | 0.636 |
| | No | 26 (32.9) | 44 (55.7) | 9 (11.4) | | 26 (32.9) | 43 (54.4) | 10 (12.2) | | 57 (72.2) | 18 (22.8) | 4 (5.1) | | 46 (58.2) | 25 (31.6) | 8 (10.1) | | 52 (65.8) | 21 (26.6) | 6 (7.6) | |
| Myalgia | Yes | 8 (47.1) | 8 (47.1) | 1 (5.8) | 0.450 | 4 (23.5) | 8 (47.1) | 5 (29.4) | 0.054 | 15 (88.2) | 2 (11.8) | 0 (0.0) | 0.170 | 14 (82.4) | 2 (11.8) | 1 (5.9) | 0.058 | 11 (64.7) | 5 (29.4) | 1 (5.9) | 0.956 |
| | No | 23 (31.5) | 42 (57.5) | 8 (11.0) | | 25 (34.2) | 42 (57.5) | 6 (8.2) | | 48 (65.8) | 20 (27.4) | 5 (6.8) | | 37 (50.7) | 27 (37.0) | 9 (12.3) | | 49 (67.1) | 19 (26.0) | 5 (6.8) | |
| Fatigue | Yes | 9 (29.0) | 19 (61.3) | 3 (9.7) | 0.709 | 7 (22.6) | 19 (61.3) | 5 (16.1) | 0.327 | 20 (64.5) | 9 (29.0) | 2 (6.5) | 0.712 | 15 (48.4) | 13 (41.9) | 3 (9.7) | 0.360 | 21 (67.7) | 8 (25.8) | 2 (6.5) | 0.988 |
| | No | 22 (37.3) | 31 (52.5) | 6 (10.2) | | 22 (37.3) | 31 (52.5) | 6 (10.2) | | 43 (72.9) | 13 (22.0) | 3 (5.1) | | 36 (61.0) | 16 (27.1) | 7 (11.9) | | 39 (66.1) | 16 (27.1) | 4 (6.8) | |
| Nausea | Yes | 9 (60.0) | 6 (40.0) | 0 (0.0) | 0.050 | 5 (33.3) | 7 (46.7) | 3 (20.0) | 0.562 | 13 (86.7) | 1 (6.7) | 1 (6.7) | 0.214 | 8 (53.3) | 5 (33.3) | 2 (13.3) | 0.941 | 10 (66.7) | 5 (33.3) | 0 (0.0) | 0.472 |
| | No | 22 (29.3) | 44 (58.7) | 9 (12.0) | | 24 (32.0) | 43 (57.3) | 8 (10.7) | | 50 (66.7) | 21 (28.0) | 4 (5.3) | | 43 (57.3) | 24 (32.0) | 8 (10.7) | | 50 (66.7) | 19 (25.3) | 6 (8.0) | |
| Vomiting | Yes | 4 (364) | 6 (54.5) | 1 (9.1) | 0.987 | 4 (36.4) | 7 (63.6) | 0 (0.0) | 0.418 | 4 (36.4) | 6 (54.5) | 1 (9.1) | **0.031** | 4 (36.4) | 5 (45.5) | 2 (18.2) | 0.340 | 7 (63.6) | 4 (36.4) | 0 (0.0) | 0.523 |
| | No | 27 (34.2) | 44 (55.7) | 8 (10.1) | | 25 (31.6) | 43 (54.4) | 11 (13.9) | | 59 (74.7) | 16 (20.3) | 4 (5.1) | | 47 (59.5) | 24 (30.4) | 8 (10.1) | | 53 (67.1) | 20 (25.3) | 6 (7.6) | |
| Parageusia | Yes | 7 (26.9) | 16 (61.5) | 3 (11.5) | 0.630 | 6 (23.1) | 17 (65.4) | 3 (11.5) | 0.450 | 19 (73.1) | 7 (26.9) | 0 (0.0) | 0.337 | 13 (50.0) | 11 (42.3) | 2 (7.7) | 0.401 | 19 (73.1) | 5 (19.2) | 2 (7.7) | 0.594 |
| | No | 24 (37.5) | 34 (53.1) | 6 (9.4) | | 23 (35.9) | 33 (51.6) | 8 (12.5) | | 44 (68.8) | 15 (23.4) | 5 (7.8) | | 38 (59.4) | 18 (28.1) | 8 (12.5) | | 41 (64.1) | 19 (29.7) | 4 (6.2) | |
| Hypertension | Yes | 18 (40.0) | 24 (53.3) | 3 (6.7) | 0.389 | 15 (33.3) | 24 (53.3) | 6 (13.3) | 0.902 | 30. (66.7) | 13 (28.9) | 2 (4.4) | 0.586 | 25 (55.6) | 15 (33.3) | 5 (11.1) | 0.973 | 29 (64.4) | 14 (31.1) | 2 (4.4) | 0.497 |
| | No | 13 (28.9) | 26 (57.8) | 6 (13.3) | | 14 (31.1) | 26 (57.8) | 5 (11.1) | | 33 (73.3) | 9 (20.0) | 3 (6.7) | | 26 (57.8) | 14 (31.1) | 5 (11.1) | | 31 (68.9) | 10 (22.2) | 4 (8.9) | |
| Diabetes | Yes | 12 (37.5) | 19 (59.4) | 1 (3.1) | 0.271 | 10 (31.2) | 18 (56.2) | 4 (12.5) | 0.989 | 23 (71.9) | 6 (18.8) | 3 (9.4) | 0.370 | 19 (59.4) | 11 (34.4) | 2 (6.2) | 0.551 | 21 (65.6) | 9 (28.1) | 2 (6.2) | 0.970 |
| | No | 19 (32.8) | 31 (53.4) | 8 (13.8) | | 19 (32.8) | 32 (55.2) | 7 (12.1) | | 40 (69.0) | 16 (27.6) | 2 (3.4) | | 32 (55.2) | 18 (31.0) | 8 (13.8) | | 39 (67.2) | 15 (25.9) | 4 (6.9) | |

(*continued on next page*)

**Table 6** (*continued*)

| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| Asthma | Yes | 6 (40.0) | 5 (33.3) | 4 (26.7) | **0.034** | 7 (46.7) | 7 (46.7) | 1 (6.7) | 0.391 | 13 (86.7) | 1 (6.7) | 1 (6.7) | 0.214 | 9 (60.0) | 6 (40.0) | 0 (0.0) | 0.305 | 7 (46.7) | 6 (40.0) | 2 (13.3) | 0.176 |
| | No | 25 (33.3) | 45 (60.0) | 5 (6.7) | | 22 (29.3) | 43 (57.3) | 10 (13.3) | | 50 (66.7) | 21 (28.0) | 4 (5.3) | | 42 (56.0) | 23 (30.7) | 10 (13.3) | | 53 (70.7) | 18 (24.0) | 4 (5.3) | |
| Cardiovascular disease | Yes | 7 (63.6) | 4 (36.4) | 0 (0.0) | 0.075 | 1 (9.1) | 8 (72.7) | 2 (18.2) | 0.211 | 8 (72.7) | 3 (27.3) | 0 (0.0) | 0.687 | 7 (63.6) | 3 (27.3) | 1 (9.1) | 0.883 | 8 (72.7) | 2 (18.2) | 1 (9.1) | 0.772 |
| | No | 24 (30.4) | 46 (58.2) | 9 (11.4) | | 28 (35.4) | 42 (53.2) | 9 (11.4) | | 55 (69.6) | 19 (24.1) | 5 (6.3) | | 44 (55.7) | 26 (32.9) | 9 (11.4) | | 52 (65.8) | 22 (27.8) | 5 (6.3) | |
| Chronic renal disease | Yes | 7 (28.0) | 15 (60.0) | 3 (12.0) | 0.712 | 8 (32.0) | 10 (40.0) | 7 (28.0) | **0.014** | 21 (84.0) | 4 (16.0) | 0 (0.0) | 0.142 | 14 (56.0) | 9 (36.0) | 2 (8.0) | 0.795 | 20 (80.0) | 4 (16.0) | 1 (4.0) | 0.250 |
| | No | 24 (36.9) | 35 (53.8) | 6 (9.2) | | 21 (32.3) | 40 (61.5) | 4 (6.2) | | 42 (64.6) | 18 (27.7) | 5 (7.7) | | 37 (56.9) | 20 (30.8) | 8 (12.3) | | 40 (61.5) | 20 (30.8) | 5 (7.7) | |
| Malignancy | Yes | 4 (40.0) | 5 (50.0) | 1 (10.0) | 0.922 | 2 (20.0) | 5 (50.0) | 3 (30.0) | 0.174 | 10 (100.0) | 0)0.0) | 0 (0.0) | 0.090 | 5 (50.0) | 4 (40.0) | 1 (10.0) | 0.856 | 5 (50.0) | 4 (40.0) | 1 (10.0) | 0.495 |
| | No | 27 (33.8) | 45 (56.2) | 8 (10.0) | | 27 (33.8) | 45 (56.2) | 8 (10.0) | | 53 (66.2) | 22 (27.5) | 5 (6.2) | | 46 (57.5) | 25 (31.2) | 9 (11.2) | | 55 (68.8) | 20 (25.0) | 5 (6.2) | |

Bold items indicate an statistically significant levels.

**Table 7**
Significant association of VDR gene polymorphisms with some clinical symptom and comorbidities in COVID-19 suffered patients.

| Genetic models | | P- value | Odds ratio (95% CI) |
|---|---|---|---|
| Mild/moderate patients | | | |
| BsmI and chronic renal disease | | | |
| *Dominant* | *BB + Bb vs. bb* | 0.189 | 0.48 (0.16–1.43) |
| | *bb vs. BB + Bb* | | 2.08 (0.70–6.25) |
| *Recessive* | *bb + Bb vs. BB* | **0.024** | 0.45 (0.22–0.90) |
| | *BB vs. bb + Bb* | | 2.22 (1.11–4.55) |
| *Overdominant* | *Bb vs. BB + bb* | **0.004** | 0.32 (0.15–0.70) |
| | *BB + bb vs. Bb* | | 3.13 (1.43–6.67) |
| *Codominant* | *bb vs. BB* | 0.636 | 1.31 (0.43–4.00) |
| | *Bb vs. BB* | **0.007** | 0.34 (0.15–0.74) |
| *Allelic* | *B vs. b* | 0.234 | 1.39 (0.81–2.41) |
| | *b vs. B* | | 0.72 (0.42–1.24) |
| EcoRV and diabetes | | | |
| *Dominant* | *EE + Ee vs. ee* | **< 0.001** | 0.19 (0.08–0.49) |
| | *ee vs. EE + Ee* | | 5.26 (2.04–12.50) |
| *Recessive* | *ee + Ee vs. EE* | **< 0.001** | 4.45 (2.13–9.29) |
| | *EE vs. ee + Ee* | | 0.23 (0.11–0.47) |
| *Overdominant* | *Ee vs. EE + ee* | **0.034** | 2.04 (1.06–3.93) |
| | *EE + ee vs. Ee* | | 0.49 (0.26–0.94) |
| *Codominant* | *ee vs. EE* | **< 0.001** | 10.17 (3.54–29.21) |
| | *Ee vs. EE* | **0.001** | 3.57 (1.65–7.75) |
| *Allelic* | *E vs. e* | **< 0.001** | 0.31 (0.19–0.50) |
| | *e vs. E* | | 3.23 (2.00–5.26) |
| Severe and critical patients | | | |
| ApaI and shortness of breath | | | |
| *Dominant* | *AA + Aa vs. aa* | 0.423 | 0.51 (0.10–2.63) |
| | *aa vs. AA + Aa* | | 1.96 (0.38–10.00) |
| *Recessive* | *aa + Aa vs. AA* | **< 0.001** | 7.93 (2.96–21.25) |
| | *AA vs. aa + Aa* | | 0.13 (0.05–0.34) |
| *Overdominant* | *Aa vs. AA + aa* | **< 0.001** | 5.57 (2.15–14.44) |
| | *AA + aa vs. Aa* | | 0.18 (0.07–0.47) |
| *Codominant* | *aa vs. AA* | **0.037** | 6.36 (1.12–36.08) |
| | *Aa vs. AA* | **< 0.001** | 8.28 (2.96–23.21) |
| *Allelic* | *A vs. a* | **0.001** | 0.30 (0.15–0.62) |
| | *a vs. A* | | 3.33 (1.61–6.67) |
| ApaI and asthma | | | |
| *Dominant* | *AA + Aa vs. aa* | **0.029** | 0.20 (0.05–0.85) |
| | *aa vs. AA + Aa* | | 5.00 (1.18–20.00) |
| *Recessive* | *aa + Aa vs. AA* | 0.621 | 0.75 (0.24–2.34) |
| | *AA vs. aa + Aa* | | 1.33 (0.43–4.17) |
| *Overdominant* | *Aa vs. AA + aa* | 0.065 | 0.33 (0.10–1.07) |
| | *AA + aa vs. Aa* | | 3.03 (0.94–10.00) |
| *Codominant* | *aa vs. AA* | 0.137 | 3.33 (0.68–16.32) |
| | *Aa vs. AA* | 0.240 | 0.46 (0.13–1.67) |
| *Allelic* | *A vs. a* | 0.493 | 0.76 (0.34–1.68) |
| | *a vs. A* | | 1.32 (0.60–2.94) |
| BsmI and chronic renal disease | | | |
| *Dominant* | *BB + Bb vs. bb* | **0.009** | 0.17 (0.04–0.64) |
| | *bb vs. BB + Bb* | | 5.88 (1.56–25.00) |
| *Recessive* | *bb + Bb vs. BB* | 0.978 | 1.01 (0.38–2.72) |
| | *BB vs. bb + Bb* | | 0.99 (0.37–2.63) |
| *Overdominant* | *Bb vs. BB + bb* | 0.069 | 0.42 (0.16–1.07) |
| | *BB + bb vs. Bb* | | 2.38 (0.94–6.25) |
| *Codominant* | *bb vs. BB* | **0.043** | 4.59 (1.05–20.06) |
| | *Bb vs. BB* | 0.440 | 0.66 (0.23–1.91) |
| *Allelic* | *B vs. b* | 0.176 | 0.63 (0.33–1.23) |
| | *b vs. B* | | 1.59 (0.81–3.03) |
| FokI and hypertension | | | |
| *Dominant* | *FF + Ff vs. ff* | **0.013** | 0.22 (0.07–0.72) |
| | *ff vs. FF + Ff* | | 4.55 (1.39–14.29) |
| *Recessive* | *ff + Ff vs. FF* | 0.655 | 1.22 (0.51–2.94) |
| | *FF vs. ff + Ff* | | 0.82 (0.34–1.96) |
| *Overdominant* | *Ff vs. FF + ff* | 0.093 | 0.49 (0.21–1.13) |
| | *ff + FF vs. Ff* | | 2.04 (0.89–4.76) |
| *Codominant* | *ff vs. FF* | **0.040** | 4.00 (1.07–15.01) |
| | *Ff vs. FF* | 0.601 | 0.78 (0.30–2.00) |
| *Allelic* | *F vs. f* | 0.072 | 0.58 (0.32–1.05) |
| | *f vs. F* | | 1.72 (0.95–3.13) |
| CDX2 and shortness of breath | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.009** | 3.59 (1.37–9.42) |
| | *cc vs. CC + Cc* | | 0.28 (0.11–0.73) |
| *Recessive* | *cc + Cc vs. CC* | 0.086 | 0.40 (0.14–1.14) |
| | *CC vs. cc + Cc* | | 2.50 (0.88–7.14) |

(*continued on next page*)

**Table 7** (*continued*)

| Genetic models | | P- value | Odds ratio (95% CI) |
|---|---|---|---|
| *Overdominant* | *Cc vs. CC + cc* | 0.433 | 1.43 (0.58–3.52) |
| | *CC + cc vs. Cc* | | 0.70 (0.28–1.72) |
| *Codominant* | *cc vs. CC* | **0.012** | 0.21 (0.07–0.71) |
| | *Cc vs. CC* | 0.452 | 0.65 (0.21–2.03) |
| *Allelic* | *C vs. c* | **0.005** | 2.47 (1.31–4.66) |
| | *c vs. C* | | 0.41 (0.22–0.76) |
| CDX2 and hypertension | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.038** | 0.36 (0.14–0.94) |
| | *cc vs. CC + Cc* | | 2.78 (1.06–7.14) |
| *Recessive* | *cc + Cc vs. CC* | 0.649 | 0.81 (0.33–1.99) |
| | *CC vs. cc + Cc* | | 1.24 (0.50–3.03) |
| *Overdominant* | *Cc vs. CC + cc* | **0.020** | 0.36 (0.15–0.85) |
| | *CC + cc vs. Cc* | | 2.78 (1.18–6.67) |
| *Codominant* | *cc vs. CC* | 0.286 | 1.84 (0.60–5.63) |
| | *Cc vs. CC* | 0.140 | 0.47 (0.17–1.28) |
| *Allelic* | *C vs. c* | 0.297 | 0.73 (0.41–1.32) |
| | *c vs. C* | | 1.37 (0.76–2.44) |
| CDX2 and diabetes | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.014** | 0.30 (0.12–0.79) |
| | *cc vs. CC + Cc* | | 3.33 (1.27–8.33) |
| *Recessive* | *cc + Cc vs. CC* | 0.354 | 1.58 (0.60–4.15) |
| | *CC vs. cc + Cc* | | 0.63 (0.24–1.67) |
| *Overdominant* | *Cc vs. CC + cc* | 0.161 | 0.52 (0.21–1.29) |
| | *CC + cc vs. Cc* | | 1.92 (0.78–4.76) |
| *Codominant* | *cc vs. CC* | **0.046** | 3.18 (1.02–9.93) |
| | *Cc vs. CC* | 0.890 | 0.93 (0.31–2.77) |
| *Allelic* | *C vs. c* | **0.029** | 0.50 (0.27–0.93) |
| | *c vs. C* | | 2.00 (1.08–3.70) |
| EcoRV and diabetes | | | |
| *Dominant* | *EE + Ee vs. ee* | 0.466 | 2.30 (0.25–21.47) |
| | *ee vs. EE + Ee* | | 0.44 (0.05–4.00) |
| *Recessive* | *ee + Ee vs. EE* | **0.033** | 2.74 (1.08–6.92) |
| | *EE vs. ee + Ee* | | 0.41 (0.15–0.93) |
| *Overdominant* | *Ee vs. EE + ee* | **0.015** | 3.12 (1.25–7.76) |
| | *EE + ee vs. Ee* | | 0.32 (0.13–0.80) |
| *Codominant* | *ee vs. EE* | 0.877 | 0.83 (0.08–8.43) |
| | *Ee vs. EE* | **0.020** | 3.06 (1.19–7.85) |
| *Allelic* | *E vs. e* | 0.171 | 0.64 (0.33–1.22) |
| | *e vs. E* | | 1.56 (0.82–3.03) |

Bold items indicate an statistically significant levels.

elevated ratios of “cc vs. CC + Cc”, “cc vs. CC", and “c vs. C", but decreased ratios of “CC + Cc vs. cc" and “C vs. c" in COVID-19 patients with these clinical features against to subjects without these variables. Furthermore, CDX2 was indicated to possess a strong association with diabetes in both allelic and all genetic models, except in the over-dominant model in combined samples of COVID-19 patients (Table 9). Accordingly, higher rates of the “cc *vs.* CC + Cc”, “cc + Cc vs. CC".“ cc vs. CC", and “c *vs.* C" were recognized in COVID-19 patients with diabetes than patients without this comorbidity, nevertheless, lower rates of the “ CC + Cc vs. cc", “ CC vs. cc + Cc”, and “ C vs. c" were illustrated. The last finding was the association between *Eco*RV allelic and genotypic distribution and diabetes in all proposed genetic models (Table 9). Our results revealed increased rates of “ee vs. EE + Ee”, “ee + Ee vs. EE", “Ee vs. EE + ee”, “ee vs. EE", “Ee vs. EE", and “e vs. E", and decreased rates of the “ EE + Ee vs. ee “, “ EE vs. ee + Ee “, “ EE + ee vs. Ee “, and “ E vs. e “ were seen in combined samples of COVID-19 subjects with diabetes compared to those with no diabetes.

## 4. Discussion

The wide spectrum of clinical manifestations of the resulting COVID-19 range from silent (asymptomatic) or mild symptoms of the upper respiratory tract such as familiar cold symptoms (fever, stuffy nose, cough, Sore throat, weakness) bronchitis to severe pneumonia with ARDS and death (Singhal, 2020). Many Risk factors recognized for this coronavirus include advanced age, male gender, comorbidities, race, obesity, hypertension, diabetes, geographic region, and ethnicity (Mendy et al., 2020). More importantly, several previous studies disclosed the association of specific human genetic variants with the predisposition of individuals to develop severe disease or susceptibility to infection (Anastassopoulou et al., 2020; Hou et al., 2020; Latini et al., 2020; Wang et al., 2020; Gómez et al., 2020). Some of the identified associations between genetic factors and different severity of COVID-19 or variable susceptibility to SARS-CoV-2 are ABO blood group, ACE2, APOE, HLA, IFITM3, TLR7, TMEM189-UBE2V1, TMPRSS2.

Mounting investigations have revealed the role of vitamin D deficiency as a pathogenic factor of COVID-19, leading to an increase in the predisposition and severity of individuals, especially *via* exacerbating acute lung injury and ARDS (Faul et al., 2020; Carpagnano et al., 2020; Parekh et al., 2013). Several types of research highlighted that patients with ARDS and also COVID-19 cases are even more vitamin D deficient than control subjects (Dancer et al., 2015; Thickett et al., 2015; Park et al., 2018; Quesada-Gomez et al., 2020). Furthermore, more vitamin D deficiency [25(OH) D levels:< 50 nmol/L] and insufficiency [25(OH) D levels:50–75 nmol/L)] was demonstrated in regions highly affected by COVID-19, such as Iran (Ebadi et al., 2019; Tabrizi et al., 2018). Undoubtedly, a complex relationship can be proposed between vitamin D and COVID-19, in which many environmental and genetic factors are implicated. Among environmental factors, seasonal variation in sun exposure, geographic latitudes, air pollution, and darker skin influence vitamin D formation by sunlight *in vitro* (Wacker and Holick, 2013). Intriguingly, In Chicago, more than half of COVID-19 cases and around 70% of COVID-19 deaths were observed in African-American individuals (Yancy, 2020) who are at a greater risk for vitamin D deficiency (Alzaman et al., 2016). The actions of vitamin D are largely mediated by its intranuclear receptor, VDR, which is extensively distributed in respiratory epithelial cells and immune cells (B cell, T cell, macrophages, and monocytes). The expression and regulation of VDR itself are influenced by several mechanisms, including cell-type-specific transcription factors (TFs), auto-regulation by vitamin D, methylation of its primary promoter, and genetic variations (Saccone et al., 2015). Genetic variations in the VDR gene such as SNPs might alter the function VD/VDR pathway in bronchial epithelium and immune-regulatory functions, which consequently influence the susceptibility to a large number of diverse conditions (Valdivielso and Fernandez, 2006; Laplana et al., 2018; Mohammadi et al., 2020; Mehrabani et al., 2019) and possibly COVID-19.

In the present study, the association of eight SNPs in the VDR gene with the severity of COVID-19 patients was evaluated. Our data showed significant associations for some of the SNP-related alleles and/or genotypes in one or more genetic models. *Fok*I polymorphism in the exon 2 at the 5′ end of the VDR gene is referred to as start codon polymorphism (SCP), in which the presence of the “T” allele (the mutated “f” allele) results in the translation of a 3 amino acid longer VDR protein, while the “C” allele (the wild type “F” allele) produces shorter VDR protein that is associated with 1.7-fold increased transcriptional activity (Köstner et al., 2009; Whitfield et al., 2001; Jurutka et al., 2000; Colin et al., 2000). In the *Fok*I variant, results showed this SNP as a pinpointed associated factor with COVID-19; in which “f” (mutated) allele frequencies were intended to be higher in symptomatic and severe/critical patients compared with asymptomatic COVID-19 affected people. Hence, it can be suggested that the “f” allele, is positively associated with signs, symptoms, and possibly the severity of COVID-19 affected peoples. FokI genotypic distributions illustrated important results based on recessive and codominant genetic models in COVID-19 individuals, including the decreased vulnerability of “FF” genotype compared with combined “Ff + ff” genotypes, and increased susceptibility of “ff” patients *versus* “FF” affected subjects to represent signs, symptoms, and possibly more serious outcomes. However, there were no significant differences between “FF” and “Ff” patients for the clinical characteristics of COVID-19. The meta-analyses showed an association of FokI polymorphism with susceptibility to virus infection (McNally et al., 2014). This association could be contributed to the changes in TFIIB-VDR interaction, transcription efficiency, the effects of FokI polymorphism on immune cell

**Table 8**
Association of VDR gene polymorphisms- related genotypes with clinical data in COVID-19 patients with positive criteria of signs and symptoms.

5′ end's VDR polymorphisms

| Variables | Status | FokI | | | | CDX2 | | | | EcoRV | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | FF | Ff | ff | P | CC | Cc | cc | P | EE | Ee | ee | P |
| Gender | Male | 76 (37.4) | 96 (47.3) | 31 (15.3) | 0.766 | 67 (33.0) | 89 (43.8) | 47 (23.2) | 0.217 | 99 (48.8) | 86 (42.4) | 18 (8.9) | 0.468 |
| | Female | 50 (36.5) | 62 (45.3) | 25 (18.2) | | 56 (40.9) | 58 (42.3) | 23 (16.8) | | 74 (54.0) | 55 (40.1) | 8 (5.8) | |
| Fever | Yes | 65 (33.7) | 88 (45.6) | 40 (20.7) | **0.042** | 70 (36.3) | 88 (45.6) | 35 (18.1) | 0.390 | 91 (47.2) | 84 (43.5) | 18 (9.3) | 0.190 |
| | No | 61 (41.5) | 70 (47.6) | 16 (10.9) | | 53 (36.1) | 59 (40.1) | 35 (23.8) | | 82 (55.8) | 57 (38.8) | 8 (5.4) | |
| Sore throat | Yes | 37 (34.3) | 51 (47.2) | 20 (18.5) | 0.685 | 33 (30.6) | 56 (51.9) | 19 (17.6) | 0.091 | 56 (51.9) | 44 (40.7) | 8 (7.4) | 0.970 |
| | No | 89 (38.4) | 107 (46.1) | 36 (15.5) | | 90 (38.8) | 91 (39.2) | 51 (22.0) | | 117 (50.4) | 97 (41.8) | 18 (7.8) | |
| Dry cough | Yes | 66 (35.1) | 96 (48.4) | 31 (16.5) | 0.680 | 76 (404) | 75 (39.9) | 37 (19.7) | 0.187 | 101 (53.7) | 71 (37.8) | 16 (8.5) | 0.291 |
| | No | 60 (39.5) | 67 (44.1) | 25 (16.4) | | 47 (30.9) | 72 (47.4) | 33 (21.7) | | 72 (47.4) | 70 (46.1) | 10 (6.6) | |
| Headache | Yes | 25 (42.4) | 26 (44.1) | 8 (13.6) | 0.607 | 19 (32.2) | 20 (33.9) | 20 (33.9) | **0.019** | 26 (44.1) | 27 (45.8) | 6 (10.2) | 0.458 |
| | No | 101 (35.9) | 132 (47.0) | 48 (17.1) | | 104 (37.0) | 127 (45.2) | 50 (17.8) | | 147 (52.3) | 114 (40.6) | 20 (7.1) | |
| Shortness of breath | Yes | 35 (38.9) | 37 (41.1) | 18 (20.0) | 0.408 | 30 (33.3) | 38 (42.2) | 22 (24.4) | 0.552 | 43 (47.8) | 37 (41.1) | 10 (11.1) | 0.340 |
| | No | 91 (36.4) | 121 (48.4) | 38 (15.2) | | 93 (37.2) | 109 (43.6) | 48 (19.2) | | 130 (52.0) | 104 (41.6) | 16 (6.4) | |
| Diarrhea | Yes | 8 (26.7) | 15 (50.0) | 7 (23.3) | 0.370 | 8 (26.7) | 15 (50.0) | 7 (23.3) | 0.524 | 17 (56.7) | 11 (36.7) | 2 (6.7) | 0.802 |
| | No | 118 (38.1) | 143 (46.1) | 49 (15.8) | | 115 (37.1) | 132 (42.6) | 63 (20.3) | | 156 (50.3) | 130 (41.9) | 24 (7.7) | |
| Myalgia | Yes | 26 (39.2) | 40 (50.6) | 13 (16.5) | 0.650 | 31 (39.2) | 33 (41.8) | 15 (19.0) | 0.800 | 45 (57.0) | 29 (36.7) | 5 (6.3) | 0.462 |
| | No | 100 (38.3) | 118 (45.2) | 43 (16.5) | | 92 (35.2) | 114 (43.7) | 55 (21.1) | | 128 (49.0) | 112 (42.9) | 21 (8.0) | |
| Fatigue | Yes | 24 (42.1) | 19 (33.3) | 14 (24.6) | 0.057 | 24 (42.1) | 24 (42.1) | 9 (15.8) | 0.484 | 32 (56.1) | 22 (38.6) | 3 (5.3) | 0.601 |
| | No | 102 (36.0) | 139 (49.1) | 42 (14.8) | | 99 (35.0) | 123 (43.5) | 61 (21.6) | | 141 (49.8) | 119 (42.0) | 23 (8.1) | |
| Nausea | Yes | 14 (35.9) | 18 (46.2) | 7 (17.9) | 0.963 | 12 (30.8) | 17 (43.6) | 10 (25.6) | 0.636 | 19 (48.7) | 16 (41.0) | 4 (10.3) | 0.805 |
| | No | 112 (37.2) | 140 46.5() | 49 (16.3) | | 111 (36.9) | 130 (43.2) | 60 (19.9) | | 154 (51.2) | 125 (41.5) | 22 (7.3) | |
| Vomiting | Yes | 6 (20.7) | 18 (62.1) | 5 (17.2) | 0.138 | 10 (34.5) | 12 (41.4) | 7 (24.1) | 0.885 | 11 (37.9) | 16 (55.2) | 2 (6.9) | 0.286 |
| | No | 120 (38.6) | 140 (45.0) | 51 (16.4) | | 113 (36.3) | 135 (43.4) | 63 (20.3) | | 162 (52.1) | 125 (40.2) | 24 (7.7) | |
| Parageusia | Yes | 17 (44.7) | 17 (44.7) | 4 (10.5) | 0.444 | 13 (34.2) | 15 (39.5) | 10 (26.3) | 0.648 | 18 (47.4) | 18 (47.4) | 2 (5.3) | 0.677 |
| | No | 109 (36.1) | 141 (46.7) | 52 (17.2) | | 110 (36.4) | 132 (43.7) | 60 (19.9) | | 155 (51.3) | 123 (40.7) | 24 (7.9) | |
| Hypertension | Yes | 28 (31.5) | 39 (43.8) | 22 (24.7) | **0.045** | 28 (31.5) | 32 (36.0) | 29 (32.6) | **0.005** | 40 (44.9) | 42 (47.2) | 7 (7.9) | 0.408 |
| | No | 98 (39.0) | 119 (47.4) | 34 (13.5) | | 95 (37.8) | 115 (45.8) | 41 (16.3) | | 133 (53.0) | 99 (39.4) | 19 (7.6) | |
| Diabetes | Yes | 26 (34.2) | 35 (46.1) | 15 (19.7) | 0.653 | 20 (26.3) | 32 (42.1) | 24 (31.6) | **0.015** | 20 (26.3) | 45 (59.2) | 11 (14.5) | **< 0.001** |
| | No | 100 (37.9) | 123 (46.6) | 41 (15.5) | | 103 (39.0) | 115 (43.6) | 46 (17.4) | | 153 (58.0) | 96 (36.4) | 15 (5.7) | |
| Asthma | Yes | 12 (41.4) | 12 (41.4) | 5 (17.2) | 0.840 | 11 (37.9) | 13 (44.8) | 5 (17.2) | 0.897 | 14 (48.3) | 13 (44.8) | 2 (6.9) | 0.927 |
| | No | 114 (36.7) | 146 (46.9) | 51 (16.4) | | 112 (36.0) | 134 (43.1) | 65 (20.9) | | 159 (51.1) | 128 (41.2) | 24 (7.7) | |
| Cardiovascular disease | Yes | 18 (51.4) | 12 (34.3) | 5 (14.3) | 0.171 | 15 (42.9) | 16 (45.7) | 4 (11.4) | 0.345 | 22 (62.9) | 11 (31.4) | 2 (5.7) | 0.326 |
| | No | 108 (35.4) | 146 (47.9) | 51 (16.7) | | 108 (35.4) | 131 (43.0) | 66 (21.6) | | 151 (49.5) | 130 (42.6) | 24 (7.9) | |
| Chronic renal disease | Yes | 24 (37.5) | 26 (40.6) | 16 (21.9) | 0.371 | 25 (39.1) | 27 (42.2) | 12 (18.8) | 0.847 | 32 (50.0) | 29 (45.3) | 3 (4.7) | 0.550 |
| | No | 102 (37.0) | 132 (47.8) | 42 (15.2) | | 98 (35.5) | 120 (43.5) | 58 (21.0) | | 141 (51.1) | 112 (40.6) | 23 (8.3) | |
| Malignancy | Yes | 6 (30.0) | 11 (55.0) | 3 (15.0) | 0.724 | 10 (50.0) | 10 (50.0) | 0 (0.0) | 0.057 | 13 (65.0) | 5 (25.0) | 2 (10.0) | 0.305 |
| | No | 120 (37.5) | 147 (45.9) | 53 (16.6) | | 113 (35.3) | 137 (42.8) | 70 (21.9) | | 160 (50.0) | 136 (42.5) | 24 (7.5) | |

3′ end's VDR polymorphisms

| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| Gender | Male | 76 (37.4) | 98 (48.3) | 29 (14.3) | 0.295 | 83 (40.9) | 99 (48.8) | 21 (10.3) | 0.484 | 154 (75.9) | 45 (22.2) | 4 (2.0) | 0.127 | 102 (50.2) | 72 (35.5) | 29 (14.3) | 0.519 | 137 (67.5) | 54 (26.6) | 12 (5.9) | 0.425 |
| | Female | 62 (45.3) | 55 (40.1) | 20 (14.4) | | 58 (42.3) | 70 (51.1) | 9 (6.6) | | 108 (78.8) | 22 (16.1) | 7 (5.1) | | 70 (51.1) | 53 (38.7) | 14 (10.2) | | 83 (60.6) | 44 (32.1) | 10 (7.3) | |
| Fever | Yes | 63 (32.6) | 102 (52.8) | 28 (14.5) | **0.001** | 86 (44.6) | 93 (48.2) | 14 (7.3) | 0.289 | 144 (74.6) | 44 (22.8) | 5 (2.6) | 0.214 | 92 (47.7) | 78 (40.4) | 23 (11.9) | 0.278 | 123 (63.7) | 58 (30.1) | 12 (6.2) | 0.842 |

(*continued on next page*)

**Table 8** (*continued*)

| 3′ end's VDR polymorphisms | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | Status | ApaI | | | | BsmI | | | | Tru9I | | | | TaqI | | | | BglI | | | |
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| | No | 75 (51.0) | 51 (34.7) | 21 (14.3) | | 55 (37.4) | 76 (51.7) | 16 (10.9) | | 118 (80.3) | 23 (15.6) | 6 (4.1) | | 80 (54.4) | 47 (32.0) | 20 (13.6) | | 97 (66.0) | 40 (27.2) | 10 (6.8) | |
| Sore throat | Yes | 48 (44.4) | 44 (40.7) | 16 (14.8) | 0.539 | 43 (39.8) | 56 (51.9) | 9 (8.3) | 0.863 | 85 (78.7) | 17 (15.7) | 6 (5.6) | 0.139 | 54 (50.0) | 38 (35.2) | 16 (14.8) | 0.702 | 68 (63.0) | 33 (30.6) | 7 (6.5) | 0.887 |
| | No | 90 (38.8) | 109 (47.0) | 33 (14.2) | | 98 (42.2) | 113 (48.7) | 21 (9.1) | | 177 (76.3) | 50 (21.6) | 5 (2.2) | | 118 (50.9) | 87 (37.5) | 27 (11.6) | | 152 (65.5) | 65 (28.0) | 15 (6.5) | |
| Dry cough | Yes | 75 (39.9) | 85 (45.2) | 28 (14.9) | 0.941 | 80 (42.6) | 94 (50.0) | 14 (7.4) | 0.598 | 137 (72.9) | 44 (23.4) | 7 (3.7) | 0.123 | 95 (50.5) | 65 (34.6) | 28 (14.9) | 0.328 | 119 (63.3) | 57 (30.3) | 12 (6.4) | 0.794 |
| | No | 63 (41.4) | 68 (44.7) | 21 (13.8) | | 61 (40.1) | 75 (49.3) | 16 (10.5) | | 125 (82.2) | 23 (15.1) | 4 (2.6) | | 77 (50.7) | 60 (39.5) | 15 (9.9) | | 101 (66.4) | 41 (27.0) | 10 (6.6) | |
| Headache | Yes | 26 (44.1) | 21 (35.6) | 12 (20.3) | 0.187 | 26 (44.1) | 28 (47.5) | 5 (8.5) | 0.905 | 46 (78.0) | 10 (16.9) | 3 (5.1) | 0.595 | 28 (47.5) | 23 (39.0) | 8 (13.6) | 0.869 | 40 (67.8) | 17 (28.8) | 2 (3.4) | 0.562 |
| | No | 112 (39.9) | 132 (47.0) | 37 (13.2) | | 115 (40.9) | 141 (50.2) | 25 (8.9) | | 216 (76.9) | 57 (20.3) | 8 (2.8) | | 144 (51.2) | 102 (36.3) | 35 (12.5) | | 180 (64.1) | 81 (28.8) | 20 (7.1) | |
| Shortness of breath | Yes | 33 (36.7) | 46 (51.1) | 11 (12.2) | 0.389 | 38 (42.2) | 42 (46.7) | 10 (11.1) | 0.616 | 61 (67.8) | 24 (26.7) | 5 (5.6) | **0.040** | 44 (48.9) | 35 (38.9) | 11 (12.2) | 0.888 | 64 (71.1) | 21 (23.3) | 5 (5.6) | 0.330 |
| | No | 105 (42.0) | 107 (42.8) | 38 (14.4) | | 103 (41.2) | 127 (50.8) | 20 (8.0) | | 201 (80.4) | 43 (17.2) | 6 (2.4) | | 128 (51.2) | 90 (36.0) | 32 (12.8) | | 156 (62.4) | 77 (30.8) | 17 (6.8) | |
| Diarrhea | Yes | 15 (50.0) | 12 (40.0) | 3 (10.0) | 0.510 | 11 (36.7) | 15 (50.0) | 4 (13.3) | 0.624 | 22 (73.3) | 7 (23.3) | 1 (3.3) | 0.869 | 15 (50.0) | 9 (30.0) | 6 (20.0) | 0.403 | 22 (73.3) | 8 (26.7) | 0 (0.0) | 0.278 |
| | No | 123 (39.7) | 141 (45.5) | 46 (14.8) | | 130 (41.9) | 154 (49.7) | 28 (8.4) | | 240 (77.4) | 60 (19.4) | 10 (3.2) | | 157 (50.6) | 116 (37.4) | 37 (11.9) | | 198 (63.9) | 90 (29.0) | 22 (7.1) | |
| Myalgia | Yes | 34 (43.0) | 38 (48.1) | 7 (8.9) | 0.276 | 30 (38.0) | 39 (49.4) | 10 (12.7) | 0.364 | 63 (79.7) | 16 (20.3) | 0 (0.0) | 0.179 | 43 (54.4) | 29 (36.7) | 7 (8.9) | 0.480 | 56 (70.9) | 17 (21.5) | 6 (7.6) | 0.257 |
| | No | 104 (39.8) | 115 (44.1) | 42 (16.1) | | 11 (42.5) | 130 (49.8) | 20 (7.7) | | 199 (76.2) | 51 (19.5) | 11 (4.2) | | 129 (49.4) | 96 (36.8) | 36 (13.8) | | 164 (62.8) | 81 (31.0) | 16 (6.1) | |
| Fatigue | Yes | 18 (31.6) | 31 (54.4) | 8 (14.0) | 0.257 | 25 (43.9) | 30 (52.6) | 2 (3.5) | 0.301 | 40 (70.2) | 13 (22.8) | 4 (7.0) | 0.151 | 23 (404) | 27 (47.4) | 7 (12.3) | 0.172 | 40 (70.2) | 14 (24.6) | 3 (5.3) | 0.637 |
| | No | 120 (42.4) | 122 (43.1) | 41 (14.5) | | 116 (41.0) | 139 (49.1) | 28 (9.9) | | 222 (78.4) | 54 (19.1) | 7 (2.5) | | 149 (52.7) | 98 (34.6) | 36 (12.7) | | 180 (63.6) | 84 (29.7) | 19 (6.7) | |
| Nausea | Yes | 17 (43.6) | 17 (43.6) | 5 (12.8) | 0.907 | 14 (35.9) | 21 (53.8) | 4 (10.3) | 0.747 | 30 (76.9) | 7 (17.9) | 2 (5.1) | 0.757 | 17 (43.6) | 19 (48.7) | 3 (7.7) | 0.224 | 26 (66.7) | 11 (28.2) | 2 (5.1) | 0.926 |
| | No | 121 (40.2) | 136 (45.2) | 44 (14.6) | | 127 (42.2) | 148 (49.2) | 26 (8.6) | | 232 (77.1) | 60 (19.9) | 9 (3.0) | | 155 (51.5) | 106 (35.2) | 40 (13.3) | | 194 (64.5) | 87 (28.9) | 20 (6.6) | |
| Vomiting | Yes | 14 (48.3) | 9 (31.0) | 6 (20.7) | 0.259 | 8 (27.6) | 19 (65.5) | 2 (6.9) | 0.202 | 21 (72.4) | 6 (20.7) | 2 (6.9) | 0.492 | 13 (44.8) | 12 (41.4) | 4 (13.8) | 0.809 | 21 (72.4) | 7 (24.1) | 1 (3.4) | 0.613 |
| | No | 124 (39.9) | 144 (46.3) | 43 (13.8) | | 133 (42.8) | 150 (48.2) | 28 (9.0) | | 241 (77.5) | 61 (19.6) | 9 (2.9) | | 159 (51.1) | 113 (36.3) | 39 (12.5) | | 199 (64.0) | 91 (29.3) | 21 (6.8) | |
| Parageusia | Yes | 14 (36.8) | 19 (50.0) | 5 (13.2) | 0.806 | 11 (28.9) | 23 (60.5) | 4 (10.5) | 0.251 | 28 (73.7) | 10 (26.3) | 0 (0.0) | 0.302 | 21 (55.3) | 15 (39.5) | 2 (5.3) | 0.374 | 26 (68.4) | 10 (26.3) | 2 (5.3) | 0.869 |
| | No | 124 (41.1) | 134 (44.4) | 44 (14.6) | | 130 (43.0) | 146 (48.3) | 26 (8.6) | | 234 (77.5) | 57 (18.9) | 11 (3.6) | | 151 (50.0) | 110 (36.4) | 41 (13.6) | | 194 (64.2) | 88 (29.1) | 20 (6.6) | |
| Hypertension | Yes | 35 (39.3) | 42 (47.2) | 12 (13.5) | 0.883 | 34 (38.2) | 46 (51.7) | 9 (10.1) | 0.729 | 60 (67.4) | 26 (29.2) | 3 (3.4) | **0.030** | 43 (48.3) | 35 (39.3) | 11 (12.4) | 0.841 | 58 (65.2) | 26 (29.2) | 5 (5.6) | 0.930 |
| | No | 103 (41.0) | 111 (44.2) | 37 (14.7) | | 107 (42.6) | 123 (49.0) | 21 (8.4) | | 202 (80.5) | 41 (16.3) | 8 (3.2) | | 129 (51.4) | 90 (35.9) | 32 (12.7) | | 162 (64.5) | 72 (28.7) | 17 (6.8) | |
| Diabetes | Yes | 30 (39.5) | 40 (52.6) | 6 (7.9) | 0.124 | 32 (42.1) | 36 (47.4) | 8 (10.5) | 0.803 | 58 (76.3) | 14 (18.4) | 4 (5.3) | 0.513 | 36 (47.4) | 31 (40.8) | 9 (11.8) | 0.711 | 50 (65.8) | 21 (27.6) | 5 (6.6) | 0.967 |
| | No | 108 (40.9) | 113 (42.8) | 43 (16.3) | | 109 (41.3) | 133 (50.4) | 22 (8.3) | | 204 (77.3) | 53 (20.1) | 7 (2.7) | | 136 (51.5) | 94 (35.6) | 34 (12.9) | | 170 (64.4) | 77 (29.2) | 17 (6.4) | |
| Asthma | Yes | 11 (37.9) | 9 (31.0) | 9 (31.0) | **0.023** | 12 (41.4) | 12 (41.4) | 5 (17.2) | 0.224 | 24 (82.8) | 4 (13.8) | 1 (3.4) | 0.704 | 16 (55.5) | 10 (34.5) | 3 (10.3) | 0.857 | 14 (48.3) | 11 (37.9) | 4 (13.8) | 0.088 |
| | No | 127 (40.8) | 144 (46.3) | 40 (12.9) | | 129 (41.5) | 157 (50.5) | 25 (8.0) | | 238 (76.5) | 63 (20.3) | 10 (3.2) | | 156 (50.2) | 115 (37.0) | 40 (12.9) | | 206 (66.2) | 87 (28.0) | 18 (5.8) | |
| | Yes | 15 (42.9) | 16 (45.7) | 4 (11.4) | 0.863 | 14 (40.0) | 16 (45.7) | 9 (14.3) | 0.481 | 25 (71.4) | 9 (25.7) | 1 (2.9) | 0.640 | 15 (42.9) | 13 (37.1) | 7 (20.0) | 0.345 | 25 (71.4) | 8 (22.9) | 2 (5.7) | 0.674 |

(*continued on next page*)

**Table 8** (*continued*)

| 3′ end's VDR polymorphisms | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | Status | ApaI | | | | BsmI | | | | TruI9I | | | | TaqI | | | | BglI | | | |
| | | AA | Aa | aa | P | BB | Bb | bb | P | UU | Uu | uu | P | TT | Tt | tt | P | GG | Gg | gg | P |
| Cardiovascular disease | No | 123 (40.3) | 137 (44.9) | 45 (14.8) | | 127 (41.6) | 153 (50.2) | 25 (8.2) | | 237 (77.7) | 58 (19.0) | 10 (3.3) | | 157 (51.5) | 112 (36.7) | 36 (11.8) | | 195 (63.9) | 90 (29.5) | 20 (6.6) | |
| Chronic renal disease | Yes | 26 (40.6) | 29 (45.3) | 9 (14.1) | 0.996 | 30 (46.9) | 24 (37.5) | 10 (15.6) | **0.029** | 54 (84.4) | 10 (15.6) | 0 (0.0) | 0.152 | 33 (51.6) | 27 (42.2) | 4 (6.2) | 0.202 | 46 (71.9) | 13 (20.3) | 5 (7.8) | 0.243 |
| | No | 112 (40.6) | 124 (44.9) | 40 (14.5) | | 111 (40.2) | 145 (52.5) | 20 (7.2) | | 208 (75.4) | 57 (20.7) | 11 (4.0) | | 139 (50.4) | 98 (35.5) | 39 (14.1) | | 174 (63.0) | 85 (30.8) | 17 (6.2) | |
| Malignancy | Yes | 5 (25.0) | 12 (60.0) | 3 (15.0) | 0.310 | 10 50.0() | 8 (40.0) | 2 (20.0) | 0.667 | 15 (75.0) | 4 (20.0) | 1 (5.0) | 0.897 | 6 (30.0) | 12 (60.0) | 2 (10.0) | 0.081 | 14 (70.0) | 4 (20.0) | 2 (10.0) | 0.584 |
| | No | 133 (41.6) | 141 (44.1) | 46 (14.4) | | 131 (40.9) | 161 (50.3) | 28 (8.8) | | 247 (77.2) | 63 (19.7) | 10 (3.1) | | 166 (51.9) | 113 (35.3) | 41 (12.8) | | 206 (64.4) | 94 (29.4) | 20 (6.2) | |

Bold items indicate an statistically significant levels.

behavior (van Etten et al., 2007). Based on a meta-analysis by Laplana et al., FokI polymorphism was associated with viral infections, wherein the TT genotype and T allele were reported to be risk factors for infections with enveloped viruses, including RSV (Laplana et al., 2018). In this line, the risk f-allele may have a lower transcription of VDR decreasing the efficiency of the vitamin D pathway by hampering the binding of vitamin D to VDR and affecting the expression of vitamin D responsive genes. Further, no significant differences were disclosed in FokI allelic and genotypic distributions between mild/moderate and asymptomatic groups, as well as between mild/moderate and severe/critical patients.

The Cdx-2 site in the 1a promoter region of the VDR gene is a functional binding site for the transcription factor Cdx-2. G to A substitution polymorphism at this site has been found to alter the transcription of the VDR gene, whereby the A-allele increases binding to the Cdx-2 protein and transcription activity of the VDR promoter compared with the G allele (Fang et al., 2003). According to the CDX2 results, "c" minor allele frequency was higher in symptomatic and severe/critical patients against asymptomatic COVID-19 cases, while "C" major allele rates were lower. Thus, the alleles "c" and "C" can be introduced as risk and protective factors, respectively, for signs, symptoms, and maybe the severity of the COVID-19. CDX2 genotypic distributions illustrated more interesting findings based on dominant, recessive, and codominant genetic models in COVID-19 patients, including protective effects of "CC" *versus* "Cc + cc", susceptible effects of "cc" *versus* both "CC + Cc" and "CC" to have clinical features and likely severity of the disease. Cdx2 is considered as a functional polymorphism of the VDR gene that has been demonstrated to impact the immune system alter the risk of contracting certain infectious illnesses (*e.g.*, tuberculosis and rubella) (Meyer and Bornman, 2018; Ovsyannikova et al., 2010). Nevertheless, no substantial link has been established between this SNP and autoimmune disorders such as T1D, MS, vitiligo, or psoriasis (Dickinson et al., 2009; Zhou et al., 2014; Frederiksen et al., 2013; Aydıngöz et al., 2012). Although it is uncertain why the polymorphism is connected to illnesses like tuberculosis, numerous studies have connected this association to VDR methylation, vitamin D-mediated control of chemokine-positive T cells, and impact adaptive cytokine responses (Meyer and Bornman, 2018; Ovsyannikova et al., 2010; Harishankar and Selvaraj, 2017).

The *Eco*RV polymorphism (rs4516035), like CDX2, is found in the promoter region of the VDR gene and is thought to play a role in the anticancer immune response. EcoRV (5′ to exon 1a) is a regulatory region SNPs that can affect VDR transcription *via* TF binding differences (Halsall et al., 2004). In the presented study, EcoRV allelic and genotypic distributions unveiled several intriguing findings. Firstly, EcoRV minor allele "e" frequencies were remarkably inclined to increase in symptomatic, mild/moderate, and severe/critical patients compared to asymptomatic COVID-19 patients, while major allele "E" rates were decreased. Therefore, negative and positive associations of "E" and "e" alleles, respectively, with clinical outcomes of COVID-19 can be proposed. Nonetheless, no significant discrepancy was found in allelic frequencies between mild/moderate and severe/critical patients. Accordingly, genetic model-based genotypic distributions of EcoRV polymorphism highlighted the protective role of "EE" *vs.* "Ee + ee", vulnerable effects of "Ee" *versus* "EE + ee", and "Ee" *versus* "EE". Amazingly, we didn't found any significant differences in the distribution of "ee" and "EE" genotypes among different clinical groups. Furthermore, increased frequencies of "Ee" *versus* "EE + ee" and "Ee" *versus* "EE" in severe/critical compared to mild/moderate patients, obviously demonstrated the important role of heterozygous "Ee" in the severity of COVID-19 patients. It is previously reported that EcoRv is correlated with optimal bone density, cancer risk, diabetes, and susceptibility to HIV-1 infection (Halsall et al., 2004; Ghodsi et al., 2021).

The *Apa*I (rs7975232) intronic variation is anticipated to impact splice site alterations, which may change VDR translation. This variation is common, as indicated by 734 and 16,751 homozygous mutants in the 1000G and ExAC databases, respectively (Hussain et al., 2019). ApaI

allelic frequencies, determined as major "A" and minor "a" alleles, didn't show significant differences between various paired groups of COVID-19. The present study highlighted that the "AA" genotype made COVID-19 affected people more prone to possess signs and symptoms *versus* both "Aa + aa" and "Aa" genotypes based on paired-groups of the symptomatic-asymptomatic and mild/moderate-asymptomatic comparisons. Additionally, heterozygous "Aa" patients were more protected to show signs and symptoms compared to combined "AA + aa" genotypes. This finding was interestingly opposite between severe/critical and mild/moderate groups, in which a rising risk of severity was demonstrated in patients with "Aa" genotype compared to "AA + aa" genotypes. This could be explained by the involvement of several factors determining the severity of the disease and might not be directly related to ApaI effects. Association of ApaI with different conditions including cancers, type 1 diabetes, asthma, multiple sclerosis, and several autoimmune diseases has previously been reported (Clendenen et al., 2008; Cheon et al., 2015; Mohammadi et al., 2020; Wjst, 2005).

*Bsm*I polymorphism was revealed not to have any significant differences in allelic and genotypic frequencies between asymptomatic COVID-19 patients and other groups, including mild/moderate, severe/critical, and also all symptomatic patients. However, remarkable discrepancies were observed in allelic and genotypic distributions between mild/moderate and severe/critical COVID-19 suffered individuals. Our finding disclosed that minor allele "b" acts as a predisposition factor to COVID-19 severity, but major allele "B" has a protective effect. Moreover, genetic model-based genotypic distributions illustrated that patients with the "BB" genotype *versus* combined "bb + Bb" genotypes have decreased risk to develop more serious forms of COVID-19. However, "Bb" symptomatic heterozygotes showed elevated vulnerability to have more seriously COVID-19 than combined "BB + Bb" genotypes. VDR has an essential function in regulating the immune system in macrophages, dendritic cells, neutrophils, B cells, natural killer (NK) cells, and T lymphocyte. Therefore, these findings could be interpreted that VDR *Bsm*I polymorphism has a significant role in susceptibility to and in the progression of viral infections such as COVID-19.

The SNP Tru9I didn't show any significant differences in allelic distribution between paired-group comparisons, except between severe/critical and mild/moderate groups, in which major "U" and minor "u" alleles were described as protective and risk factors, respectively. Tru9I genotypic frequencies didn't exhibit any significant association with clinical manifestations and also severity COVID-19. TaqI and *Bgl*I variants-related allelic and genotypic frequencies showed no significant association with clinical manifestations and also severity of COVID-19 affected peoples based on any genetic models in the present study. TaqI is a synonymous mutation at codon 352 in exon 9 at the 3′ end of the VDR gene, in which "T" and "t" alleles were identified as absent and presence of the restriction site, respectively. The TT genotype has been reported to be associated with lower circulating levels of active vitamin D3 (Morrison et al., 1994; Hustmyer et al., 1993; Ma et al., 1998). *Apa*I, BsmI, Tru9I, and BglI are located in intron 8 at the 3′ end of the VDR gene, which are considered silent SNPs. These polymorphisms do not change the amino acid sequence of the encoded protein, however, they may affect gene expression through the regulation of mRNA stability or linkage disequilibrium with other SNPs affecting the susceptibility to diseases (Jurutka et al., 2001).

Evaluating the potential association of VDR gene SNPs with signs and symptoms of COVID-19 patients, especially respiratory complications, surely highlights the more detailed importance of these variants in the severity of the disease. Despite the significant associations of some VDR gene variants with signs and symptoms of mild/moderate COVID-19 patients, amazing findings were pinpointed in group III. Accordingly, we found a strong association between both allelic and genotypic distributions of ApaI and CDX2 SNPs with shortness of breath. Regarding the ApaI, we found that major "A" and minor allele "a" provide a protective and susceptible effect, respectively, in severe/critical patients. According, our findings disclosed that severe/critical COVID-19 patients with "Aa" genotype and then "aa" genotype are more at risk of shortness of breath than "AA" patients. The minor "c" and major "C" alleles of CDX2 were found to have positive and negative associations with symptomatic and severe/critical COVID-19 groups, respectively. Moreover, negative association of "CC" genotype *versus* combined "Cc + cc" genotypes, positive associations of "cc" genotype *versus* both combined "CC + Cc" genotypes, and "CC" genotype to have clinical features and likely severity of disease are suggested. Nevertheless, "cc" *versus* both combined "CC + Cc" genotypes and "CC" genotype revealed a strong protective effect against shortness of breath. Unfortunately, we can't provide a rational explanation for these contradictory findings, therefore, it needs to be re-evaluated in other studies with larger sample sizes, in other ethnicities, and geographical regions.

Despite the high prevalence of conflicting results in previous investigations, we separately assessed the potential association of these VDR gene SNPs with some comorbidities including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy in various COVID-19 groups to further clarify how these genetic variants affect the prognosis of COVID-19 patients. No significant association was found between VDR gene variants and comorbidities in the asymptomatic COVID-19 group, while a strong association of VDR gene SNPs was seen with some of these conditions in mild/moderate and severe/critical groups.

Our results revealed that mild/moderate COVID-19 patients with the "BB" genotype are more prone to chronic renal disease, while patients with "Bb" are more protective. Therefore, it can be proposed that homozygotes subjects ("BB" and "bb") are at increased risk of chronic renal disease than heterozygotes in mild/moderate patients. Unlikely, we found an increased risk of the "bb" genotype *versus* the combined "BB + Bb" and "BB" genotype, and no significant discrepancy was observed between the distribution of the "Bb" and "BB" to have chronic renal disease in severe/critical COVID-19 patients. Consequently, we can suggest that the "Bb" genotype provides a protective role to have chronic renal disease in both mild/moderate and severe/critical COVID-19 patients, but the effects of "BB" and "bb" genotypes entirely depend on the stage of the disease. Regarding the *Eco*RV variant and diabetes in mild/moderate COVID-19 patients, we observed a negative association of the "E" allele and a positive association of the "e" allele. Also, our data revealed the protective effect of the "EE" genotype, but predisposing impacts of "ee" genotype, as well as increased risk of "Ee" genotype *versus* combined "EE + ee" and "EE" genotypes against diabetes. Therefore, it can be proposed that mild/moderate COVID-19 patients with 0, 1, and 2 alleles of minor allele "e" have a low, intermediate, and high risk of diabetes, respectively. Similar findings were observed in severe/critical patients, however, the distribution of "EE" and "ee" didn't show any remarkable difference. Overall, it can be argued that how the EcoRV variant is associated with diabetes depends entirely on the stage of COVID-19 disease, wherein the additive and overdominant genetic model better explains the observed findings in mild/moderate and severe/critical groups, respectively.

In addition to EcoRV, CDX2 polymorphism has also been disclosed to have a significant association with diabetes in severe/critical COVID-19 patients. The major "C" and minor "c" alleles exhibited a negative and positive association with diabetes, respectively. Moreover, it was demonstrated that severe/critical patients with the "cc" genotype are more susceptible to have diabetes. Also, the CDX2 was recognized to have an association with hypertension, in which severe/critical COVID-19 patients with genotype "cc" have an increased risk for hypertension. Collectively, it can be proposed that the "cc" genotype causes an increased risk on severe/critical COVID-19 to exhibit both diabetes and hypertension comorbidities. Similarly, *Fok*I SNP illustrated a remarkable association with hypertension in severe/critical COVID-19 patients, in which elevated risk of hypertension was detected in "ff" genotype. *Apa*I genotypes were deciphered to possess a significant association with asthma, in which severe/critical COVID-19 patients with "aa" genotype strongly have increased risk than "AA + Aa" patients. Briefly, our data

**Table 9**
Significant association of VDR gene polymorphisms with some clinical symptom and comorbidities in COVID-19 patients.

| Genetic models | | P- value | Odds ratio (95% CI) |
|---|---|---|---|
| ApaI and fever | | | |
| *Dominant* | *AA + Aa vs. aa* | 0.954 | 0.98 (0.53–1.81) |
| | *aa vs. AA + Aa* | | 1.02 (0.55–1.89) |
| *Recessive* | *aa + Aa vs. AA* | **< 0.001** | 2.15 (1.38–3.34) |
| | *AA vs. aa + Aa* | | 0.47 (0.30–0.73) |
| *Overdominant* | *Aa vs. AA + aa* | **< 0.001** | 2.11 (1.36–3.28) |
| | *AA + aa vs. Aa* | | 0.47 (0.31–0.74) |
| *Codominant* | *aa vs. AA* | 0.168 | 1.59 (0.82–3.06) |
| | *Aa vs. AA* | **< 0.001** | 2.38 (1.48–3.83) |
| *Allelic* | *A vs. a* | **0.013** | 0.67 (0.49–0.92) |
| | *a vs. A* | | 1.49 (1.09–2.04) |
| ApaI and asthma | | | |
| *Dominant* | *AA + Aa vs. aa* | **0.011** | 0.33 (0.14–0.77) |
| | *aa vs. AA + Aa* | | 3.03 (1.30–7.14) |
| *Recessive* | *aa + Aa vs. AA* | 0.761 | 1.13 (0.52–2.47) |
| | *AA vs. aa + Aa* | | 0.89 (0.41–1.92) |
| *Overdominant* | *Aa vs. AA + aa* | 0.119 | 0.52 (0.23–1.18) |
| | *AA + aa vs. Aa* | | 1.92 (0.85–4.35) |
| *Codominant* | *aa vs. AA* | **0.049** | 2.60 (1.01–6.72) |
| | *Aa vs. AA* | 0.484 | 0.72 (0.29–1.80) |
| *Allelic* | *A vs. a* | 0.114 | 0.65 (0.38–1.11) |
| | *a vs. A* | | 1.54 (0.90–2.63) |
| BsmI and chronic renal disease | | | |
| *Dominant* | *BB + Bb vs. bb* | **0.038** | 0.42 (0.19–0.95) |
| | *bb vs. BB + Bb* | | 2.38 (1.05–5.26) |
| *Recessive* | *bb + Bb vs. BB* | 0.331 | 0.76 (0.44–1.32) |
| | *BB vs. bb + Bb* | | 1.32 (0.76–2.27) |
| *Overdominant* | *Bb vs. BB + bb* | **0.032** | 0.54 (0.31–0.95) |
| | *BB + bb vs. Bb* | | 1.85 (1.05–3.23) |
| *Codominant* | *bb vs. BB* | 0.161 | 1.85 (0.78–4.37) |
| | *Bb vs. BB* | 0.104 | 0.61 (0.34–1.11) |
| *Allelic* | *B vs. b* | 0.853 | 0.96 (0.64–1.44) |
| | *b vs. B* | | 1.04 (0.69–1.56) |
| Tru9I and shortness of breath | | | |
| *Dominant* | *UU + Uu vs. uu* | 0.159 | 0.42 (0.12–1.41) |
| | *uu vs. UU + Uu* | | 2.38 (0.71–8.33) |
| *Recessive* | *uu + Uu vs. UU* | **0.016** | 1.95 (1.14–3.35) |
| | *UU vs. uu + Uu* | | 0.51 (0.30–0.88) |
| *Overdominant* | *Uu vs. UU + uu* | 0.055 | 1.75 (0.99–3.10) |
| | *UU + uu vs. Uu* | | 0.57 (0.32–1.01) |
| *Codominant* | *uu vs. UU* | 0.105 | 2.75 (0.81–9.31) |
| | *Uu vs. UU* | **0.038** | 1.84 (1.03–3.27) |
| *Allelic* | *U vs. u* | **0.008** | 0.53 (0.33–0.85) |
| | *u vs. U* | | 1.89 (1.18–3.03) |
| Tru9I and hypertension | | | |
| *Dominant* | *UU + Uu vs. uu* | 0.933 | 0.94 (0.25–3.64) |
| | *uu vs. UU + Uu* | | 1.06 (0.28–4.00) |
| *Recessive* | *uu + Uu vs. UU* | **0.013** | 1.99 (1.16–3.43) |
| | *UU vs. uu + Uu* | | 0.50 (0.29–0.86) |
| *Overdominant* | *Uu vs. UU + uu* | **0.010** | 2.11 (1.20–3.72) |
| | *UU + uu vs. Uu* | | 0.47 (0.27–0.83) |
| *Codominant* | *uu vs. UU* | 0.737 | 1.26 (0.32–4.91) |
| | *Uu vs. UU* | **0.009** | 2.14 (1.21–3.77) |
| *Allelic* | *U vs. u* | **0.026** | 0.58 (0.37–0.94) |
| | *u vs. U* | | 1.72 (1.06–2.70) |
| FokI and fever | | | |
| *Dominant* | *FF + Ff vs. ff* | **0.017** | 0.47 (0.25–0.87) |
| | *ff vs. FF + Ff* | | 2.13 (1.15–4.00) |
| *Recessive* | *ff + Ff vs. FF* | 0.140 | 1.40 (0.90–2.18) |
| | *FF vs. ff + Ff* | | 0.71 (0.46–1.11) |
| *Overdominant* | *Ff vs. FF + ff* | 0.711 | 0.92 (0.60–1.42) |
| | *ff + FF vs. Ff* | | 1.09 (0.70–1.67) |
| *Codominant* | *ff vs. FF* | **0.014** | 2.35 (1.19–4.62) |
| | *Ff vs. FF* | 0.490 | 1.18 (0.74–1.89) |
| *Allelic* | *F vs. f* | **0.020** | 0.69 (0.50–0.94) |
| | *f vs. F* | | 1.45 (1.06–2.00) |
| FokI and hypertension | | | |
| *Dominant* | *FF + Ff vs. ff* | **0.016** | 0.48 (0.26–0.87) |
| | *ff vs. FF + Ff* | | 2.08 (1.15–3.85) |
| *Recessive* | *ff + Ff vs. FF* | 0.204 | 1.40 (0.83–2.33) |
| | *FF vs. ff + Ff* | | 0.71 (0.43–1.21) |
| *Overdominant* | *Ff vs. FF + ff* | 0.560 | 0.87 (0.53–1.41) |
| | *ff + FF vs. Ff* | | 1.15 (0.71–1.89) |
| *Codominant* | *ff vs. FF* | **0.019** | 2.27 (1.15–4.48) |
| | *Ff vs. FF* | 0.628 | 1.15 (0.66–2.00) |
| *Allelic* | *F vs. f* | **0.028** | 0.68 (0.48–0.96) |
| | *f vs. F* | | 1.47 (1.04–2.08) |
| CDX2 and headache | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.006** | 0.42 (0.23–0.78) |
| | *cc vs. CC + Cc* | | 2.38 (1.28–4.35) |
| *Recessive* | *cc + Cc vs. CC* | 0.485 | 1.24 (0.68–2.25) |
| | *CC vs. cc + Cc* | | 0.81 (0.44–1.47) |
| *Overdominant* | *Cc vs. CC + cc* | 0.113 | 0.62 (0.35–1.12) |
| | *CC + cc vs. Cc* | | 1.61 (0.89–2.86) |
| *Codominant* | *cc vs. CC* | **0.031** | 2.19 (1.07–4.47) |
| | *Cc vs. CC* | 0.668 | 0.86 (0.44–1.70) |
| *Allelic* | *C vs. c* | **0.037** | 0.66 (0.44–0.98) |
| | *c vs. C* | | 1.51 (1.02–2.27) |
| CDX2 and hypertension | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.001** | 0.40 (0.23–0.70) |
| | *cc vs. CC + Cc* | | 2.50 (1.43–4.35) |
| *Recessive* | *cc + Cc vs. CC* | 0.282 | 1.33 (0.79–2.22) |
| | *CC vs. cc + Cc* | | 0.75 (0.45–1.27) |
| *Overdominant* | *Cc vs. CC + cc* | 0.108 | 0.66 (0.40–1.09) |
| | *CC + cc vs. Cc* | | 1.52 (0.92–2.50) |
| *Codominant* | *cc vs. CC* | **0.007** | 2.40 (1.27–4.53) |
| | *Cc vs. CC* | 0.845 | 0.94 (0.53–1.68) |
| *Allelic* | *C vs. c* | **0.009** | 0.63 (0.45–0.89) |
| | *c vs. C* | | 1.59 (1.12–2.22) |
| CDX2 and diabetes | | | |
| *Dominant* | *CC + Cc vs. cc* | **0.008** | 0.46 (0.26–0.82) |
| | *cc vs. CC + Cc* | | 2.17 (1.22–3.85) |
| *Recessive* | *cc + Cc vs. CC* | **0.044** | 1.79 (1.06–3.16) |
| | *CC vs. cc + Cc* | | 0.56 (0.32–0.94) |
| *Overdominant* | *Cc vs. CC + cc* | 0.823 | 0.94 (0.56–1.58) |
| | *CC + cc vs. Cc* | | 1.06 (0.63–1.79) |
| *Codominant* | *cc vs. CC* | **0.005** | 2.69 (1.35–5.35) |
| | *Cc vs. CC* | 0.254 | 1.43 (0.77–2.66) |
| *Allelic* | *C vs. c* | **0.003** | 0.58 (0.40–0.84) |
| | *c vs. C* | | 1.72 (1.19–2.50) |
| EcoRV and diabetes | | | |
| *Dominant* | *EE + Ee vs. ee* | **0.014** | 0.36 (0.16–0.81) |
| | *ee vs. EE + Ee* | | 2.78 (1.24–6.25) |
| *Recessive* | *ee + Ee vs. EE* | **< 0.001** | 3.86 (2.19–6.80) |
| | *EE vs. ee + Ee* | | 0.26 (0.15–0.46) |
| *Overdominant* | *Ee vs. EE + ee* | **< 0.001** | 2.54 (1.51–4.28) |
| | *EE + ee vs. Ee* | | 0.39 (0.23–0.66) |
| *Codominant* | *ee vs. EE* | **< 0.001** | 5.61 (2.27–13.89) |
| | *Ee vs. EE* | **< 0.001** | 3.59 (2.00–6.44) |
| *Allelic* | *E vs. e* | **< 0.001** | 0.40 (0.27–0.58) |
| | *e vs. E* | | 2.50 (1.72–3.70) |

Bold items indicate an statistically significant levels.

highlighted that ApaI SNP is associated with respiratory complications, including shortness of breath and asthma in severe/critical COVID-19 patients more likely based on overdominant and dominant genetic models, respectively.

To evaluate the reproducibility of the results and increase the accuracy of the study, the association of VDR gene SNPs with clinical outcomes and comorbidities was examined, regardless of the severity grouping of COVID-19 patients that in turn led to obtaining a larger sample size. Here, we found a significant association of VDR gene polymorphisms with several clinical outcomes of COVID-19 patients, including the association of ApaI and FokI variants with fever, Tru9I with shortness of breath, and CDX2 with the headache. By comparing these findings with the results described earlier, it is clear that these associations are quietly different. ApaI allelic and genotypic frequencies revealed that alleles "A" and "a" contribute to decreased and increased susceptibility of COVID-19 patients to fever, respectively. Our data revealed that patients with genotype "AA", are more protected to exhibit

fever than "Aa + aa" patients, but the "Aa" patients are more susceptible to exhibit fever than "AA + aa", "AA" and "aa" genotypes. All of these findings pinpointed that the overdominant genetic model is the most likely model, in which an increased chance to have a fever might be occurred in heterozygotes compared to both dominant and recessive homozygotes. In respect of FokI SNP, we found that the major "F" allele associate with diminished susceptibility to fever, however the minor "f" allele associate with increased risk. Accordingly, we demonstrated that COVID-19 patients with the "ff" genotype have a higher chance to exhibit fever than "FF + Ff", "FF", and "Ff" patients. We didn't find a significant difference in the distribution of "FF" and "Ff" genotypes between patients with positive and negative fever histories. Consequently, the dominant genetic model is the most likely model, in which "ff" homozygotes are more vulnerable to fever than "Ff" heterozygotes and "FF" homozygotes. Our results disclosed that Tru9I major "U" and minor "u" alleles possess protective and predisposing effects to the shortness of breath, respectively. Further, "UU" COVID-19 patients are more protective to shortness of breath than "Uu + uu", while "Uu" patients are more susceptible to this respiratory complication than COVID-19 subjects with "UU" or "uu" genotypes. Consequently, although no significant difference between "Uu" and combined "UU + uu" was detected, we can propose an overdominant genetic model for this SNP, in which the heterozygotes "Uu" are at elevated risk compared to both "UU" and "uu" homozygotes. The findings of the present study identified the association of CDX2 allelic and genotypic association with headache. It was highlighted that the "C" major allele was negatively associated with headache, but the "c" minor allele was positively associated in COVID-19 patients. Accordingly, we found an increased risk of headache in COVID-19 subjects with "cc" genotype than combined "CC + Cc", "Cc", and "CC" genotypes. However, any significant differences in the distribution of "CC" and "Cc" genotypes didn't observe between COVID-19 cases with and without headache though.

The results of VDR gene SNPs association with comorbidities in the combined COVID-19 patient samples regardless of severity groups ($N = 500$ cases) were interestingly almost consistent with associations found in COVID-19 subgroups. *Apa*I was identified to associate with asthma in the dominant genetic model, in which COVID-19 patients with the "aa" genotype were at higher risk than "AA + Aa" to have asthma. The "bb" homozygotes of *Bsm*I SNP were more susceptible to chronic renal disease in the combined samples (consists of 500 cases) and severe/critical subgroup, while both "BB" and "bb" genotypes increase the risk of chronic renal disease in mild/moderate group. The association of *Eco*RV polymorphism with diabetes was disclosed in combined COVID-19 samples and the most likely of proposed genetic models is additive genetic model, similar to mild/moderate group, in which the COVID-19 affected individuals with 0, 1, and 2 alleles of minor allele "e" are at low, intermediate, and high risk of diabetes, respectively, nonetheless, the overdominant model works better in the severe/critical group. Similar to the severe/critical class of COVID-19, we found a significant association of the CDX2 allelic and genotypic distributions with diabetes and hypertension, in which major "C" and minor "c" alleles exhibited a negative and positive association with both diabetes and hypertension, respectively. According to the results, the strongest genetic model is the dominant model, in which COVID-19 patients with the "cc" genotype have an increased risk of both diabetes and hypertension comorbidities compared to "CC + Cc", "CC", and "Cc" genotypes. Moreover, we found that *Fok*I's major "F" and minor "f" alleles showed protective and susceptible effects on hypertension in combined COVID-19 samples, respectively. Similar to severe/critical patients, COVID-19 patients with "ff" genotype have elevated risk to hypertension *versus* "FF + Ff", "Ff", and "FF" genotypes. The last detected association between VDR gene variants and comorbidities was an association of Tru9I with hypertension, which was not observed in subtypes of COVID-19 patients. The results disclosed major "U" and minor "u" alleles as susceptible and protective factors for hypertension, respectively. Tru9I genotypic distributions suggested an overdominant genetic model as the most likely model, in which COVID-19 patients with "Uu" genotype had increased risk to hypertension than "UU + uu", "UU", "uu" patients.

To appropriately recognize individuals who may require hospital and/or ICU admission, risk stratification based on clinical, radiographic, and laboratory data appears to be essential. The existence of comorbidities is among the most alarming clinical characteristics. Some underlying illnesses such as hypertension, diabetes, lung disease, cardiovascular disease, age may be health issues for severe COVID-19 patients who have poorer outcomes than non-severe COVID-19 patients (Yang et al., 2020). Current evidence from the present study suggests that comorbidities including age, hypertension, diabetes, and chronic renal disease may work as a risk for the worst prognosis of COVID-19 patients. Consistent with previously reported data, our results revealed that severe/critical patients were older than mild/moderate and asymptomatic patients (Williamson et al., 2020). Therefore, a positive association between elder ages and more severity of COVID-19 patients could be proposed. We observed greater frequencies of these diseases in severe/critical patients *versus* mild/moderate and asymptomatic patients, which is consistent with several reports (Singh et al., 2020; Henry and Lippi, 2020; Pranata et al., 2020). Asthma has been considered as a risk factor that makes people susceptible to more severe COVID-19 illness (Lee et al., 2020). However, managing COVID-19 in severe asthma is difficult, and it's uncertain if individuals with severe asthma are at a higher risk of having the poorest results, at least partially due to safety concerns about biologics and systemic corticosteroids (SCSs) (Adir et al., 2021). Our results showed an increased frequency of asthma conditions in severe/critical patients *versus* mild/moderate patients. Interestingly, a lower frequency of this condition was observed in mild/moderate patients than asymptomatic COVID-19 cases. Similar to our results, many recent studies revealed the strong positive association of cancer with the severity of COVID-19, even though inconsistent findings were also observed (Zhang et al., 2020b). Intriguingly, our results didn't show any significant discrepancies of cancer frequency between severe/critical and asymptomatic COVID-19 patients. Despite early studies suggested that cancer might be a separate risk factor for severe COVID-19, recent matched researches comparing outcomes between hospitalized cancer patients and matched controls found no statistically significant differences in death (Brar et al., 2020; Klein et al., 2021). As a result, a history of cancer and cancer-directed treatments might not even be associated with a greater risk of the most serious COVID-19 outcomes in hospitalized individuals. A proinflammatory state and a weakened innate immune response are suggested as the common characteristics between these chronic illnesses and infectious diseases, which may be connected etiologically to its pathogenesis. More importantly, the co-existence of multiple comorbidities in patients seems to increase the risk of severity or death in COVID-19 disease. Regarding the signs and symptoms in symptomatic patients, increased significant frequencies of the shortness of breath, fatigue, and parageusia were illustrated in the severe/critical group compared to the mild/moderate group, which is similar to previous investigations (Liu et al., 2020). Breathlessness is a distressing and common symptom in patients with severe illness, and it is thought to be caused by physiological and structural abnormalities in the lungs. The increased ventilatory drive may rationalize our findings since individuals with moderate COVID-19 nevertheless respond physiologically to hypoxia.

## 5. Conclusion

Vitamin D has been shown to regulate macrophage responses, stopping them from producing excessive amounts of inflammatory cytokines and chemokines, which are common in COVID-19. Therefore, the prevalence and mortality rate of COVID-19 may depend on the modulatory effect of bioavailable Vitamin D levels of individuals, which is determined by the genetic background, such as VDR gene polymorphisms. Therefore, we designed the present study to explore the association of eight VDR gene SNPs with the clinical status and prognosis of COVID-19

patients. We found significant associations of VDR gene variants with several clinical outcomes such as severity and shortness of breath in mild/moderate and severe/critical cases of COVID-19. Nevertheless, the VDR gene SNPs could not be proposed as either independent or dependent risk factors to COVID-19-co-existing conditions, including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy. Our data showed that some VDR SNPs have a clinical impact on the COVID-19 patients and might be helpful to identify the individuals at high risk of COVID-19 severity in the Iranian population. Moreover, the variations in the prevalence of COVID-19 and its mortality rates among countries may be explained by vitamin D function differed by the VDR polymorphisms. However, the present study is preliminary with partially limited sample size. Thus, further experiments are suggested to identify the role of VDR polymorphisms as the cause-effect of COVID-19 severity in a larger population, in other ethnicities and geographical regions.

## Author's Contributions

Asaad Azarnezhad and Rasoul Abdollahzadeh: Conceptualization, Methodology, Funding acquisition, and Project Administration. Mohammad Hossein Shushizadeh, Rasoul Abdollahzadeh, and Asaad Azarnezhad: Data curation, Data Interpretation, and Writing- Original draft preparation. Mina Barazandehrokh and Sepideh Choopani: Data curation, Visualization, Investigation, Reviewing and Editing, and Software, Sahereh Paknahad, Maryam Pirhoushiaran, S.Zahra Makani, Razieh, and Zarifian Yeganeh: Data curation, Data Interpretation, Laboratory works, and revising. Ahmed Al-Kateb and Roozbeh Heidarzadehpilehrood: Reviewing, Editing, Software, Validation, and Revising.

## Declaration of competing interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Acknowledgments

The authors would like to thank the participants enrolled in this study. The author(s) received no specific funding for this work. We also thank all of the individuals who provided insight and expertise that greatly assisted the research, although they may not agree with all of the interpretations/conclusions of this paper.

## References

Abdollahzadeh, R., Fard, M.S., Rahmani, F., Moloudi, K., Azarnezhad, A., 2016. Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: a case-control study. J. Neurol. Sci. 367, 148–151.
Abdollahzadeh, R., Moradi Pordanjani, P., Rahmani, F., Mashayekhi, F., Azarnezhad, A., Mansoori, Y., 2018. Association of VDR gene polymorphisms with risk of relapsing-remitting multiple sclerosis in an Iranian Kurdish population. Int. J. Neurosci. 128 (6), 505–511.
Adir, Y., Humbert, M., Saliba, W., 2021. COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence. J. Allergy Clin. Immunol. 148 (2), 361–367.
Ali, N., 2020. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J. Infect. Publ. Health 13 (10), 1373–1380.
Alzaman, N.S., Dawson-Hughes, B., Nelson, J., D'Alessio, D., Pittas, A.G., 2016. Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation. Am. J. Clin. Nutr. 104 (1), 205–214.
Amrein, K., Scherkl, M., Hoffmann, M., Neuwersch-Sommeregger, S., Köstenberger, M., Berisha, A.T., et al., 2020. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur. J. Clin. Nutr. 1–16.
Anastassopoulou, C., Gkizarioti, Z., Patrinos, G.P., Tsakris, A., 2020. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum. Genom. 14 (1), 1–8.
Aydıngöz, İ.E., Bingül, İ., Doğru-Abbasoğlu, S., Vural, P., Uysal, M., 2012. Analysis of vitamin D receptor gene polymorphisms in vitiligo. Dermatology 224 (4), 361–368.
Aygun, H., 2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedeberg's Arch. Pharmacol. 1–4.
Biesalski, H.K., 2020. Vitamin D deficiency and co-morbidities in COVID-19 patients–A fatal relationship? NFS Journal 20, 10–21.
Bizzaro, G., Antico, A., Fortunato, A., Bizzaro, N., 2017. Vitamin D and autoimmune diseases: is vitamin D receptor (VDR) polymorphism the culprit. Isr. Med. Assoc. J. 19 (7), 438–443.
Brar, G., Pinheiro, L.C., Shusterman, M., Swed, B., Reshetnyak, E., Soroka, O., et al., 2020. COVID-19 severity and outcomes in patients with Cancer: a matched cohort study. J. Clin. Oncol. 3914–3924.
Cameron, M.J., Bermejo-Martin, J.F., Danesh, A., Muller, M.P., Kelvin, D.J., 2008. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 133 (1), 13–19.
Carpagnano, G.E., Di Lecce, V., Quaranta, V.N., Zito, A., Buonamico, E., Capozza, E., et al., 2020. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J. Endocrinol. Investig. 1–7.
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In: Channappanavar, R., Perlman, S. (Eds.), 2017. Seminars in Immunopathology. Springer.
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (10223), 507–513.
Cheon, C.K., Nam, H.K., Lee, K.H., Kim, S.Y., Song, J.S., Kim, C., 2015. Vitamin D receptor gene polymorphisms and type 1 diabetes mellitus in a Korean population. Pediatr. Int. 57 (5), 870–874.
Clendenen, T.V., Arslan, A.A., Koenig, K.L., Enquist, K., Wirgin, I., Ågren, Å., et al., 2008. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 260 (1–2), 209–215.
Colin, E.M., Weel, A.E., Uitterlinden, A.G., Buurman, C.J., Birkenhäger, J.C., Pols, H.A., et al., 2000. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. 52 (2), 211–216.
Dancer, R.C., Parekh, D., Lax, S., D'Souza, V., Zheng, S., Bassford, C.R., et al., 2015. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 70 (7), 617–624.
De Wit, E., Van Doremalen, N., Falzarano, D., Munster, V.J., 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14 (8), 523.
Dickinson, J.L., Perera, D.I., Van der Mei, A., Ponsonby, A.-L., Polanowski, A.M., Thomson, R.J., et al., 2009. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult. Scler. J. 15 (5), 563–570.
Ebadi, M., Bhanji, R.A., Mazurak, V.C., Lytvyak, E., Mason, A., Czaja, A.J., et al., 2019. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Aliment. Pharmacol. Ther. 49 (2), 173–182.
Fang, Y., Van Meurs, J.B., Bergink, A.P., Hofman, A., Van Duijn, C.M., Van Leeuwen, J.P., et al., 2003. Cdx-2 polymorphism in the promoter region of the human vitamin D receptor gene determines susceptibility to fracture in the elderly. J. Bone Miner. Res. 18 (9), 1632–1641.
Faul, J., Kerley, C., Love, B., O'Neill, E., Cody, C., Tormey, W., et al., 2020. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection.
Frederiksen, B., Liu, E., Romanos, J., Steck, A., Yin, X., Kroehl, M., et al., 2013. Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). J. Steroid Biochem. Mol. Biol. 133, 51–57.
Ghodsi, M., Keshtkar, A.A., Razi, F., Mohammad Amoli, M., Nasli-Esfahani, E., Zarrabi, F., et al., 2021. Association of vitamin D receptor gene polymorphism with the occurrence of low bone density, osteopenia, and osteoporosis in patients with type 2 diabetes. J. Diabetes Metab. Dis. 1–9.
Gómez, J., Albaiceta, G.M., García-Clemente, M., López-Larrea, C., Amado-Rodríguez, L., Lopez-Alonso, I., et al., 2020. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene 762, 145102.
Grant, W.B., Lahore, H., McDonnell, S.L., Baggerly, C.A., French, C.B., Aliano, J.L., et al., 2020. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12 (4), 988.
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., et al., 2020. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323 (16), 1574–1581.
Halsall, J., Osborne, J., Potter, L., Pringle, J., Hutchinson, P., 2004. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br. J. Cancer 91 (4), 765–770.
Harishankar, M., Selvaraj, P., 2017. Influence of Cdx2 and TaqI gene variants on vitamin D3 modulated intracellular chemokine positive T-cell subsets in pulmonary tuberculosis. Clin. Ther. 39 (5), 946–957.
Henry, B.M., Lippi, G., 2020. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int. Urol. Nephrol. 1–2.
Hou, Y., Zhao, J., Martin, W., Kallianpur, A., Chung, M.K., Jehi, L., et al., 2020. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 18 (1), 1–8.
Hribar, C.A., Cobbold, P.H., Church, F.C., 2020. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson's disease. Brain Sciences. 10 (5), 284.
Hussain, T., Naushad, S.M., Ahmed, A., Alamery, S., Mohammed, A.A., Abdelkader, M. O., et al., 2019. Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis. BMC Med. Genet. 20 (1), 1–8.

Hustmyer, F.G., DeLuca, H.F., Peacock, M., 1993. Apal, Bsml, Eco RV and Taql polymorphisms at the human vitamin D receptor gene locus in Caucasians, Blacks and Asians. Hum. Mol. Genet. 2 (4), 487.
Ilie, P.C., Stefanescu, S., Smith, L., 2020. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin. Exp. Res. 1–4.
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., et al., 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (7047), 112–116.
Jurutka, P.W., Remus, L.S., Whitfield, G.K., Thompson, P.D., Hsieh, J.-C., Zitzer, H., et al., 2000. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14 (3), 401–420.
Jurutka, P.W., Whitfield, G.K., Hsieh, J.-C., Thompson, P.D., Haussler, C.A., Haussler, M. R., 2001. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Disord. 2 (2), 203–216.
K-i, Miyamoto, Kesterson, R.A., Yamamoto, H., Taketani, Y., Nishiwaki, E., Tatsumi, S., et al., 1997. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol. 11 (8), 1165–1179.
Klein, I.A., Rosenberg, S.M., Reynolds, K.L., Zubiri, L., Rosovsky, R., Piper-Vallillo, A.J., et al., 2021. Impact of cancer history on outcomes among hospitalized patients with COVID-19. Oncologist 26 (8), 685–693.
Kong, J., Zhu, X., Shi, Y., Liu, T., Chen, Y., Bhan, I., et al., 2013. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol. Endocrinol. 27 (12), 2116–2125.
Köstner, K., Denzer, N., Mueller, C.S., Klein, R., Tilgen, W., Reichrath, J., 2009. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 29 (9), 3511–3536.
Kunadian, V., Ford, G.A., Bawamia, B., Qiu, W., Manson, J.E., 2014. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am. Heart J. 167 (3), 283–291.
Laplana, M., Royo, J.L., Fibla, J., 2018. Vitamin D receptor polymorphisms and risk of enveloped virus infection: a meta-analysis. Gene 678, 384–394.
Latini, A., Agolini, E., Novelli, A., Borgiani, P., Giannini, R., Gravina, P., et al., 2020. COVID-19 and genetic variants of protein involved in the SARS-CoV-2 entry into the host cells. Genes 11 (9), 1010.
Lee, S.C., Son, K.J., Han, C.H., Jung, J.Y., Park, S.C., 2020. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci. Rep. 10 (1), 1–9.
Liu, J., Zhang, S., Wu, Z., Shang, Y., Dong, X., Li, G., et al., 2020. Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study. Ann. Intensive Care 10 (1), 1–21.
Ma, J., Stampfer, M.J., Gann, P.H., Hough, H.L., Giovannucci, E., Kelsey, K.T., et al., 1998. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Prev. Biomark. 7 (5), 385–390.
McNally, J.D., Sampson, M., Matheson, L.A., Hutton, B., Little, J., 2014. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis. Pediatr. Pulmonol. 49 (8), 790–799.
Mehrabani, S.Z.N., Shushizadeh, M.H., Abazari, M.F., Aleagha, M.N., Ardalan, A., Abdollahzadeh, R., et al., 2019. Association of SHMT1, MAZ, ERG, and L3MBTL3 gene polymorphisms with susceptibility to multiple sclerosis. Biochem. Genet. 57 (3), 355–370.
Meltzer, D.O., Best, T.J., Zhang, H., Vokes, T., Arora, V., Solway, J., 2020. Association of Vitamin D deficiency and treatment with COVID-19 incidence. medRxiv.
Mendy, A., Apewokin, S., Wells, A.A., Morrow, A.L., 2020. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. MedRxiv.
Meyer, V., Bornman, L., 2018. Cdx-2 polymorphism in the vitamin D receptor gene (VDR) marks VDR expression in monocyte/macrophages through VDR promoter methylation. Immunogenetics 70 (8), 523–532.
Mohammadi, A., Azarnezhad, A., Khanbabaei, H., Izadpanah, E., Abdollahzadeh, R., Barreto, G.E., et al., 2020. Vitamin D receptor genetic polymorphisms and the risk of multiple sclerosis: a systematic review and meta-analysis. Steroids 158, 108615.
Morrison, N.A., Qi, J.C., Tokita, A., Kelly, P.J., Crofts, L., Nguyen, T.V., et al., 1994. Prediction of bone density from vitamin D receptor alleles. Nature 367 (6460), 284–287.
Organization WH, 2020. Clinical Management of COVID-19: Interim Guidance, 27 May 2020. World Health Organization.
Ovsyannikova, I.G., Dhiman, N., Haralambieva, I.H., Vierkant, R.A., O'Byrne, M.M., Jacobson, R.M., et al., 2010. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum. Genet. 127 (2), 207–221.
Parekh, D., Thickett, D.R., Turner, A.M., 2013. Vitamin D deficiency and acute lung injury. Inflamm. Allergy Drug Targets 12 (4), 253–261 (Formerly Current Drug Targets-Inflammation & Allergy).
Park, S., Lee, M.G., Hong, S.-B., Lim, C.-M., Koh, Y., Huh, J.W., 2018. Effect of vitamin D deficiency in Korean patients with acute respiratory distress syndrome. Korean J. Intern. Med. 33 (6), 1129.
Pranata, R., Lim, M.A., Huang, I., Raharjo, S.B., Lukito, A.A., 2020. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J. Renin-Angiotensin-Aldosterone Syst. 21 (2).
Quesada-Gomez, J.M., Castillo, M.E., Bouillon, R., 2020. Vitamin D receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: revised Ms SBMB 2020_166. J. Steroid Biochem. Mol. Biol. 105719.
Rhodes, J.M., Subramanian, S., Laird, E., Griffin, G., Kenny, R.A., 2020. Perspective: vitamin D deficiency and COVID-19 severity–plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. J. Intern. Med. 289 (1), 97–115.
Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K. W., et al., 2020. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 323 (20), 2052–2059.
Saccone, D., Asani, F., Bornman, L., 2015. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene 561 (2), 171–180.
Shi, Y.Y., Liu, T.J., Fu, J.H., Xu, W., Wu, L.L., Hou, A.N., et al., 2016. Vitamin D/VDR signaling attenuates lipopolysaccharide-induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier. Mol. Med. Rep. 13 (2), 1186–1194.
Singh, A.K., Gupta, R., Ghosh, A., Misra, A., 2020. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. Clin. Res. Rev. 14 (4), 303–310.
Singhal, T., 2020. A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 1–6.
Sohrabi, C., Alsafi, Z., O'Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., et al., 2020. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int. J. Surg. 76, 71–76.
Tabrizi, R., Moosazadeh, M., Akbari, M., Dabbaghmanesh, M.H., Mohamadkhani, M., Asemi, Z., et al., 2018. High prevalence of vitamin D deficiency among Iranian population: a systematic review and meta-analysis. Iran. J. Med. Sci. 43 (2), 125.
Thickett, D.R., Moromizato, T., Litonjua, A.A., Amrein, K., Quraishi, S.A., Lee-Sarwar, K. A., et al., 2015. Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: a retrospective cohort study. BMJ Open Respir. Res. 2 (1).
Tuoresmäki, P., Väisänen, S., Neme, A., Heikkinen, S., Carlberg, C., 2014. Patterns of genome-wide VDR locations. PLoS One 9 (4), e96105.
Valdivielso, J.M., Fernandez, E., 2006. Vitamin D receptor polymorphisms and diseases. Clin. Chim. Acta 371 (1–2), 1–12.
van Etten, E., Verlinden, L., Giulietti, A., Ramos-Lopez, E., Branisteanu, D.D., Ferreira, G. B., et al., 2007. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur. J. Immunol. 37 (2), 395–405.
Wacker, M., Holick, M.F., 2013. Sunlight and vitamin D: a global perspective for health. Dermato-endocrinology 5 (1), 51–108.
Wang, W., Zhang, W., Zhang, J., He, J., Zhu, F., 2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). Hla 96 (2), 194–196.
Weir, E.K., Thenappan, T., Bhargava, M., Chen, Y., 2020. Does vitamin D deficiency increase the severity of COVID-19? Clin. Med. 24 (2), e107–e108.
Whitfield, G.K., Remus, L.S., Jurutka, P.W., Zitzer, H., Oza, A.K., Dang, H.T., et al., 2001. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell. Endocrinol. 177 (1–2), 145–159.
Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., et al., 2020. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 584 (7821), 430–436.
Wjst, M., 2005. Variants in the vitamin D receptor gene and asthma. BMC Genet. 6 (1), 1–8.
Xie, M., Chen, Q., 2020. Insight into 2019 novel coronavirus—an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int. J. Infect. Dis. 94, 119–124.
Xu, J., Yang, J., Chen, J., Luo, Q., Zhang, Q., Zhang, H., 2017. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol. Med. Rep. 16 (5), 7432–7438.
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8 (4), 420–422.
Yancy, C.W., 2020. COVID-19 and African Americans. JAMA 323 (19), 1891–1892.
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., et al., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95.
Zdrenghea, M.T., Makrinioti, H., Bagacean, C., Bush, A., Johnston, S.L., Stanciu, L.A., 2017. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev. Med. Virol. 27 (1), e1909.
Zemb, P., Bergman, P., Camargo Jr., C.A., Cavalier, E., Cormier, C., Courbebaisse, M., et al., 2020. Vitamin D deficiency and COVID-19 pandemic. J. Glob. Antimicrob. Resist. 22, 133–134.
Zhang, J., McCullough, P.A., Tecson, K.M., 2020a. Vitamin D deficiency in association with endothelial dysfunction: implications for patients with COVID-19. Rev. Cardiovasc. Med. 21 (3), 339–344.
Zhang, H., Han, H., He, T., Labbe, K.E., Hernandez, A.V., Chen, H., et al., 2020b. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J. Natl. Cancer Inst.
Zheng, S., Yang, J., Hu, X., Li, M., Wang, Q., Dancer, R.C., et al., 2020. Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-β induced epithelial to mesenchymal transition. Biochem. Pharmacol. 113955.
Zhou, X., Xu, L.-d., Li, Y.-z., 2014. The association of polymorphisms of the vitamin D receptor gene with psoriasis in the Han population of northeastern China. J. Dermatol. Sci. 73 (1), 63–66.